

LISTADO DE SECUENCIAS

<110> SANOFI

<120> ANTICUERPOS BIESPECÍFICOS QUE SE UNEN ESPECÍFICAMENTE A CD3 Y CD123

<130> FR2014/021-WO-PCT

<150> EP15305077.8

<151> 2015-01-23

<160> 400

<170> PatentIn version 3.5

<210> 1

<211> 207

<212> PRT

<213> Homo sapiens

<400> 1

Met	Gln	Ser	Gly	Thr	His	Trp	Arg	Val	Leu	Gly	Leu	Cys	Leu	Leu	Ser
1.	5					10				15					

Val	Gly	Val	Trp	Gly	Gln	Asp	Gly	Asn	Glu	Glu	Met	Gly	Gly	Ile	Thr
		20						25					30		

Gln	Thr	Pro	Tyr	Lys	Val	Ser	Ile	Ser	Gly	Thr	Thr	Val	Ile	Leu	Thr
		35					40					45			

Cys	Pro	Gln	Tyr	Pro	Gly	Ser	Glu	Ile	Leu	Trp	Gln	His	Asn	Asp	Lys
	50					55					60				

Asn	Ile	Gly	Gly	Asp	Glu	Asp	Asp	Lys	Asn	Ile	Gly	Ser	Asp	Glu	Asp
65					70					75				80	

His	Leu	Ser	Leu	Lys	Glu	Phe	Ser	Glu	Leu	Glu	Gln	Ser	Gly	Tyr	Tyr
				85					90					95	

Val	Cys	Tyr	Pro	Arg	Gly	Ser	Lys	Pro	Glu	Asp	Ala	Asn	Phe	Tyr	Leu
			100					105					110		

Tyr	Leu	Arg	Ala	Arg	Val	Cys	Glu	Asn	Cys	Met	Glu	Met	Asp	Val	Met
		115					120					125			

Ser Val Ala Thr Ile Val Ile Val Asp Ile Cys Ile Thr Gly Gly Leu
130 135 140

Leu Leu Leu Val Tyr Tyr Trp Ser Lys Asn Arg Lys Ala Lys Ala Lys
145 150 155 160

Pro Val Thr Arg Gly Ala Gly Ala Gly Gly Arg Gln Arg Gly Gln Asn
165 170 175

Lys Glu Arg Pro Pro Pro Val Pro Asn Pro Asp Tyr Glu Pro Ile Arg
180 185 190

Lys Gly Gln Arg Asp Leu Tyr Ser Gly Leu Asn Gln Arg Arg Ile
195 200 205

<210> 2

<211> 198

<212> PRT

<213> *Macaca fascicularis*

<400> 2

Met Gln Ser Gly Thr Arg Trp Arg Val Leu Gly Leu Cys Leu Leu Ser
1. 5 10 15

Ile Gly Val Trp Gly Gln Asp Gly Asn Glu Glu Met Gly Ser Ile Thr
20 25 30

Gln Thr Pro Tyr Gln Val Ser Ile Ser Gly Thr Thr Val Ile Leu Thr
35 40 45

Cys Ser Gln His Leu Gly Ser Glu Ala Gln Trp Gln His Asn Gly Lys
50 55 60

Asn Lys Glu Asp Ser Gly Asp Arg Leu Phe Leu Pro Glu Phe Ser Glu
65 70 75 80

Met Glu Gln Ser Gly Tyr Tyr Val Cys Tyr Pro Arg Gly Ser Asn Pro
85 90 95

Glu Asp Ala Ser His His Leu Tyr Leu Lys Ala Arg Val Cys Glu Asn
100 105 110

Cys Met Glu Met Asp Val Met Ala Val Ala Thr Ile Val Ile Val Asp
115 120 125

Ile Cys Ile Thr Leu Gly Leu Leu Leu Leu Val Tyr Tyr Trp Ser Lys
130 135 140

Asn Arg Lys Ala Lys Ala Lys Pro Val Thr Arg Gly Ala Gly Ala Gly
145 150 155 160

Gly Arg Gln Arg Gly Gln Asn Lys Glu Arg Pro Pro Pro Val Pro Asn
165 170 175

Pro Asp Tyr Glu Pro Ile Arg Lys Gly Gln Gln Asp Leu Tyr Ser Gly
180 185 190

Leu Asn Gln Arg Arg Ile
195

<210> 3
<211> 340
<212> PRT
<213> Homo sapiens

<220>
<221> DOMAIN
<222> (1)..(104)
<223> extracellular domain of human CD3 epsilon

<220>
<221> MISC_FEATURE
<222> (105)..(340)
<223> His-tagged FC-Fusion

<400> 3

Asp Gly Asn Glu Glu Met Gly Gly Ile Thr Gln Thr Pro Tyr Lys Val
1. 5 10 15

Ser Ile Ser Gly Thr Thr Val Ile Leu Thr Cys Pro Gln Tyr Pro Gly
20 25 30

Ser Glu Ile Leu Trp Gln His Asn Asp Lys Asn Ile Gly Gly Asp Glu
35 40 45

Asp Asp Lys Asn Ile Gly Ser Asp Glu Asp His Leu Ser Leu Lys Glu
50 55 60

Phe Ser Glu Leu Glu Gln Ser Gly Tyr Tyr Val Cys Tyr Pro Arg Gly
65 70 75 80

Ser Lys Pro Glu Asp Ala Asn Phe Tyr Leu Tyr Leu Arg Ala Arg Val
85 90 95

Cys Glu Asn Cys Met Glu Met Asp Gly Ser Asp Lys Thr His Thr Cys
100 105 110

Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu
115 120 125

Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu
130 135 140

Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys
145 150 155 160

Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys
165 170 175

Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu
180 185 190

Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys
195 200 205

Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys
210 215 220

Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser
225 230 235 240

Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys
245 250 255

Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln
260 265 270

Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly
275 280 285

Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln
290 295 300

Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn
305 310 315 320

His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly His His His His
325 330 335

His His His His
340

<210> 4
<211> 333
<212> PRT
<213> Macaca fascicularis

<220>
<221> Domain
<222> (1)..(95)
<223> extracellular domain of Macaca fascicularis CD3epsilon protein

<220>
<221> MISC_FEATURE
<222> (96)..(333)
<223> Fc fusion

<400> 4

Asp Gly Asn Glu Glu Met Gly Ser Ile Thr Gln Thr Pro Tyr Gln Val
1. 5 10 15

Ser Ile Ser Gly Thr Thr Val Ile Leu Thr Cys Ser Gln His Leu Gly
20 25 30

Ser Glu Val Gln Trp Gln His Asn Gly Lys Asn Lys Glu Asp Ser Gly
35 40 45

Asp Arg Leu Phe Leu Pro Glu Phe Ser Glu Met Glu Gln Ser Gly Tyr
50 55 60

Tyr Val Cys Tyr Pro Arg Gly Ser Asn Pro Glu Asp Ala Ser His His
65 70 75 80

Leu Tyr Leu Lys Ala Arg Val Cys Glu Asn Cys Met Glu Met Asp Gly
85 90 95

Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu
100 105 110

Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
115 120 125

Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser
130 135 140

His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu
145 150 155 160

Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr
165 170 175

Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn
180 185 190

Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro
195 200 205

Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
210 215 220

Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val
225 230 235 240

Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val
245 250 255

Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
260 265 270

Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr
275 280 285

Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val
290 295 300

Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu
305 310 315 320

Ser Pro Gly Ser Ala Trp Ser His Pro Gln Phe Glu Lys
325 330

<210> 5
<211> 121
<212> PRT
<213> Artificial Sequence

<220>
<223> VH of the so-called "20G6-F3" anti-CD3 antibody

<400> 5

Glu Val Gln Leu Val Glu Thr Gly Gly Ser Leu Val Gln Pro Gly Lys
1. 5 10 15

Ser Leu Lys Leu Thr Cys Ala Thr Ser Gly Phe Thr Phe Thr Lys Ala
20 25 30

Trp Met His Trp Val Arg Gln Ser Pro Glu Lys Gln Leu Glu Trp Val
35 40 45

Ala Gln Ile Lys Asp Lys Ser Asn Ser Tyr Ala Thr Tyr Tyr Ala Glu
50 55 60

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr
65 70 75 80

Ile Tyr Leu Gln Met Asn Ser Leu Lys Glu Glu Asp Thr Ala Ile Tyr
85 90 95

Tyr Cys Arg Gly Val Tyr Tyr Ala Leu Ser Pro Phe Asp Tyr Trp Gly
100 105 110

Gln Gly Val Met Val Thr Val Ser Ser
115 120

<210> 6
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR1-H of the so-called "20G6-F3" anti-CD3antibody

<400> 6

Gly Phe Thr Phe Thr Lys Ala Trp
1. 5

<210> 7
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR2-H of the so-called "20G6-F3" anti-CD3antibody

<400> 7

Ile Lys Asp Lys Ser Asn Ser Tyr Ala Thr
1. 5 10

<210> 8
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR3-H of the so-called "20G6-F3" anti-CD3antibody

<400> 8

Arg Gly Val Tyr Tyr Ala Leu Ser Pro Phe Asp Tyr
1. 5 10

<210> 9
<211> 112
<212> PRT
<213> Artificial Sequence

<220>

<223> VL of the so-called "20G6-F3" anti-CD3 antibody

<400> 9

Asp Val Val Met Thr Gln Thr Pro Val Ser Leu Ser Val Ser Leu Gly
1. 5 10 15

Gly Gln Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asn
20 25 30

Asn Gly Asn Thr Tyr Leu Ser Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45

Pro Gln Ser Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Phe Ser
50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80

Ser Arg Val Asp Pro Asp Asp Leu Gly Val Tyr Tyr Cys Gly Gln Gly
85 90 95

Thr Gln Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
100 105 110

<210> 10

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> CDR1-L of the so-called called "20G6-F3", "11D7-C3" , "13H2-C2"
,
"13C1-F6", "1E6-C9, "10F4-C10", "18G9-H11", "12G3-E8", "5B1-
G2",
"16F8-A7", "11F9-F8", "8C2-F7", "20E5-F10" and "3H6-D2" anti-
CD3
antibodies

<400> 10

Gln Ser Leu Val His Asn Asn Gly Asn Thr Tyr
1. 5 10

<210> 11

<211> 9

<212> PRT
<213> Artificial Sequence

<220>
<223> CDR3-L of the so-called "20G6-F3", "4B4-D7" , "11H3-E5" ,
"13H2-C2", "13C1-F6", "10F4-C10", "4E7-C9", "11F3-B9", "12G3-
E8",
"5B1-G2", "6F4-D10", "16F8-A7", "20E5-F10" and "3H6-D2" anti-
CD3
antibodies

<400> 11

Gly Gln Gly Thr Gln Tyr Pro Phe Thr
1. 5

<210> 12
<211> 121
<212> PRT
<213> Artificial Sequence

<220>
<223> VH of the so-called "4B4-D7" anti-CD3 antibody.

<400> 12

Glu Val Gln Leu Val Glu Thr Gly Gly Arg Leu Val Gln Pro Gly Arg
1. 5 10 15

Ser Leu Lys Leu Thr Cys Ala Thr Ser Gly Phe Thr Phe Ser Asn Ala
20 25 30

Trp Met His Trp Val Arg Gln Ser Pro Glu Lys Gln Leu Glu Trp Val
35 40 45

Ala Gln Ile Lys Ala Arg Ser Asn Asn Tyr Ala Thr Tyr Tyr Ala Glu
50 55 60

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr
65 70 75 80

Ile Tyr Leu Gln Met Asn Ser Leu Lys Glu Glu Asp Thr Ala Ile Tyr
85 90 95

Tyr Cys Arg Gly Thr Tyr Tyr Ala Ser Lys Pro Phe Asp Tyr Trp Gly
100 105 110

Gln Gly Val Met Val Thr Val Ser Ser
115 120

<210> 13
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR3-L of the so-called "20G6-F3", "4B4-D7" , "11H3-E5" ,
"13H2-C2", "13C1-F6", "10F4-C10", "4E7-C9", "11F3-B9", "12G3-
E8",
"5B1-G2", "16F8-A7", "20E5-F10" and "3H6-D2" anti-CD3
antibodies.

<400> 13

Gly Phe Thr Phe Ser Asn Ala Trp
1. 5

<210> 14
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR2-H of the so-called "4B4-D7" anti-CD3 antibody

<400> 14

Ile Lys Ala Arg Ser Asn Asn Tyr Ala Thr
1. 5 10

<210> 15
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR3-H of the so-called "4B4-D7" anti-CD3 antibody.

<400> 15

Arg Gly Thr Tyr Tyr Ala Ser Lys Pro Phe Asp Tyr
1. 5 10

<210> 16
<211> 112
<212> PRT

<213> Artificial Sequence

<220>

<223> VL of the so-called "4B4-D7" anti-CD3 antibody

<400> 16

Asp Val Val Met Thr Gln Thr Pro Val Ser Leu Ser Val Ser Leu Gly
1. 5 10 15

Gly Gln Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asp
20 25 30

Asn Gly Asn Thr Tyr Leu Ser Trp Ser Leu Gln Arg Pro Gly Gln Ser
35 40 45

Pro Gln Val Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Thr Ser
50 55 60

Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80

Ser Arg Val Glu Pro Asp Asp Leu Gly Val Tyr Tyr Cys Gly Gln Gly
85 90 95

Thr Gln Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
100 105 110

<210> 17

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> CDR1-L of the so-called "4B4-D7", "11H3-E5" and "11F3-B9"
anti-CD3 antibodies.

<400> 17

Gln Ser Leu Val His Asp Asn Gly Asn Thr Tyr
1. 5 10

<210> 18

<211> 122

<212> PRT

<213> Artificial Sequence

<220>

<223> VH of the so-called "4E7-C9" anti-CD3 antibody

<400> 18

Glu Val Gln Val Val Glu Thr Gly Gly Ser Leu Val Gln Pro Gly Lys
1. 5 10 15

Ser Leu Lys Leu Thr Cys Ala Thr Ser Gly Phe Thr Phe Ser Asn Ala
20 25 30

Trp Met His Trp Val Arg Gln Ser Pro Glu Lys Gln Leu Glu Trp Val
35 40 45

Ala Gln Ile Lys Asp Lys Ser Asn Asn Tyr Ala Thr Tyr Tyr Ala Glu
50 55 60

Ser Leu Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Pro Lys Arg Ser
65 70 75 80

Ile Tyr Leu Gln Met Asn Ser Leu Arg Glu Glu Asp Thr Ala Ile Tyr
85 90 95

Tyr Cys Arg Tyr Val His Tyr Gly Ile Gly Tyr Ala Met Asp Ala Trp
100 105 110

Gly Gln Gly Thr Ser Val Thr Val Ser Ser
115 120

<210> 19

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> CDR2-H of the so-called "4E7-C9", "18F5-H10", "20E5-F10" and
"3H6-D2" anti-CD3 antibodies

<400> 19

Ile Lys Asp Lys Ser Asn Asn Tyr Ala Thr
1. 5 10

<210> 20

<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR3-H of the so-called "4E7-C9" anti-CD3 antibody

<400> 20

Arg Tyr Val His Tyr Gly Ile Gly Tyr Ala Met Asp Ala
1. 5 10

<210> 21
<211> 112
<212> PRT
<213> Artificial Sequence

<220>
<223> VL of the so-called "4E7-C9" anti-CD3 antibody

<400> 21

Asp Val Val Met Thr Gln Thr Pro Val Ser Leu Ser Val Ser Leu Gly
1. 5 10 15

Gly Gln Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Glu His Asn
20 25 30

Asn Gly Asn Thr Tyr Leu Ser Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45

Pro Gln Pro Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Ile Ser
50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80

Ser Arg Val Glu Pro Asp Asp Leu Gly Val Tyr Tyr Cys Gly Gln Gly
85 90 95

Thr Gln Tyr Pro Phe Thr Phe Gly Pro Gly Thr Lys Leu Glu Leu Lys
100 105 110

<210> 22
<211> 11
<212> PRT

<213> Artificial Sequence

<220>

<223> CDR1-H of the so-called "4E7-C9" anti-CD3 antibody

<400> 22

Gln Ser Leu Glu His Asn Asn Gly Asn Thr Tyr
1. 5 10

<210> 23

<211> 122

<212> PRT

<213> Artificial Sequence

<220>

<223> VH of the so-called "18F5-H10" anti-CD3 antibody

<400> 23

Glu Val Gln Val Val Glu Thr Gly Gly Ser Leu Val Gln Pro Gly Lys
1. 5 10 15

Ser Leu Lys Leu Thr Cys Ala Thr Ser Gly Phe Thr Phe Thr Asn Ala
20 25 30

Trp Met His Trp Val Arg Arg Ser Pro Glu Lys Gln Leu Glu Trp Val
35 40 45

Ala Gln Ile Lys Asp Lys Ser Asn Asn Tyr Ala Thr Tyr Tyr Ala Glu
50 55 60

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser
65 70 75 80

Ile Tyr Leu Gln Met Asn Ser Leu Lys Glu Glu Asp Thr Ala Ile Tyr
85 90 95

Tyr Cys Arg Tyr Val His Tyr Arg Phe Ala Tyr Ala Leu Asp Ala Trp
100 105 110

Gly Arg Gly Thr Ser Val Ser Val Ser Ser
115 120

<210> 24

<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR1-H of the so-called "18F5-H10" anti-CD3 antibody

<400> 24

Gly Phe Thr Phe Thr Asn Ala Trp
1. 5

<210> 25
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR3-H of the so-called "18F5-H10" anti-CD3 antibody

<400> 25

Arg Tyr Val His Tyr Arg Phe Ala Tyr Ala Leu Asp Ala
1. 5 10

<210> 26
<211> 112
<212> PRT
<213> Artificial Sequence

<220>
<223> VL of the so-called "18F5-H10" anti-CD3 antibody

<400> 26

Asp Val Leu Met Thr Gln Thr Pro Val Ser Leu Ser Val Ser Leu Gly
1. 5 10 15

Gly Gln Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Thr
20 25 30

Asn Gly Asn Thr Tyr Leu Ser Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45

Pro Gln Leu Leu Ile Tyr Lys Val Ser Asn Arg Leu Ser Gly Ile Ser
50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile

65

70

75

80

Ser Arg Val Glu Pro Asp Asp Leu Gly Val Tyr Tyr Cys Gly Gln Gly
85 90 95

Thr His Tyr Pro Phe Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys
100 105 110

<210>	27
<211>	11
<212>	PRT
<213>	Artificial Sequence

<220>
<223> CDR1-L of the so-called "18F5-H10" anti-CD3 antibody

<400> 27

Gln Ser Leu Val His Thr Asn Gly Asn Thr Tyr
1. 5 10

<210>	28
<211>	9
<212>	PRT
<213>	Artificial Sequence

<220>
<223> CDR3-L of the so-called "18F5-H10", "11D7-C3", "1E6-C9" and "10E6-G6" anti-CD3 antibodies

<400> 28

Gly Gln Gly Thr His Tyr Pro Phe Thr
1. 5

```
<210> 29
<211> 118
<212> PRT
<213> Artificial Sequence
```

<220>
<223> VH of the so-called "12D2-E5" anti-CD3 antibody

<400> 29

Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg
1. 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Phe Tyr Ala Tyr
20 25 30

Trp Met Gly Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45

Gly Glu Ile Lys Lys Asp Gly Thr Thr Ile Asn Tyr Thr Pro Ser Leu
50 55 60

Lys Asp Arg Phe Thr Ile Ser Arg Asp Asn Ala Gln Asn Thr Leu Tyr
65 70 75 80

Leu Gln Met Thr Lys Leu Gly Ser Glu Asp Thr Ala Leu Tyr Tyr Cys
85 90 95

Ala Arg Glu Glu Arg Asp Gly Tyr Phe Asp Tyr Trp Gly Gln Gly Val
100 105 110

Met Val Thr Val Ser Ser
115

<210> 30
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR1-H of the so-called "12D2-E5" anti-CD3 antibody

<400> 30

Gly Phe Asn Phe Tyr Ala Tyr Trp
1. 5

<210> 31
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR2-H of the so-called "12D2-E5" anti-CD3 antibody

<400> 31

Ile Lys Lys Asp Gly Thr Thr Ile
1. 5

<210> 32
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR3-H of the so-called "12D2-E5" and "3G5-E10" anti-CD3 antibody

<400> 32

Ala Arg Glu Glu Arg Asp Gly Tyr Phe Asp Tyr
1. 5 10

<210> 33
<211> 109
<212> PRT
<213> Artificial Sequence

<220>
<223> VL of the so-called "12D2-E5" anti-CD3 antibody.

<400> 33

Gln Phe Val Leu Thr Gln Pro Asn Ser Val Ser Thr Asn Leu Gly Ser
1. 5 10 15

Thr Val Lys Leu Ser Cys Lys Arg Ser Thr Gly Asn Ile Gly Ser Asn
20 25 30

Tyr Val Asn Trp Tyr Gln Gln His Glu Gly Arg Ser Pro Thr Thr Met
35 40 45

Ile Tyr Arg Asp Asp Lys Arg Pro Asp Gly Val Pro Asp Arg Phe Ser
50 55 60

Gly Ser Ile Asp Arg Ser Ser Asn Ser Ala Leu Leu Thr Ile Asn Asn
65 70 75 80

Val Gln Thr Glu Asp Glu Ala Asp Tyr Phe Cys Gln Ser Tyr Ser Ser
85 90 95

Gly Ile Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105

<210> 34
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR1-H of the so-called "12D2-E5" anti-CD3 antibody

<400> 34

Thr Gly Asn Ile Gly Ser Asn Tyr
1. 5

<210> 35
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR3-H of the so-called "12D2-E5" anti-CD3 antibody

<400> 35

Gln Ser Tyr Ser Ser Gly Ile Val
1. 5

<210> 36
<211> 121
<212> PRT
<213> Artificial Sequence

<220>
<223> VH of the so-called "11D7-C3" anti-CD3 antibody

<400> 36

Glu Val Gln Phe Val Glu Thr Gly Gly Ser Leu Val Gln Pro Gly Lys
1. 5 10 15

Ser Leu Lys Leu Thr Cys Ala Thr Ser Gly Phe Thr Phe Ser Asn Ala
20 25 30

Trp Met His Trp Val Arg Gln Ser Pro Glu Lys Gln Leu Glu Trp Val
35 40 45

Ala Gln Ile Lys Ala Lys Ser Asn Asn Tyr Ala Thr Tyr Tyr Ala Glu
50 55 60

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser
65 70 75 80

Val Tyr Leu Gln Met Asn Ser Leu Lys Glu Glu Asp Thr Ala Thr Tyr
85 90 95

Tyr Cys Arg Gly Leu Tyr Tyr Gly Leu Ser Pro Ser Asp Tyr Trp Gly
100 105 110

Gln Gly Val Met Val Thr Val Ser Ser
115 120

<210> 37
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR2-H of the so-called "11D7-C3", "11H3-E5", "13H2-C2",
"13C1-F6", "1E6-C9", "10F4-C10", "18G9-H11", "11F3-B9",
"6F4-D10", "16F8-A7", "11F9-F8" and "20B5-F10" anti-CD3
antibodies

<400> 37

Ile Lys Ala Lys Ser Asn Asn Tyr Ala Thr
1. 5 10

<210> 38
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR3-H of the so-called "11D7-C3" anti-CD3 antibody

<400> 38

Arg Gly Leu Tyr Tyr Gly Leu Ser Pro Ser Asp Tyr
1. 5 10

<210> 39
<211> 112
<212> PRT
<213> Artificial Sequence

<220>

<223> VL of the so-called "11D7-C3" anti-CD3 antibody.

<400> 39

Asp Val Val Met Thr Gln Thr Pro Val Ser Leu Ser Val Ser Leu Gly
1. 5 10 15

Gly Gln Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asn
20 25 30

Asn Gly Asn Thr Tyr Leu Ser Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45

Pro Gln Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Ile Ser
50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80

Ser Arg Val Glu Pro Asp Asp Leu Gly Val Tyr Tyr Cys Gly Gln Gly
85 90 95

Thr His Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
100 105 110

<210> 40

<211> 121

<212> PRT

<213> Artificial Sequence

<220>

<223> VH of the so-called "11H3-E5" anti-CD3 antibody

<400> 40

Glu Val Gln Leu Val Glu Thr Gly Gly Ser Leu Val Gln Pro Gly Lys
1. 5 10 15

Ser Leu Lys Leu Thr Cys Ala Thr Ser Gly Phe Thr Phe Ser Asn Ala
20 25 30

Trp Met His Trp Val Arg Gln Ser Pro Glu Lys Gln Leu Glu Trp Val
35 40 45

Ala Gln Ile Lys Ala Lys Ser Asn Asn Tyr Ala Thr Tyr Tyr Ala Glu
50 55 60

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser
65 70 75 80

Val Tyr Leu Gln Met Asn Ser Leu Lys Glu Glu Asp Thr Ala Ile Tyr
85 90 95

Tyr Cys Arg Gly Thr Tyr Tyr Ala Tyr Lys Pro Phe Asp Tyr Trp Gly
100 105 110

Gln Gly Val Met Val Thr Val Ser Ser
115 120

<210> 41
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR3-H of the so-called called "11H3-E5" anti-CD3 antibody

<400> 41

Arg Gly Thr Tyr Tyr Ala Tyr Lys Pro Phe Asp Tyr
1. 5 10

<210> 42
<211> 112
<212> PRT
<213> Artificial Sequence

<220>
<223> VL of the so-called "11H3-E5" anti-CD3 antibody

<400> 42

Asp Val Val Met Thr Gln Thr Pro Val Ser Leu Ser Val Ser Leu Gly
1. 5 10 15

Gly Gln Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asp
20 25 30

Asn Gly Asn Thr Tyr Leu Ser Trp Ser Leu Gln Lys Pro Gly Gln Ser
35 40 45

Pro Gln Val Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Thr Ser
50 55 60

Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80

Ser Arg Val Glu Pro Asp Asp Leu Gly Val Tyr Tyr Cys Gly Gln Gly
85 90 95

Thr Gln Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
100 105 110

<210> 43
<211> 121
<212> PRT
<213> Artificial Sequence

<220>
<223> VH of the so-called "13H2-C2" anti-CD3 antibody.

<400> 43

Glu Glu Glu Leu Val Glu Thr Gly Gly Ser Leu Val Gln Pro Gly Lys
1. 5 10 15

Ser Leu Lys Leu Thr Cys Ala Thr Ser Gly Phe Thr Phe Ser Asn Ala
20 25 30

Trp Met His Trp Val Arg Gln Ser Pro Asp Lys Gln Leu Glu Trp Val
35 40 45

Ala Gln Ile Lys Ala Lys Ser Asn Asn Tyr Ala Thr Tyr Tyr Ala Glu
50 55 60

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser
65 70 75 80

Val Tyr Leu Gln Met Asn Asn Leu Lys Glu Glu Asp Thr Ala Ile Tyr
85 90 95

Tyr Cys Arg Tyr Val His Tyr Gly Leu Ala Pro Met Asp Ala Trp Gly
100 105 110

Gln Gly Thr Ser Val Thr Val Ser Ser
115 120

<210> 44
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR3-H of the so-called "13H2-C2" anti-CD3 antibody

<400> 44

Arg Tyr Val His Tyr Gly Leu Ala Pro Met Asp Ala
1. 5 10

<210> 45
<211> 112
<212> PRT
<213> Artificial Sequence

<220>
<223> VL of the so-called "13H2-C2" anti-CD3 antibody

<400> 45

Asp Val Val Met Thr Gln Thr Pro Val Ser Leu Ser Val Ser Leu Gly
1. 5 10 15

Gly Gln Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asn
20 25 30

Asn Gly Asn Thr Tyr Leu Ser Trp Tyr Leu Gln Lys Ala Gly Gln Ser
35 40 45

Pro Gln Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Ile Ser
50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Ile Leu Lys Ile
65 70 75 80

Ser Arg Val Glu Pro Asp Asp Leu Gly Val Phe Tyr Cys Gly Gln Gly
85 90 95

Thr Gln Tyr Pro Phe Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys
100 105 110

<210> 46

<211> 121

<212> PRT

<213> Artificial Sequence

<220>

<223> VH of the so-called "13C1-F6" and "11F9-F8" anti-CD3 antibodies

<400> 46

Glu Val Gln Leu Val Glu Thr Gly Gly Thr Leu Val Gln Pro Gly Lys
1. 5 10 15

Ser Leu Lys Leu Thr Cys Ala Thr Ser Gly Phe Thr Phe Ser Asn Ala
20 25 30

Trp Met His Trp Val Arg Gln Ser Pro Glu Lys Gln Leu Glu Trp Val
35 40 45

Ala Gln Ile Lys Ala Lys Ser Asn Asn Tyr Ala Thr Tyr Tyr Ala Glu
50 55 60

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Thr Ser
65 70 75 80

Val Tyr Leu Gln Leu Asn Ser Leu Arg Glu Glu Asp Thr Ala Ile Tyr
85 90 95

Tyr Cys Arg Gly Thr Gln Tyr Gly Tyr Asn Pro Phe Asp Tyr Trp Gly
100 105 110

Gln Gly Val Met Val Thr Val Ser Ser
115 120

<210> 47

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> CDR3-H of so-called "13C1-F6", "10E6-G6" and "11F9-F8" anti-CD3 antibodies

<400> 47

Arg Gly Thr Gln Tyr Gly Tyr Asn Pro Phe Asp Tyr
1. 5 10

<210> 48

<211> 112

<212> PRT

<213> Artificial Sequence

<220>

<223> VL of the so-called "13H2-C2" anti-CD3 antibody

<400> 48

Asp Val Val Met Thr Gln Ser Pro Val Ser Leu Ser Val Ser Leu Gly
1. 5 10 15

Gly Gln Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asn
20 25 30

Asn Gly Asn Thr Tyr Leu Ser Trp Tyr Leu Gln Arg Ser Gly Gln Ser
35 40 45

Pro Gln Leu Leu Ile Tyr Lys Val Ser Asn Arg Leu Ser Gly Ile Ser
50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80

Ser Arg Ile Glu Pro Asp Asp Leu Gly Val Tyr Tyr Cys Gly Gln Gly
85 90 95

Thr Gln Tyr Pro Phe Thr Phe Gly Ser Gly Thr Arg Leu Glu Ile Lys
100 105 110

<210> 49

<211> 118

<212> PRT

<213> Artificial Sequence

<220>

<223> VH of the so-called "18H11-F10" anti-CD3 antibody

<400> 49

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg
1. 5 10 15

Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Ile Phe Ser Asp Tyr
20 25 30

Tyr Met Ala Trp Val Arg Gln Ala Pro Lys Lys Gly Leu Glu Trp Val
35 40 45

Ala Thr Ile Ser Ile Ser Gly Ser Arg Thr Tyr Tyr Pro Asp Ser Val
50 55 60

Lys Gly Arg Phe Thr Val Ser Arg Asp Asn Ala Lys Ser Ser Leu Tyr
65 70 75 80

Leu Gln Met Asn Ser Leu Lys Ser Glu Asp Thr Ala Thr Tyr Tyr Cys
85 90 95

Ala Thr Asn Asn Pro Gly Gly Trp Phe Val Tyr Trp Gly Gln Gly Thr
100 105 110

Leu Val Thr Val Ser Ser
115

<210> 50
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR1-H of the so-called "18H11-F10" anti-CD3 antibody

<400> 50

Gly Phe Ile Phe Ser Asp Tyr Tyr
1. 5

<210> 51
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR2-H of the so-called "18H11-F10" anti-CD3 antibody

<400> 51

Ile Ser Ile Ser Gly Ser Arg Thr
1. 5

<210> 52

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> CDR3-H of the so-called "18H11-F10" anti-CD3 antibody

<400> 52

Ala Thr Asn Asn Pro Gly Gly Trp Phe Val Tyr
1. 5 10

<210> 53

<211> 106

<212> PRT

<213> Artificial Sequence

<220>

<223> VL of the so-called "18H11-F10" anti-CD3 antibody

<400> 53

Asn Ile Gln Met Thr Gln Ser Pro Ser Leu Leu Ser Ala Ser Val Gly
1. 5 10 15

Asp Arg Val Thr Leu Ser Cys Lys Ala Gly Gln Asn Ile Asn Asn Asp
20 25 30

Leu Ala Trp Tyr Gln Gln Lys Leu Gly Glu Ala Pro Arg Leu Leu Ile
35 40 45

Tyr Asn Ala Asn Ser Leu Gln Thr Gly Ile Pro Ser Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Ala Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80

Glu Asp Val Ala Thr Tyr Phe Cys Gln Gln Tyr Ser Ser Gly Asp Thr
85 90 95

Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys
100 105

<210> 54
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR1-L of the so-called "18H11-F10" anti-CD3 antibody

<400> 54

Gln Asn Ile Asn Asn Asp
1. 5

<210> 55
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR3-L of the so-called "18H11-F10" anti-CD3 antibody

<400> 55

Gln Gln Tyr Ser Ser Gly Asp Thr
1. 5

<210> 56
<211> 121
<212> PRT
<213> Artificial Sequence

<220>
<223> VH of the so-called "1E6-C9" anti-CD3 antibody

<400> 56

Glu Val Gln Leu Val Glu Thr Gly Gly Ser Leu Val Gln Pro Gly Lys
1. 5 10 15

Ser Leu Lys Leu Thr Cys Ala Thr Ser Gly Phe Thr Phe Ser Tyr Ala
20 25 30

Trp Met His Trp Val Arg Gln Ser Pro Asp Lys Gln Leu Gln Trp Val
35 40 45

Ala Gln Ile Lys Ala Lys Ser Asn Asn Tyr Ala Thr Tyr Tyr Ala Glu
50 55 60

Ser Val Glu Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser
65 70 75 80

Val Tyr Leu Gln Met Asn Ser Leu Lys Glu Glu Asp Thr Ala Ile Tyr
85 90 95

Tyr Cys Arg Gly Val Tyr Tyr Gly Leu Leu Gly Leu Asp Ala Trp Gly
100 105 110

Gln Gly Thr Ser Val Thr Val Ser Ser
115 120

<210> 57

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> CDR1-H of the so-called "1E6-C9" anti-CD3 antibody

<400> 57

Gly Phe Thr Phe Ser Tyr Ala Trp
1. 5

<210> 58

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> CDR3-H of the so-called "1E6-C9" anti-CD3 antibody

<400> 58

Arg Gly Val Tyr Tyr Gly Leu Leu Gly Leu Asp Ala
1. 5 10

<210> 59

<211> 112

<212> PRT

<213> Artificial Sequence

<220>

<223> VL of the so-called "1E6-C9" anti-CD3 antibody

<400> 59

Asp Val Val Met Thr Gln Thr Pro Val Ser Leu Ser Val Arg Leu Gly
1. 5 10 15

Gly Gln Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asn
20 25 30

Asn Gly Asn Thr Tyr Leu Ser Trp Phe Leu Gln Lys Pro Gly Gln Ser
35 40 45

Pro Gln Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Ile Ser
50 55 60

Asp Arg Phe Ser Gly Ser Ala Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80

Ser Arg Val Glu Pro Asp Asp Leu Gly Val Tyr Tyr Cys Gly Gln Gly
85 90 95

Thr His Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
100 105 110

<210> 60

<211> 121

<212> PRT

<213> Artificial Sequence

<220>

<223> VH of the so-called "10F4-C10" anti-CD3 antibody

<400> 60

Glu Val Gln Leu Val Glu Thr Gly Gly Ser Leu Val Gln Pro Gly Lys
1. 5 10 15

Ser Leu Lys Ile Thr Cys Ala Thr Ser Gly Phe Thr Phe Ser Asn Ala
20 25 30

Trp Met His Trp Val Arg Gln Ser Pro Glu Lys Gln Leu Glu Trp Val
35 40 45

Ala Gln Ile Lys Ala Lys Ser Asn Asn Tyr Ala Thr Tyr Tyr Ala Glu
50 55 60

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser
65 70 75 80

Ile Tyr Leu Gln Met Asn Ser Leu Lys Glu Glu Asp Thr Ala Ile Tyr
85 90 95

Tyr Cys Arg Ala Val Asn Tyr Gly Asn Tyr Pro Leu Asp Tyr Trp Gly
100 105 110

Gln Gly Val Met Val Thr Val Ser Ser
115 120

<210> 61
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR3-H of the so-called "10F4-C10" anti-CD3 antibody

<400> 61

Arg Ala Val Asn Tyr Gly Asn Tyr Pro Leu Asp Tyr
1. 5 10

<210> 62
<211> 112
<212> PRT
<213> Artificial Sequence

<220>
<223> VL of the so-called "10F4-C10" anti-CD3 antibody

<400> 62

Asp Val Val Met Thr Gln Thr Pro Val Ser Leu Ser Val Ser Leu Gly
1. 5 10 15

Gly Gln Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asn
20 25 30

Asn Gly Asn Thr Tyr Leu Ser Trp Cys Leu Gln Lys Pro Gly Gln Ser

35

40

45

Pro Gln Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Ile Ser
50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80

Ser Arg Val Glu Pro Asp Asp Leu Gly Val Tyr Tyr Cys Gly Gln Gly
85 90 95

Thr Gln Tyr Pro Phe Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys
100 105 110

<210> 63

<211> 121

<212> PRT

<213> Artificial Sequence

<220>

<223> VH of the so-called "10E6-G6" anti-CD3 antibody

<400> 63

Glu Val Gln Leu Val Glu Thr Gly Gly Gly Leu Val Gln Ser Gly Lys
1. 5 10 15

Ser Leu Lys Leu Thr Cys Ala Thr Ser Gly Phe Thr Val Thr Asn Ala
20 25 30

Trp Met His Trp Val Arg Gln Ser Pro Glu Lys Gln Leu Glu Trp Val
35 40 45

Ala Gln Ile Lys Ala Lys Ser Asn Asn Tyr Glu Thr Tyr Tyr Ala Glu
50 55 60

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser
65 70 75 80

Val Tyr Leu Gln Met Asn Ser Leu Lys Glu Glu Asp Thr Ala Ile Tyr
85 90 95

Tyr Cys Arg Gly Thr Gln Tyr Gly Tyr Asn Pro Phe Asp Tyr Trp Gly

100

105

110

Gln Gly Val Met Val Thr Val Ser Ser
 115 120

<210> 64

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> CDR1-H of the so-called "10E6-G6" anti-CD3 antibody

<400> 64

Gly Phe Thr Val Thr Asn Ala Trp
 1. 5

<210> 65

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> CDR3-H of the so-called "10E6-G6" anti-CD3 antibody

<400> 65

Ile Lys Ala Lys Ser Asn Asn Tyr Glu Thr
 1. 5 10

<210> 66

<211> 112

<212> PRT

<213> Artificial Sequence

<220>

<223> VL of the so-called "10E6-G6" anti-CD3 antibody

<400> 66

Asp Val Val Met Thr Gln Ser Pro Val Ser Leu Ser Val Ser Leu Gly
 1. 5 10 15

Gly Gln Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asn
 20 25 30

Asn Gly Tyr Thr Tyr Leu Ser Trp Tyr Leu Gln Lys Pro Gly Gln Ser

35

40

45

Pro Gln Val Phe Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Ile Ser
 50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
 65 70 75 80

Ser Arg Ile Glu Pro Asp Asp Leu Gly Val Tyr Tyr Cys Gly Gln Gly
 85 90 95

Thr His Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
 100 105 110

<210> 67

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> CDR1-L of the so-called "10E6-G6" anti-CD3 antibody

<400> 67

Gln Ser Leu Val His Asn Asn Gly Tyr Thr Tyr
 1. 5 10

<210> 68

<211> 122

<212> PRT

<213> Artificial Sequence

<220>

<223> VH of the so-called "18G9-H11" anti-CD3 antibody

<400> 68

Glu Val Gln Leu Val Glu Thr Gly Gly Ser Leu Val Gln Pro Gly Lys
 1. 5 10 15

Ser Leu Lys Leu Thr Cys Ala Thr Ser Gly Phe Thr Phe Ser Asn Ala
 20 25 30

Trp Ile Gln Trp Val Arg Gln Ser Pro Glu Lys Gln Leu Glu Trp Val
 35 40 45

Ala Gln Ile Lys Ala Lys Ser Asn Asn Tyr Ala Thr Tyr Tyr Ala Glu
50 55 60

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser
65 70 75 80

Val Tyr Leu Gln Met Asn Ser Leu Lys Glu Glu Asp Thr Ala Leu Tyr
85 90 95

Tyr Cys Thr Trp Arg His Tyr Tyr Ser Ser His Thr Met Asp Ala Trp
100 105 110

Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 69
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR3-H of the so-called "18G9-H11" anti-CD3 antibody

<400> 69

Thr Trp Arg His Tyr Tyr Ser Ser His Thr Met Asp Ala
1. 5 10

<210> 70
<211> 112
<212> PRT
<213> Artificial Sequence

<220>
<223> VL of the so-called "18G9-H11" anti-CD3 antibody

<400> 70

Asp Val Val Met Thr Gln Thr Pro Val Ser Leu Ser Val Ser Leu Gly
1. 5 10 15

Gly Gln Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asn
20 25 30

Asn Gly Asn Thr Tyr Leu Ser Trp Tyr Leu Gln Lys Pro Gly Gln Ser

35

40

45

Pro Gln Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Ile Ser
 50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
 65 70 75 80

Ser Arg Val Ala Pro Thr Asp Leu Gly Val Tyr Tyr Cys Gly Gln Gly
 85 90 95

Ser Gln Tyr Pro Phe Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys
 100 105 110

<210> 71

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> CDR3-L of the so-called "18G9-H11" anti-CD3 antibody

<400> 71

Gly Gln Gly Ser Gln Tyr Pro Phe Thr
 1. 5

<210> 72

<211> 121

<212> PRT

<213> Artificial Sequence

<220>

<223> VH of the so-called "11F3-B9" anti-CD3 antibody

<400> 72

Glu Val Gln Leu Val Glu Thr Gly Gly Ser Leu Val Gln Pro Gly Lys
 1. 5 10 15

Ser Leu Thr Leu Thr Cys Ala Thr Ser Gly Phe Thr Phe Ser Asn Ala
 20 25 30

Trp Met His Trp Val Arg Gln Ser Pro Glu Lys Gln Leu Glu Trp Val
 35 40 45

Ala Gln Ile Lys Ala Lys Ser Asn Asn Tyr Ala Thr Tyr Tyr Ala Glu
50 55 60

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Arg Ser
65 70 75 80

Val Tyr Leu Gln Met Asn Ser Leu Lys Glu Glu Asp Thr Ala Ile Tyr
85 90 95

Tyr Cys Arg Tyr Val Asn Tyr Gly Leu Ala Pro Met Asp Val Trp Gly
100 105 110

Gln Gly Thr Ser Val Thr Val Ser Ser
115 120

<210> 73
<211> 112
<212> PRT
<213> Artificial Sequence

<220>
<223> VL of the so-called "11F3-B9" anti-CD3 antibody

<400> 73

Asp Val Val Met Thr Gln Thr Pro Val Ser Leu Ser Val Ser Leu Gly
1. 5 10 15

Gly Gln Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asp
20 25 30

Asn Gly Asn Thr Tyr Leu Ser Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45

Pro Gln Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Phe Ser
50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80

Ser Arg Val Glu Pro Asp Asp Leu Gly Val Tyr Tyr Cys Gly Gln Gly
85 90 95

Thr Gln Tyr Pro Phe Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys
100 105 110

<210> 74

<211> 123

<212> PRT

<213> Artificial Sequence

<220>

<223> VH of the so-called "12G3-E8" anti-CD3 antibody

<400> 74

Glu Val Arg Val Val Glu Thr Gly Gly Ser Leu Val Gln Pro Gly Lys
1. 5 10 15

Ser Leu Lys Leu Thr Cys Ala Thr Ser Gly Phe Thr Phe Ser Leu Ala
20 25 30

Trp Met His Trp Val Arg Gln Ser Pro Glu Lys Lys Leu Glu Trp Val
35 40 45

Ala Gln Ile Lys Asp Lys Ala Asn Asn Tyr Ala Thr Tyr Tyr Ala Glu
50 55 60

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Arg Ser
65 70 75 80

Val Tyr Leu Gln Met Asn Arg Leu Lys Glu Glu Asp Thr Ala Ile Tyr
85 90 95

Tyr Cys Arg Gly Val Tyr Tyr Gly Phe Ser Met Thr Pro Phe Asp Tyr
100 105 110

Trp Gly Gln Gly Val Met Val Thr Val Ser Ser
115 120

<210> 75

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> CDR1-H of the so-called "18G9-H11" anti-CD3 antibody

<400> 75

Gly Phe Thr Phe Ser Leu Ala Trp
1. 5

<210> 76

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> CDR2-H of the so-called "18G9-H11" anti-CD3 antibody

<400> 76

Ile Lys Asp Lys Ala Asn Asn Tyr Ala Thr
1. 5 10

<210> 77

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> CDR3-H of the so-called "18G9-H11" anti-CD3 antibody

<400> 77

Arg Gly Val Tyr Tyr Gly Phe Ser Met Thr Pro Phe Asp Tyr
1. 5 10

<210> 78

<211> 112

<212> PRT

<213> Artificial Sequence

<220>

<223> VL of the so-called "12G3-E8" anti-CD3 antibody

<400> 78

Asp Val Ala Met Thr Gln Thr Pro Val Ser Leu Ser Val Ser Leu Gly
1. 5 10 15

Gly Gln Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asn
20 25 30

Asn Gly Asn Thr Tyr Leu Ser Trp Tyr Leu Gln Lys Pro Gly Gln Ser

35

40

45

Pro Gln Val Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Ile Ser
50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Ala Asp Phe Thr Leu Lys Ile
65 70 75 80

Ser Arg Val Glu Pro Asp Asp Leu Gly Val Tyr Tyr Cys Gly Gln Gly
85 90 95

Thr Gln Tyr Pro Phe Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys
100 105 110

<210> 79

<211> 121

<212> PRT

<213> Artificial Sequence

<220>

<223> VH of the so-called "5B1-G2" anti-CD3 antibody

<400> 79

Glu Val Gln Val Val Glu Thr Gly Gly Ser Leu Val Gln Pro Gly Lys
1. 5 10 15

Ser Leu Lys Leu Thr Cys Ala Thr Ser Gly Phe Ser Phe Ser Asn Ala
20 25 30

Trp Met His Trp Val Arg Gln Ser Pro Glu Lys Gln Leu Glu Trp Val
35 40 45

Ala Gln Ile Lys Asp Lys Ala Asn Asn Tyr Ala Thr Tyr Tyr Ala Glu
50 55 60

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Gly Ser
65 70 75 80

Ile Tyr Leu Gln Met Asn Ser Leu Lys Glu Glu Asp Thr Ala Val Tyr
85 90 95

Tyr Cys Arg Gly Leu Tyr Tyr Gly Leu Phe Pro Ser Asp Tyr Trp Gly

	100	105	110
Gln Gly Val Met Val Thr Val Ser Ser			
	115	120	
<210>	80		
<211>	8		
<212>	PRT		
<213>	Artificial Sequence		
<220>			
<223>	CDR1-H of the so-called "5B1-G2" anti-CD3 antibody		
<400>	80		
Gly Phe Ser Phe Ser Asn Ala Trp			
1. 5			
<210>	81		
<211>	12		
<212>	PRT		
<213>	Artificial Sequence		
<220>			
<223>	CDR3-H of the so-called "5B1-G2" anti-CD3 antibody		
<400>	81		
Arg Gly Leu Tyr Tyr Gly Leu Phe Pro Ser Asp Tyr			
1. 5		10	
<210>	82		
<211>	112		
<212>	PRT		
<213>	Artificial Sequence		
<220>			
<223>	VL of the so-called "5B1-G2" anti-CD3 antibody		
<400>	82		
Asp Val Val Met Thr Gln Thr Pro Val Ser Leu Ser Val Ser Leu Gly			
1. 5		10	15
Gly Gln Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asn			
	20	25	30
Asn Gly Asn Thr Tyr Leu Ser Trp Tyr Leu Leu Lys Pro Gly Gln Ser			

35

40

45

Pro Gln Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Ile Ser
50 55 60

Asp Arg Phe Ser Gly Gly Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80

Ser Arg Leu Glu Pro Asp Asp Leu Gly Ile Tyr Tyr Cys Gly Gln Gly
85 90 95

Thr Gln Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
100 105 110

<210> 83

<211> 117

<212> PRT

<213> Artificial Sequence

<220>

<223> part of VH of the so-called "16F8-A7" anti-CD3 antibody

<400> 83

Val Glu Thr Gly Gly Asn Leu Val Gln Pro Gly Lys Ser Leu Lys Leu
1. 5 10 15

Thr Cys Ala Thr Ser Gly Phe Thr Phe Ser Asn Ala Trp Met His Trp
20 25 30

Val Arg Gln Ser Pro Glu Lys Gln Leu Glu Trp Val Ala Gln Ile Lys
35 40 45

Ala Lys Ser Asn Asn Tyr Ala Thr Tyr Tyr Ala Glu Ser Val Lys Gly
50 55 60

Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr Leu Gln
65 70 75 80

Met Asn Ser Leu Lys Glu Glu Asp Thr Ala Ile Tyr Tyr Cys Arg Tyr
85 90 95

Val Asn Tyr Gly Leu Ala Pro Met Asp Val Trp Gly Gln Gly Thr Ser

100	105	110
-----	-----	-----

Val Thr Val Ser Ser
115

<210> 84
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CDR3-H of the so-called "16F8-A7" and "11F3-B9" anti-CD3 antibodies

<400> 84

Arg Tyr Val Asn Tyr Gly Leu Ala Pro Met Asp Val
 1. 5 10

<210> 85
 <211> 112
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> VL of the so-called "16F8-A7" anti-CD3 antibody

<400> 85

Asp Val Val Met Thr Gln Thr Pro Val Ser Leu Ser Val Ser Leu Gly
 1. 5 10 15

Gly Gln Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asn
 20 25 30

Asn Gly Asn Thr Tyr Leu Ser Trp Tyr Leu Gln Lys Pro Gly Gln Ser
 35 40 45

Pro Gln Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Phe Ser
 50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
 65 70 75 80

Ser Arg Val Glu Pro Asp Asp Leu Gly Val Tyr Tyr Cys Gly Gln Gly
 85 90 95

Thr Gln Tyr Pro Phe Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys
100 105 110

<210> 86
<211> 171
<212> PRT
<213> Homo sapiens

<400> 86

Met Glu His Ser Thr Phe Leu Ser Gly Leu Val Leu Ala Thr Leu Leu
1. 5 10 15

Ser Gln Val Ser Pro Phe Lys Ile Pro Ile Glu Glu Leu Glu Asp Arg
20 25 30

Val Phe Val Asn Cys Asn Thr Ser Ile Thr Trp Val Glu Gly Thr Val
35 40 45

Gly Thr Leu Leu Ser Asp Ile Thr Arg Leu Asp Leu Gly Lys Arg Ile
50 55 60

Leu Asp Pro Arg Gly Ile Tyr Arg Cys Asn Gly Thr Asp Ile Tyr Lys
65 70 75 80

Asp Lys Glu Ser Thr Val Gln Val His Tyr Arg Met Cys Gln Ser Cys
85 90 95

Val Glu Leu Asp Pro Ala Thr Val Ala Gly Ile Ile Val Thr Asp Val
100 105 110

Ile Ala Thr Leu Leu Leu Ala Leu Gly Val Phe Cys Phe Ala Gly His
115 120 125

Glu Thr Gly Arg Leu Ser Gly Ala Ala Asp Thr Gln Ala Leu Leu Arg
130 135 140

Asn Asp Gln Val Tyr Gln Pro Leu Arg Asp Arg Asp Ala Gln Tyr
145 150 155 160

Ser His Leu Gly Gly Asn Trp Ala Arg Asn Lys

165

170

<210> 87
 <211> 112
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> VL of the so-called "11F9-F8" anti-CD3 antibody

<400> 87

Asp Val Val Leu Thr Gln Thr Pro Val Ser Leu Ser Val Ser Leu Gly
 1. 5 10 15

Gly Gln Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asn
 20 25 30

Asn Gly Asn Thr Tyr Leu Ser Trp Ser Leu Gln Lys Pro Gly Gln Ser
 35 40 45

Pro Gln Val Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Ile Ser
 50 55 60

Asn Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
 65 70 75 80

Ser Arg Val Glu Pro Asp Asp Leu Gly Val Tyr Tyr Cys Gly Gln Gly
 85 90 95

Ala His Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
 100 105 110

<210> 88
 <211> 9
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CDR3-L of the so-called "11F9-F8" anti-CD3 antibody

<400> 88

Gly Gln Gly Ala His Tyr Pro Phe Thr
 1. 5

<210> 89
<211> 118
<212> PRT
<213> Artificial Sequence

<220>
<223> VH of the so-called "3G5-E10" anti-CD3 antibody

<400> 89

Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg
1. 5 10 15

Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Asn Phe Asn Val Tyr
20 25 30

Trp Met Gly Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45

Gly Glu Ile Lys Lys Asp Ser Asn Ser Ile Asn Tyr Thr Pro Ser Leu
50 55 60

Lys Glu Lys Phe Thr Ile Ser Arg Asp Asn Ala Gln Asn Thr Leu Tyr
65 70 75 80

Leu Gln Val Asn Lys Leu Gly Ser Glu Asp Thr Ala Ile Tyr Tyr Cys
85 90 95

Ala Arg Glu Glu Arg Asp Gly Tyr Phe Asp Tyr Trp Gly Gln Gly Val
100 105 110

Met Val Thr Val Ser Ser
115

<210> 90
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR1-H of the so-called "3G5-E10" anti-CD3 antibody

<400> 90

Gly Phe Asn Phe Asn Val Tyr Trp

1. 5

<210> 91
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR2-H of the so-called "3G5-E10" anti-CD3 antibody

<400> 91

Ile Lys Lys Asp Ser Asn Ser Ile
1. 5

<210> 92
<211> 107
<212> PRT
<213> Artificial Sequence

<220>
<223> VL of the so-called "3G5-E10" anti-CD3 antibody

<400> 92

Asn Ile Val Met Thr Gln Ser Pro Lys Ser Met Ser Met Ser Val Gly
1. 5 10 15

Glu Arg Val Thr Leu Thr Cys Lys Ala Ser Glu Asn Val Val Thr Tyr
20 25 30

Val Ser Trp Tyr Gln Gln Lys Pro Glu Gln Ser Pro Lys Leu Leu Ile
35 40 45

Tyr Gly Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly
50 55 60

Ser Gly Ser Ala Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Ala
65 70 75 80

Glu Asp Leu Ala Asp Tyr His Cys Gly Gln Gly Tyr Ser Tyr Pro Tyr
85 90 95

Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105

<210> 93
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR1-L of the so-called "3G5-E10" anti-CD3 antibody

<400> 93

Glu Asn Val Val Thr Tyr
1. 5

<210> 94
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR3-L of the so-called "3G5-E10" anti-CD3 antibody

<400> 94

Gly Gln Gly Tyr Ser Tyr Pro Tyr Thr
1. 5

<210> 95
<211> 119
<212> PRT
<213> Artificial Sequence

<220>
<223> VH of the so-called "9D7-F3" anti-CD3 antibody

<400> 95

Ala Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Lys Glu
1. 5 10 15

Ser Leu Lys Ile Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Ala
20 25 30

Ala Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ala Arg Ile Arg Thr Lys Pro Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp
50 55 60

Ser Val Thr Gly Arg Phe Ile Ile Ser Arg Asp Asp Ser Arg Ser Met
65 70 75 80

Val Tyr Leu Gln Met Asp Asn Leu Gln Thr Glu Asp Thr Ala Met Tyr
85 90 95

Tyr Cys Thr Ala Leu Ile Ser Thr Ala Met Ala Ala Trp Gly Gln Gly
100 105 110

Thr Ser Val Thr Val Ser Ser
115

<210> 96
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR1-H of the so-called "9D7-F3" anti-CD3 antibody

<400> 96

Gly Phe Thr Phe Ser Asn Ala Ala
1. 5

<210> 97
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR2-H of the so-called "9D7-F3" anti-CD3 antibody

<400> 97

Ile Arg Thr Lys Pro Asn Asn Tyr Ala Thr
1. 5 10

<210> 98
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR3-H of the so-called "9D7-F3" anti-CD3 antibody

<400> 98

Thr Ala Leu Ile Ser Thr Ala Met Ala Ala
1. 5 10

<210> 99
<211> 106
<212> PRT
<213> Artificial Sequence

<220>
<223> VL of the so-called "9D7-F3" anti-CD3 antibody

<400> 99

Asp Ile Gln Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly
1. 5 10 15

Asp Arg Val Thr Ile Asn Cys Lys Ala Ser Gln Asn Ile Asn Lys Tyr
20 25 30

Leu Asn Trp Tyr His Gln Met Leu Gly Glu Ala Pro Lys Leu Val Ile
35 40 45

Ser Asn Thr Asn Asn Leu Gln Ala Gly Ile Pro Ser Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80

Glu Asp Val Ala Thr Tyr Phe Cys Leu Gln His Arg Ser Gly Tyr Thr
85 90 95

Phe Gly Leu Gly Thr Lys Leu Glu Leu Lys
100 105

<210> 100
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR1-L of the so-called "9D7-F3" and "6C9-C9" anti-CD3 antibody

<400> 100

Gln Asn Ile Asn Lys Tyr

1. 5

<210> 101
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR3-L of the so-called "9D7-F3" anti-CD3 antibody

<400> 101

Leu Gln His Arg Ser Gly Tyr Thr
1. 5

<210> 102
<211> 114
<212> PRT
<213> Artificial Sequence

<220>
<223> VH of the so-called "8C2-F7" anti-CD3 antibody

<400> 102

Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu
1. 5 10 15

Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Phe
20 25 30

Ala Met Asn Trp Val Lys Gln Ala Pro Gly Asn Gly Leu Lys Trp Met
35 40 45

Gly Trp Ile Asn Thr Gln Thr Gly Lys Pro Thr Tyr Ala Asp Gly Phe
50 55 60

Lys Gln Arg Phe Val Phe Ser Leu Glu Thr Ser Ala Ser Thr Ile Tyr
65 70 75 80

Leu Gln Ile Asn Asn Leu Asn Ile Glu Asp Thr Ala Thr Tyr Phe Cys
85 90 95

Thr Arg Gly Ala Leu Ala Ser Val Gly Gln Gly Val Leu Val Thr Val
100 105 110

Ser Ser

<210> 103
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR1-H of the so-called "8C2-F7" anti-CD3 antibody

<400> 103

Gly Tyr Thr Phe Thr Asp Phe Ala
1. 5

<210> 104
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR2-H of the so-called "8C2-F7" anti-CD3 antibody

<400> 104

Ile Asn Thr Gln Thr Gly Lys Pro
1. 5

<210> 105
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR3-H of the so-called "8C2-F7" anti-CD3 antibody

<400> 105

Thr Arg Gly Ala Leu Ala Ser
1. 5

<210> 106
<211> 112
<212> PRT
<213> Artificial Sequence

<220>
<223> VL of the so-called "8C2-F7" anti-CD3 antibody

<400> 106

Asp Val Val Met Thr Gln Thr Pro Val Ser Leu Ser Val Ser Leu Gly
1. 5 10 15

Ser His Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asn
20 25 30

Asn Gly Asn Thr Tyr Leu Ser Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45

Pro Gln Pro Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Ile Ser
50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Glu Ile
65 70 75 80

Asn Arg Val Glu Pro Asp Asp Leu Gly Val Tyr Tyr Cys Gly Gln Gly
85 90 95

Ala Gln Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
100 105 110

<210> 107

<211> 124

<212> PRT

<213> Artificial Sequence

<220>

<223> VH of the so-called "20E5-F10" anti-CD3 antibody

<400> 107

Glu Val Gln Leu Val Glu Thr Gly Glu Asn Leu Val Gln Pro Gly Lys
1. 5 10 15

Ser Leu Arg Leu Thr Cys Ala Thr Ser Gly Phe Ser Phe Ser Asn Ala
20 25 30

Trp Met His Trp Ile Arg Gln Ser Pro Glu Lys Gln Leu Glu Trp Val
35 40 45

Ala Gln Ile Lys Asp Lys Ser Asn Asn Tyr Ala Thr Tyr Tyr Ala Glu

50

55

60

Ser Val Asn Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser
65 70 75 80

Ile Tyr Leu His Met Asp Asn Leu Lys Glu Glu Asp Ser Ala Ile Tyr
85 90 95

Tyr Cys Arg Tyr Val His Tyr Gly Val Arg Phe Phe Tyr Thr Met Asp
100 105 110

Val Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser
115 120

<210> 108

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> CDR3-H of the so-called "20E5-F10" anti-CD3 antibody

<400> 108

Arg Tyr Val His Tyr Gly Val Arg Phe Phe Tyr Thr Met Asp Val
1. 5 10 15

<210> 109

<211> 112

<212> PRT

<213> Artificial Sequence

<220>

<223> VL of the so-called "20E5-F10" anti-CD3 antibody

<400> 109

Asp Val Val Met Thr Gln Thr Pro Val Ser Leu Ser Val Ser Leu Gly
1. 5 10 15

Asp Gln Val Ser Ile Ser Cys Arg Pro Ser Gln Ser Leu Val His Asn
20 25 30

Asn Gly Asn Thr Tyr Leu Ser Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45

Pro His Pro Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Ile Ser
50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80

Ser Arg Val Glu Pro Asp Asp Leu Gly Val Tyr Tyr Cys Gly Gln Gly
85 90 95

Thr Gln Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
100 105 110

<210> 110

<211> 121

<212> PRT

<213> Artificial Sequence

<220>

<223> VH of the so-called "20B5-F10" anti-CD3 antibody

<400> 110

Glu Val Gln Leu Val Glu Thr Gly Gly Ser Leu Val Gln Pro Gly Lys
1. 5 10 15

Ser Leu Lys Leu Thr Cys Ala Thr Ser Gly Phe Thr Phe Ser Asn Ala
20 25 30

Trp Met His Trp Val Arg Gln Ser Pro Glu Lys Gln Leu Glu Trp Val
35 40 45

Ala Gln Ile Lys Ala Lys Ser Asn Asn Tyr Ala Thr Tyr Tyr Ala Glu
50 55 60

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Ile Ser Ser
65 70 75 80

Val Tyr Leu Gln Met Asn Asn Leu Lys Glu Glu Asp Thr Ala Ile Tyr
85 90 95

Tyr Cys Arg Gly Val Tyr Tyr Gly Phe Leu Gly Met Asp Ala Trp Gly
100 105 110

Gln Gly Thr Ser Val Thr Val Ser Ser
115 120

<210> 111

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> CDR3-H of the so-called "20B5-F10" anti-CD3 antibody

<400> 111

Arg Gly Val Tyr Tyr Gly Phe Leu Gly Met Asp Ala
1. 5 10

<210> 112

<211> 112

<212> PRT

<213> Artificial Sequence

<220>

<223> VL of the so-called "20B5-F10" anti-CD3 antibody

<400> 112

Asp Val Val Met Thr Gln Thr Pro Val Ser Leu Ser Val Ser Leu Gly
1. 5 10 15

Gly Gln Val Ser Ile Ser Cys Arg Ser Ser Gln Arg Leu Val His Asn
20 25 30

Asn Gly Asn Thr Tyr Leu Ser Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45

Pro Gln Leu Leu Val Tyr Lys Val Ser Asn Arg Phe Ser Gly Ile Ser
50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80

Ser Arg Val Glu Pro Asp Asp Leu Gly Val Tyr Tyr Cys Gly Gln Gly
85 90 95

Thr Glu Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys

100

105

110

<210> 113

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> CDR1-L of the so-called "20B5-F10" anti-CD3 antibody

<400> 113

Gln Arg Leu Val His Asn Asn Gly Asn Thr Tyr

1. 5 10

<210> 114

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> CDR3-L of the so-called "20B5-F10" anti-CD3 antibody

<400> 114

Gly Gln Gly Thr Glu Tyr Pro Phe Thr

1. 5

<210> 115

<211> 119

<212> PRT

<213> Artificial Sequence

<220>

<223> VH of the so-called "6C9-C9" anti-CD3 antibody

<400> 115

Ala Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Arg Pro Lys Glu

1. 5 10 15

Ser Leu Lys Ile Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Asn Ala

20 25 30

Ala Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ala Arg Ile Arg Thr Gln Pro Asn Asn Tyr Ala Lys Tyr Tyr Ala Asp

50

55

60

Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Met
65 70 75 80

Val Tyr Leu Gln Met Asp Asn Leu Lys Thr Glu Asp Thr Ala Met Tyr
85 90 95

Tyr Cys Thr Gly Leu Val Val Thr Ala Met Asp Ala Trp Gly Gln Gly
100 105 110

Thr Ser Val Thr Val Ser Ser
115

<210> 116

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> CDR1-H of the so-called "6C9-C9" anti-CD3 antibody

<400> 116

Gly Phe Thr Phe Arg Asn Ala Ala
1. 5

<210> 117

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> CDR2-H of the so-called "6C9-C9" anti-CD3 antibody

<400> 117

Ile Arg Thr Gln Pro Asn Asn Tyr Ala Lys
1. 5 10

<210> 118

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> CDR3-H of the so-called "6C9-C9" anti-CD3 antibody

<400> 118

Thr Gly Leu Val Val Thr Ala Met Asp Ala
1. 5 10

<210> 119

<211> 106

<212> PRT

<213> Artificial Sequence

<220>

<223> VL of the so-called "6C9-C9" anti-CD3 antibody

<400> 119

Asp Ile Gln Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly
1. 5 10 15

Asp Arg Val Thr Ile Asn Cys Lys Ala Ser Gln Asn Ile Asn Lys Tyr
20 25 30

Leu Asn Trp Tyr Gln Gln Lys Leu Gly Glu Ala Pro Lys Leu Leu Ile
35 40 45

Tyr Val Thr Asn Asn Leu Gln Thr Gly Ile Pro Ser Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80

Glu Asp Val Ala Thr Tyr Phe Cys Leu Gln His Arg Ser Met Tyr Thr
85 90 95

Phe Gly Thr Gly Thr Lys Leu Glu Leu Lys
100 105

<210> 120

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> CDR3-L of the so-called "6C9-C9" anti-CD3 antibody

<400> 120

Leu Gln His Arg Ser Met Tyr Thr
1. 5

<210> 121
<211> 118
<212> PRT
<213> Artificial Sequence

<220>
<223> VH the so-called "3E8-G1" anti-CD3 antibody

<400> 121

Glu Val Gln Val Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg
1. 5 10 15

Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr
20 25 30

Tyr Met Asp Trp Val Arg Gln Ala Pro Lys Lys Gly Leu Glu Trp Val
35 40 45

Ala Thr Ile Thr Ala Ser Gly Ser Arg Ile Tyr Tyr Pro Asp Ser Val
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Ser Ser Leu Tyr
65 70 75 80

Leu Leu Met Asn Ser Leu Lys Ser Glu Asp Thr Ala Thr Tyr Tyr Cys
85 90 95

Ala Arg Glu Arg Thr Asp Ala Tyr Phe Asp Tyr Trp Gly Gln Gly Val
100 105 110

Met Val Thr Val Ser Ser
115

<210> 122
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR1-H of the so-called "3E8-G1" anti-CD3 antibody

<400> 122

Gly Phe Thr Phe Ser Asn Tyr Tyr
1. 5

<210> 123

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> CDR2-H of the so-called "3E8-G1" anti-CD3 antibody

<400> 123

Ile Thr Ala Ser Gly Ser Arg Ile
1. 5

<210> 124

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> CDR3-H of the so-called "3E8-G1" anti-CD3 antibody

<400> 124

Ala Arg Glu Arg Thr Asp Ala Tyr Phe Asp Tyr
1. 5 10

<210> 125

<211> 111

<212> PRT

<213> Artificial Sequence

<220>

<223> VL of the so-called "3E8-G1" anti-CD3 antibody

<400> 125

Gln Phe Ile Leu Thr Gln Pro Asn Ser Val Ser Thr Ile Leu Gly Ser
1. 5 10 15

Thr Val Lys Leu Ser Cys Lys Arg Ser Thr Gly Asn Ile Gly Thr Asn
20 25 30

Tyr Val Ser Trp Tyr Gln His His Glu Gly Arg Ser Pro Thr Thr Met

35

40

45

Ile Tyr Arg Asp Asp Lys Arg Pro Asp Gly Val Pro Asp Arg Phe Ser
 50 55 60

Gly Ser Ile Asp Arg Ser Ser Asn Ser Ala Leu Leu Thr Ile Asn Asn
 65 70 75 80

Val Gln Thr Glu Asp Glu Ala Asp Tyr Phe Cys Gln Ser Tyr Ile Ser
 85 90 95

Gly Leu Asn Pro Val Phe Gly Gly Gly Ser Lys Leu Thr Val Leu
 100 105 110

<210> 126

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> CDR1-L of the so-called "3E8-G1" anti-CD3 antibody

<400> 126

Thr Gly Asn Ile Gly Thr Asn Tyr
 1. 5

<210> 127

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> CDR3-L of the so-called "3E8-G1" anti-CD3 antibody

<400> 127

Gln Ser Tyr Ile Ser Gly Leu Asn Pro Val
 1. 5 10

<210> 128

<211> 124

<212> PRT

<213> Artificial Sequence

<220>

<223> VH of the so-called "3H6-D2" anti-CD3 antibody.

<400> 128

Glu Val Gln Leu Val Glu Thr Gly Gly Arg Leu Val Gln Pro Gly Lys
1. 5 10 15

Ser Leu Lys Leu Thr Cys Ala Thr Ser Gly Phe Thr Phe Ser Asn Ala
20 25 30

Trp Met His Trp Val Arg Gln Ser Pro Glu Lys Gln Leu Glu Trp Val
35 40 45

Ala Gln Ile Lys Asp Lys Ser Asn Asn Tyr Ala Thr Tyr Tyr Ala Glu
50 55 60

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ile
65 70 75 80

Ile Tyr Leu Gln Met Asn Ser Leu Lys Glu Glu Asp Thr Ala Ile Tyr
85 90 95

Tyr Cys Arg Ala Leu Thr Tyr Tyr Gly Tyr Lys Arg Asp Ala Met Asp
100 105 110

Gly Trp Gly His Gly Thr Ser Val Thr Val Ser Ser
115 120

<210> 129

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> CDR3-H of the so-called "3H6-D2" anti-CD3 antibody

<400> 129

Arg Ala Leu Thr Tyr Tyr Gly Tyr Lys Arg Asp Ala Met Asp Gly
1. 5 10 15

<210> 130

<211> 112

<212> PRT

<213> Artificial Sequence

<220>

<223> VL of the so-called "3H6-D2" anti-CD3 antibody.

<400> 130

Asp Val Val Met Thr Gln Thr Pro Val Ser Leu Ser Val Ser Leu Gly
1. 5 10 15

Gly Gln Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asn
20 25 30

Asn Gly Asn Thr Tyr Leu Ser Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45

Pro Gln Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Ile Ser
50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80

Ser Arg Val Glu Pro Asp Asp Leu Gly Val Tyr Tyr Cys Gly Gln Gly
85 90 95

Thr Gln Tyr Pro Phe Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys
100 105 110

<210> 131

<211> 114

<212> PRT

<213> Artificial Sequence

<220>

<223> VH of the so-called "8H2" anti-CD3 antibody

<400> 131

Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu
1. 5 10 15

Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Phe
20 25 30

Ala Met Asn Trp Val Lys Gln Ala Pro Gly Asn Gly Leu Lys Trp Met
35 40 45

Gly Trp Ile Asn Thr Gln Thr Gly Lys Pro Thr Tyr Ala Asp Gly Phe
50 55 60

Lys Gln Arg Phe Val Phe Ser Leu Glu Thr Ser Ala Ser Thr Ile Tyr
65 70 75 80

Leu Gln Ile Asn Asn Leu Asn Ile Glu Asp Thr Ala Thr Tyr Phe Cys
85 90 95

Thr Arg Gly Ala Leu Ala Ser Val Gly Gln Gly Val Met Val Thr Val
100 105 110

Ser Ser

<210> 132

<211> 112

<212> PRT

<213> Artificial Sequence

<220>

<223> VL of the so-called "8H2" anti-CD3 antibody

<400> 132

Asp Val Val Met Thr Gln Thr Pro Val Ser Leu Ser Val Ala Ile Gly
1. 5 10 15

Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Val Gly Thr
20 25 30

Ser Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Arg Pro Gly Gln Ser
35 40 45

Pro Lys Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp Ser Gly Ile Pro
50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Glu Thr Asp Phe Thr Leu Lys Ile
65 70 75 80

Ser Arg Val Glu Thr Asp Asp Leu Gly Val Tyr Tyr Cys Leu Gln Gly
85 90 95

Ser His Phe Pro Leu Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
100 105 110

<210> 133

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> CDR1-L of the so-called "8H2" anti-CD3 antibody

<400> 133

Gln Ser Leu Val Gly Thr Ser Gly Lys Thr Tyr
1. 5 10

<210> 134

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> CDR3-L of the so-called "8H2" anti-CD3 antibody

<400> 134

Leu Gln Gly Ser His Phe Pro Leu Thr
1. 5

<210> 135

<211> 121

<212> PRT

<213> Artificial Sequence

<220>

<223> VH1a of humanized "20G6" anti-CD3 antibody

<400> 135

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1. 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Thr Lys Ala
20 25 30

Trp Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ala Gln Ile Lys Asp Lys Ser Asn Ser Tyr Ala Thr Tyr Tyr Ala Asp
50 55 60

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr
65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr
85 90 95

Tyr Cys Arg Gly Val Tyr Tyr Ala Leu Ser Pro Phe Asp Tyr Trp Gly
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 136

<211> 121

<212> PRT

<213> Artificial Sequence

<220>

<223> VH1b of humanized "20G6" anti-CD3 antibody.

<400> 136

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1. 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Thr Lys Ala
20 25 30

Trp Met His Trp Val Arg Gln Ala Pro Gly Lys Gln Leu Glu Trp Val
35 40 45

Ala Gln Ile Lys Asp Lys Ser Asn Ser Tyr Ala Thr Tyr Tyr Ala Asp
50 55 60

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr
65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr
85 90 95

Tyr Cys Arg Gly Val Tyr Tyr Ala Leu Ser Pro Phe Asp Tyr Trp Gly
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 137

<211> 121

<212> PRT

<213> Artificial Sequence

<220>

<223> VH1c of humanized "20G6" anti-CD3 antibody.

<400> 137

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1. 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Thr Lys Ala
20 25 30

Trp Met His Trp Val Arg Gln Ala Pro Gly Lys Gln Leu Glu Trp Val
35 40 45

Ala Gln Ile Lys Asp Lys Ser Asn Ser Tyr Ala Thr Tyr Tyr Ala Ala
50 55 60

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr
65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr
85 90 95

Tyr Cys Arg Gly Val Tyr Tyr Ala Leu Ser Pro Phe Asp Tyr Trp Gly
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 138

<211> 121

<212> PRT

<213> Artificial Sequence

<220>

<223> VH1d of humanized "20G6" anti-CD3 antibody

<400> 138

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1. 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Thr Lys Ala
20 25 30

Trp Met His Trp Val Arg Gln Ala Pro Gly Lys Gln Leu Glu Trp Val
35 40 45

Ala Gln Ile Lys Asp Lys Ser Asn Ser Tyr Ala Thr Tyr Tyr Ala Asp
50 55 60

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr
65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr
85 90 95

Tyr Cys Arg Gly Val Tyr Tyr Ala Leu Ser Pro Phe Asp Tyr Trp Gly
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 139

<211> 112

<212> PRT

<213> Artificial Sequence

<220>

<223> VL1a of humanized "20G6" anti-CD3 antibody

<400> 139

Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Ser Val Thr Pro Gly
1. 5 10 15

Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Val His Asn

	20		25		30										
Asn	Gly	Asn	Thr	Tyr	Leu	Ser	Trp	Tyr	Leu	Gln	Lys	Pro	Gly	Gln	Ser
	35					40					45				
Pro	Gln	Leu	Leu	Ile	Tyr	Lys	Val	Ser	Asn	Arg	Phe	Ser	Gly	Val	Pro
	50					55					60				
Asp	Arg	Phe	Ser	Gly	Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Lys	Ile
65					70					75				80	
Ser	Arg	Val	Glu	Ala	Glu	Asp	Val	Gly	Val	Tyr	Tyr	Cys	Gly	Gln	Gly
				85					90					95	
Thr	Gln	Tyr	Pro	Phe	Thr	Phe	Gly	Gln	Gly	Thr	Lys	Leu	Glu	Ile	Lys
			100					105						110	

<210> 140
 <211> 112
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> VL1b of humanized "20G6" anti-CD3 antibody

 <400> 140

Asp	Ile	Val	Met	Thr	Gln	Thr	Pro	Leu	Ser	Leu	Ser	Val	Thr	Pro	Gly
1.	5					10					15				
Gln	Pro	Ala	Ser	Ile	Ser	Cys	Lys	Ser	Ser	Gln	Ser	Leu	Val	His	Asn
			20					25					30		
Asn	Gly	Asn	Thr	Tyr	Leu	Ser	Trp	Tyr	Leu	Gln	Lys	Pro	Gly	Gln	Ser
	35						40					45			
Pro	Gln	Leu	Leu	Ile	Tyr	Lys	Val	Ser	Asn	Arg	Phe	Ser	Gly	Val	Pro
	50					55					60				
Asp	Arg	Phe	Ser	Gly	Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Lys	Ile
65					70					75				80	
Ser	Arg	Val	Glu	Ala	Glu	Asp	Val	Gly	Val	Tyr	Tyr	Cys	Gly	Gln	Gly

85

90

95

Thr Gln Tyr Pro Phe Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
 100 105 110

<210> 141

<211> 112

<212> PRT

<213> Artificial Sequence

<220>

<223> VL1c of humanized "20G6" anti-CD3 antibody.

<400> 141

Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Ser Val Thr Pro Gly
 1. 5 10 15

Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Val His Asn
 20 25 30

Asn Ala Asn Thr Tyr Leu Ser Trp Tyr Leu Gln Lys Pro Gly Gln Ser
 35 40 45

Pro Gln Ser Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
 50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
 65 70 75 80

Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gly Gln Gly
 85 90 95

Thr Gln Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Val Glu Ile Lys
 100 105 110

<210> 142

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> CDR1-L of the VL1c variant of the humanized "20G6" anti-CD3 antibody.

<400> 142

Gln Ser Leu Val His Asn Asn Ala Asn Thr Tyr
1. 5 10

<210> 143

<211> 112

<212> PRT

<213> Artificial Sequence

<220>

<223> VL1d of humanized "20G6" anti-CD3 antibody

<400> 143

Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Ser Val Thr Pro Gly
1. 5 10 15

Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Val His Asn
20 25 30

Asn Gly Asn Thr Tyr Leu Ser Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45

Pro Gln Ser Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80

Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gly Gln Gly
85 90 95

Thr Gln Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Val Glu Ile Lys
100 105 110

<210> 144

<211> 121

<212> PRT

<213> Artificial Sequence

<220>

<223> VH2a of humanized "20G6" anti-CD3 antibody

<400> 144

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1. 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Thr Lys Ala
20 25 30

Trp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ser Gln Ile Lys Asp Lys Ser Asn Ser Tyr Ala Thr Tyr Tyr Ala Asp
50 55 60

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser
65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Arg Asp Glu Asp Thr Ala Val Tyr
85 90 95

Tyr Cys Arg Gly Val Tyr Tyr Ala Leu Ser Pro Phe Asp Tyr Trp Gly
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 145
<211> 121
<212> PRT
<213> Artificial Sequence

<220>
<223> VH2b of humanized "20G6" anti-CD3 antibody.

<400> 145

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1. 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Thr Lys Ala
20 25 30

Trp Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ser Gln Ile Lys Asp Lys Ser Asn Ser Tyr Ala Thr Tyr Tyr Ala Asp
50 55 60

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser
65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Arg Asp Glu Asp Thr Ala Val Tyr
85 90 95

Tyr Cys Arg Gly Val Tyr Tyr Ala Leu Ser Pro Phe Asp Tyr Trp Gly
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 146

<211> 121

<212> PRT

<213> Artificial Sequence

<220>

<223> VH2c of humanized "20G6" anti-CD3 antibody

<400> 146

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1. 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Thr Lys Ala
20 25 30

Trp Met His Trp Val Arg Gln Ala Pro Gly Lys Gln Leu Glu Trp Val
35 40 45

Ser Gln Ile Lys Asp Lys Ser Asn Ser Tyr Ala Thr Tyr Tyr Ala Ala
50 55 60

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ala Lys Asn Ser
65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Arg Asp Glu Asp Thr Ala Val Tyr
85 90 95

Tyr Cys Arg Gly Val Tyr Tyr Ala Leu Ser Pro Phe Asp Tyr Trp Gly
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 147

<211> 121

<212> PRT

<213> Artificial Sequence

<220>

<223> VH2d of humanized "20G6" anti-CD3 antibody

<400> 147

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1. 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Thr Lys Ala
20 25 30

Trp Met His Trp Val Arg Gln Ala Pro Gly Lys Gln Leu Glu Trp Val
35 40 45

Ser Gln Ile Lys Asp Lys Ser Asn Ser Tyr Ala Thr Tyr Tyr Ala Asp
50 55 60

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ala Lys Asn Ser
65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Arg Asp Glu Asp Thr Ala Val Tyr
85 90 95

Tyr Cys Arg Gly Val Tyr Tyr Ala Leu Ser Pro Phe Asp Tyr Trp Gly
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 148

<211> 112

<212> PRT

<213> Artificial Sequence

<220>

<223> VL2a of humanized "20G6" anti-CD3 antibody

<400> 148

Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
1. 5 10 15

Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asn
20 25 30

Asn Gly Asn Thr Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45

Pro Gln Leu Leu Ile Tyr Lys Val Ser Asn Arg Ala Ser Gly Val Pro
50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80

Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gly Gln Gly
85 90 95

Thr Gln Tyr Pro Phe Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105 110

<210> 149

<211> 112

<212> PRT

<213> Artificial Sequence

<220>

<223> VL2b of humanized "20G6" anti-CD3 antibody

<400> 149

Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
1. 5 10 15

Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asn
20 25 30

Asn Gly Asn Thr Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45

Pro Gln Leu Leu Ile Tyr Lys Val Ser Asn Arg Ala Ser Gly Val Pro
50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80

Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gly Gln Gly
85 90 95

Thr Gln Tyr Pro Phe Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105 110

<210> 150

<211> 112

<212> PRT

<213> Artificial Sequence

<220>

<223> VL2c of humanized "20G6" anti-CD3 antibody

<400> 150

Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
1. 5 10 15

Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asn
20 25 30

Asn Gly Asn Thr Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45

Pro Gln Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80

Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gly Gln Gly
85 90 95

Thr Gln Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Val Glu Ile Lys
100 105 110

<210> 151
<211> 112
<212> PRT
<213> Artificial Sequence

<220>
<223> VL2d of humanized "20G6" anti-CD3 antibody

<400> 151

Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
1. 5 10 15

Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asn
20 25 30

Asn Gly Asn Thr Tyr Leu Ser Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45

Pro Gln Ser Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80

Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gly Gln Gly
85 90 95

Thr Gln Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Val Glu Ile Lys
100 105 110

<210> 152
<211> 121
<212> PRT
<213> Artificial Sequence

<220>
<223> VH3a of humanized "20G6" anti-CD3 antibody

<400> 152

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1. 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Thr Phe Thr Lys Ala
20 25 30

Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45

Gly Gln Ile Lys Asp Lys Ser Asn Ser Tyr Ala Thr Tyr Tyr Ala Gln
50 55 60

Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr
65 70 75 80

Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr
85 90 95

Tyr Cys Arg Gly Val Tyr Tyr Ala Leu Ser Pro Phe Asp Tyr Trp Gly
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 153

<211> 121

<212> PRT

<213> Artificial Sequence

<220>

<223> VH3b of humanized "20G6" anti-CD3 antibody

<400> 153

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1. 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Thr Phe Thr Lys Ala
20 25 30

Trp Met His Trp Val Arg Gln Ala Pro Gly Lys Gln Leu Glu Trp Met
35 40 45

Gly Gln Ile Lys Asp Lys Ser Asn Ser Tyr Ala Thr Tyr Tyr Ala Gln
50 55 60

Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr
65 70 75 80

Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr
85 90 95

Tyr Cys Arg Gly Val Tyr Tyr Ala Leu Ser Pro Phe Asp Tyr Trp Gly
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 154

<211> 112

<212> PRT

<213> Artificial Sequence

<220>

<223> VL3a of humanized "20G6" anti-CD3 antibody

<400> 154

Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
1. 5 10 15

Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Leu Val His Asn
20 25 30

Asn Gly Asn Thr Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser
35 40 45

Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Glu Ser Gly Val Pro
50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile
65 70 75 80

Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gly Gln Gly
85 90 95

Thr Gln Tyr Pro Phe Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105 110

<210> 155
<211> 112
<212> PRT
<213> Artificial Sequence

<220>
<223> VL3b of humanized "20G6" anti-CD3 antibody

<400> 155

Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
1. 5 10 15

Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Leu Val His Asn
20 25 30

Asn Gly Asn Thr Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser
35 40 45

Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Glu Ser Gly Val Pro
50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile
65 70 75 80

Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gly Gln Gly
85 90 95

Thr Gln Tyr Pro Phe Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105 110

<210> 156
<211> 112
<212> PRT
<213> Artificial Sequence

<220>
<223> VL3c of humanized "20G6" anti-CD3 antibody

<400> 156

Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ala Val Ser Leu Gly
1. 5 10 15

Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Leu Val His Asn
20 25 30

Asn Gly Asn Thr Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser
35 40 45

Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile
65 70 75 80

Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gly Gln Gly
85 90 95

Thr Gln Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Val Glu Ile Lys
100 105 110

<210> 157

<211> 112

<212> PRT

<213> Artificial Sequence

<220>

<223> VL3d of humanized "20G6" anti-CD3 antibody

<400> 157

Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
1. 5 10 15

Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Leu Val His Asn
20 25 30

Asn Gly Asn Thr Tyr Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser
35 40 45

Pro Lys Ser Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile
65 70 75 80

Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gly Gln Gly
85 90 95

Thr Gln Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Val Glu Ile Lys
100 105 110

<210> 158

<211> 112

<212> PRT

<213> Artificial Sequence

<220>

<223> VL1A of humanized "4B4" anti-CD3 antibody

<400> 158

Asp Val Val Met Thr Gln Thr Pro Val Ser Leu Ser Val Ser Val Gly
1. 5 10 15

Gly Arg Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asp
20 25 30

Asn Gly Asn Thr Tyr Leu Ser Trp Ser Leu Gln Lys Pro Gly Lys Ser
35 40 45

Pro Lys Val Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Ser
50 55 60

Ser Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80

Ser Ser Val Gln Pro Asp Asp Leu Gly Val Tyr Tyr Cys Gly Gln Gly
85 90 95

Thr Gln Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
100 105 110

<210> 159

<211> 112

<212> PRT

<213> Artificial Sequence

<220>

<223> VL1B of humanized "4B4" anti-CD3 antibody.

<400> 159

Asp Val Val Met Thr Gln Thr Pro Val Ser Leu Ser Val Ser Val Gly
1. 5 10 15

Gly Arg Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asp
20 25 30

Asn Ala Asn Thr Tyr Leu Ser Trp Ser Leu Gln Lys Pro Gly Lys Ser
35 40 45

Pro Lys Val Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Ser
50 55 60

Ser Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80

Ser Ser Val Gln Pro Asp Asp Leu Gly Val Tyr Tyr Cys Gly Gln Gly
85 90 95

Thr Gln Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
100 105 110

<210> 160

<211> 112

<212> PRT

<213> Artificial Sequence

<220>

<223> VL2A of humanized "4B4" anti-CD3 antibody

<400> 160

Asp Val Val Met Thr Gln Thr Pro Val Ser Leu Ser Val Ser Pro Gly
1. 5 10 15

Gly Pro Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asp
20 25 30

Asn Gly Asn Thr Tyr Leu Ser Trp Ser Leu Gln Lys Pro Gly Gln Ser
35 40 45

Pro Gln Val Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Ser
50 55 60

Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80

Ser Arg Val Glu Pro Asp Asp Leu Gly Val Tyr Tyr Cys Gly Gln Gly
85 90 95

Thr Gln Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
100 105 110

<210> 161

<211> 112

<212> PRT

<213> Artificial Sequence

<220>

<223> VL2B of humanized "4B4" anti-CD3 antibody

<400> 161

Asp Val Val Met Thr Gln Thr Pro Val Ser Leu Ser Val Ser Pro Gly
1. 5 10 15

Gly Pro Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asp
20 25 30

Asn Ala Asn Thr Tyr Leu Ser Trp Ser Leu Gln Lys Pro Gly Gln Ser
35 40 45

Pro Gln Val Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Ser
50 55 60

Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80

Ser Arg Val Glu Pro Asp Asp Leu Gly Val Tyr Tyr Cys Gly Gln Gly
85 90 95

Thr Gln Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
100 105 110

<210> 162

<211> 112

<212> PRT

<213> Artificial Sequence

<220>

<223> VL1Cmodif1 of humanized "4B4" anti-CD3 antibody

<400> 162

Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly
1. 5 10 15

Gln Pro Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asp
20 25 30

Asn Gly Asn Thr Tyr Leu Ser Trp Ser Leu Gln Arg Pro Gly Gln Ser
35 40 45

Pro Arg Val Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80

Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gly Gln Gly
85 90 95

Thr Gln Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
100 105 110

<210> 163

<211> 112

<212> PRT

<213> Artificial Sequence

<220>

<223> VL1Cmodif2 of humanized "4B4" anti-CD3 antibody

<400> 163

Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Ser Val Thr Leu Gly
1. 5 10 15

Gln Pro Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asp
20 25 30

Asn Gly Asn Thr Tyr Leu Ser Trp Ser Leu Gln Arg Pro Gly Gln Ser
35 40 45

Pro Arg Val Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80

Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gly Gln Gly
85 90 95

Thr Gln Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
100 105 110

<210> 164

<211> 112

<212> PRT

<213> Artificial Sequence

<220>

<223> VL1Cmodif3 of humanized "4B4" anti-CD3 antibody

<400> 164

Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Ser Val Thr Leu Gly
1. 5 10 15

Gln Pro Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asp
20 25 30

Asn Ala Asn Thr Tyr Leu Ser Trp Ser Leu Gln Arg Pro Gly Gln Ser
35 40 45

Pro Arg Val Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80

Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gly Gln Gly
85 90 95

Thr Gln Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
100 105 110

<210> 165
<211> 112
<212> PRT
<213> Artificial Sequence

<220>
<223> VL1Amodif1of humanized "4B4" anti-CD3 antibody

<400> 165

Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly
1. 5 10 15

Gln Pro Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asp
20 25 30

Asn Gly Asn Thr Tyr Leu Asn Trp Phe Leu Gln Arg Pro Gly Gln Ser
35 40 45

Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Arg Asp Ser Gly Val Pro
50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80

Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gly Gln Gly
85 90 95

Thr Gln Tyr Pro Phe Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105 110

<210> 166
<211> 112
<212> PRT
<213> Artificial Sequence

<220>
<223> VL1Amodif2of humanized "4B4" anti-CD3 antibody

<400> 166

Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Ser Val Thr Leu Gly
1. 5 10 15

Gln Pro Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asp
20 25 30

Asn Gly Asn Thr Tyr Leu Asn Trp Phe Leu Gln Arg Pro Gly Gln Ser
35 40 45

Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Arg Asp Ser Gly Val Pro
50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80

Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gly Gln Gly
85 90 95

Thr Gln Tyr Pro Phe Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105 110

<210> 167

<211> 112

<212> PRT

<213> Artificial Sequence

<220>

<223> VL1Amodif3 of humanized "4B4" anti-CD3 antibody

<400> 167

Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Ser Val Thr Leu Gly
1. 5 10 15

Gln Pro Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asp
20 25 30

Asn Gly Asn Thr Tyr Leu Asn Trp Phe Leu Gln Arg Pro Gly Gln Ser
35 40 45

Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Arg Asp Ser Gly Val Pro
50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80

Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gly Gln Gly
85 90 95

Thr Gln Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
100 105 110

<210> 168

<211> 112

<212> PRT

<213> Artificial Sequence

<220>

<223> VL2C of humanized "4B4" anti-CD3 antibody

<400> 168

Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Ser Val Thr Pro Gly
1. 5 10 15

Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Val His Asp
20 25 30

Asn Gly Asn Thr Tyr Leu Ser Trp Ser Leu Gln Lys Pro Gly Gln Ser
35 40 45

Pro Gln Val Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80

Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gly Gln Gly
85 90 95

Thr Gln Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
100 105 110

<210> 169

<211> 112

<212> PRT

<213> Artificial Sequence

<220>

<223> VL2D of humanized "4B4" anti-CD3 antibody

<400> 169

Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Ser Val Thr Pro Gly
1. 5 10 15

Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Val His Asp
20 25 30

Asn Gly Asn Thr Tyr Leu Ser Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45

Pro Gln Ser Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80

Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gly Gln Gly
85 90 95

Thr Gln Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Val Glu Ile Lys
100 105 110

<210> 170

<211> 112

<212> PRT

<213> Artificial Sequence

<220>

<223> VL2F of humanized "4B4" anti-CD3 antibody

<400> 170

Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Ser Val Thr Pro Gly
1. 5 10 15

Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Val His Asp
20 25 30

Asn Ala Asn Thr Tyr Leu Ser Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45

Pro Gln Ser Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80

Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gly Gln Gly
85 90 95

Thr Gln Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Val Glu Ile Lys
100 105 110

<210> 171

<211> 121

<212> PRT

<213> Artificial Sequence

<220>

<223> VH1A of humanized "4B4" anti-CD3 antibody

<400> 171

Gln Val Gln Leu Val Glu Thr Gly Gly Gly Leu Val Lys Pro Gly Gln
1. 5 10 15

Ser Leu Lys Leu Thr Cys Ala Thr Ser Gly Phe Thr Phe Ser Asn Ala
20 25 30

Trp Met His Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val
35 40 45

Ala Gln Ile Lys Ala Arg Ser Asn Asn Tyr Ala Thr Tyr Tyr Ala Glu
50 55 60

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr
65 70 75 80

Ile Tyr Leu Gln Met Asn Ser Leu Thr Pro Glu Asp Thr Ala Ile Tyr
85 90 95

Tyr Cys Arg Gly Thr Tyr Tyr Ala Ser Lys Pro Phe Asp Tyr Trp Gly
100 105 110

Gln Gly Val Met Val Thr Val Ser Ser
115 120

<210> 172
<211> 121
<212> PRT
<213> Artificial Sequence

<220>
<223> VH1B of humanized "4B4" anti-CD3 antibody

<400> 172

Gln Val Gln Leu Val Glu Thr Gly Gly Gly Leu Val Lys Pro Gly Gln
1. 5 10 15

Ser Leu Lys Leu Thr Cys Ala Thr Ser Gly Phe Thr Phe Ser Asn Ala
20 25 30

Trp Met His Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val
35 40 45

Ala Gln Ile Lys Ala Arg Ser Asn Asn Tyr Ala Thr Tyr Tyr Ala Val
50 55 60

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr
65 70 75 80

Ile Tyr Leu Gln Met Asn Ser Leu Thr Pro Glu Asp Thr Ala Ile Tyr
85 90 95

Tyr Cys Arg Gly Thr Tyr Tyr Ala Ser Lys Pro Phe Asp Tyr Trp Gly
100 105 110

Gln Gly Val Met Val Thr Val Ser Ser
115 120

<210> 173
<211> 121
<212> PRT
<213> Artificial Sequence

<220>
<223> VH2A of humanized "4B4" anti-CD3 antibody

<400> 173

Glu Val Gln Leu Val Glu Thr Gly Gly Gly Leu Val Gln Pro Gly Gly
1. 5 10 15

Ser Leu Lys Leu Thr Cys Ala Thr Ser Gly Phe Thr Phe Ser Asn Ala
20 25 30

Trp Met His Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val
35 40 45

Ala Gln Ile Lys Ala Arg Ser Asn Asn Tyr Ala Thr Tyr Tyr Ala Glu
50 55 60

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr
65 70 75 80

Ile Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Ile Tyr
85 90 95

Tyr Cys Arg Gly Thr Tyr Tyr Ala Ser Lys Pro Phe Asp Tyr Trp Gly
100 105 110

Gln Gly Val Met Val Thr Val Ser Ser
115 120

<210> 174

<211> 121

<212> PRT

<213> Artificial Sequence

<220>

<223> VH2B of humanized "4B4" anti-CD3 antibody

<400> 174

Glu Val Gln Leu Val Glu Thr Gly Gly Gly Leu Val Gln Pro Gly Gly
1. 5 10 15

Ser Leu Lys Leu Thr Cys Ala Thr Ser Gly Phe Thr Phe Ser Asn Ala
20 25 30

Trp Met His Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val
35 40 45

Ala Gln Ile Lys Ala Arg Ser Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp
50 55 60

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr
65 70 75 80

Ile Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Ile Tyr
85 90 95

Tyr Cys Arg Gly Thr Tyr Tyr Ala Ser Lys Pro Phe Asp Tyr Trp Gly
100 105 110

Gln Gly Val Met Val Thr Val Ser Ser
115 120

<210> 175

<211> 121

<212> PRT

<213> Artificial Sequence

<220>

<223> VH6Bmodif1 of humanized "4B4" anti-CD3 antibody

<400> 175

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1. 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Ala
20 25 30

Trp Met His Trp Val Arg Gln Ala Pro Gly Lys Gln Leu Glu Trp Val
35 40 45

Ala Gln Ile Lys Ala Arg Ser Asn Asn Tyr Ala Thr Tyr Tyr Ala Glu
50 55 60

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr
65 70 75 80

Ile Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr
85 90 95

Tyr Cys Arg Gly Thr Tyr Tyr Ala Ser Lys Pro Phe Asp Tyr Trp Gly
100 105 110

Gln Gly Thr Thr Val Thr Val Ser Ser
115 120

<210> 176

<211> 121

<212> PRT

<213> Artificial Sequence

<220>

<223> VH6Bmodif2 of humanized "4B4" anti-CD3 antibody

<400> 176

Gln Val Gln Leu Val Glu Ser Gly Gly Arg Val Val Gln Pro Gly Arg
1. 5 10 15

Ser Leu Arg Leu Thr Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Ala
20 25 30

Trp Met His Trp Val Arg Gln Ala Pro Gly Lys Gln Leu Glu Trp Val
35 40 45

Ala Gln Ile Lys Ala Arg Ser Asn Asn Tyr Ala Thr Tyr Tyr Ala Glu
50 55 60

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr
65 70 75 80

Ile Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr
85 90 95

Tyr Cys Arg Gly Thr Tyr Tyr Ala Ser Lys Pro Phe Asp Tyr Trp Gly
100 105 110

Gln Gly Thr Thr Val Thr Val Ser Ser
115 120

<210> 177

<211> 121

<212> PRT

<213> Artificial Sequence

<220>

<223> VH6Amodif1 of humanized "4B4" anti-CD3 antibody

<400> 177

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1. 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Ala
20 25 30

Trp Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ala Gln Ile Lys Ala Arg Ser Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp
50 55 60

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr
65 70 75 80

Ile Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr
85 90 95

Tyr Cys Arg Gly Thr Tyr Tyr Ala Ser Lys Pro Phe Asp Tyr Trp Gly
100 105 110

Gln Gly Thr Thr Val Thr Val Ser Ser
115 120

<210> 178

<211> 121

<212> PRT

<213> Artificial Sequence

<220>

<223> VH6Amodif2 of humanized "4B4" anti-CD3 antibody

<400> 178

Gln Val Gln Leu Val Glu Ser Gly Gly Arg Val Val Gln Pro Gly Arg
1. 5 10 15

Ser Leu Arg Leu Thr Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Ala
20 25 30

Trp Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ala Gln Ile Lys Ala Arg Ser Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp
50 55 60

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr
65 70 75 80

Ile Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr
85 90 95

Tyr Cys Arg Gly Thr Tyr Tyr Ala Ser Lys Pro Phe Asp Tyr Trp Gly
100 105 110

Gln Gly Thr Thr Val Thr Val Ser Ser
115 120

<210> 179

<211> 121

<212> PRT

<213> Artificial Sequence

<220>

<223> VH6Amodif3 of humanized "4B4" anti-CD3 antibody

<400> 179

Gln Val Gln Leu Val Glu Ser Gly Gly Arg Val Val Gln Pro Gly Arg
1. 5 10 15

Ser Leu Arg Leu Thr Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Ala
20 25 30

Trp Met His Trp Val Arg Gln Ala Pro Gly Lys Gln Leu Glu Trp Val
35 40 45

Ala Gln Ile Lys Ala Arg Ser Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp
50 55 60

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr
65 70 75 80

Ile Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr
85 90 95

Tyr Cys Arg Gly Thr Tyr Tyr Ala Ser Lys Pro Phe Asp Tyr Trp Gly
100 105 110

Gln Gly Thr Thr Val Thr Val Ser Ser
115 120

<210> 180

<211> 121

<212> PRT

<213> Artificial Sequence

<220>

<223> VH6C of humanized "4B4" anti-CD3 antibody

<400> 180

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1. 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Ala
20 25 30

Trp Met His Trp Val Arg Gln Ala Pro Gly Lys Gln Leu Glu Trp Val
35 40 45

Ala Gln Ile Lys Ala Arg Ser Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp
50 55 60

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr
65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr
85 90 95

Tyr Cys Arg Gly Thr Tyr Tyr Ala Ser Lys Pro Phe Asp Tyr Trp Gly
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 181
<211> 121
<212> PRT
<213> Artificial Sequence

<220>
<223> VH6D of humanized "4B4" anti-CD3 antibody

<400> 181

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1. 5 10 15

Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly Phe Thr Phe Ser Asn Ala
20 25 30

Trp Met His Trp Val Arg Gln Ala Pro Gly Lys Gln Leu Glu Trp Val
35 40 45

Ala Gln Ile Lys Ala Arg Ser Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp
50 55 60

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr
65 70 75 80

Ile Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr
85 90 95

Tyr Cys Arg Gly Thr Tyr Tyr Ala Ser Lys Pro Phe Asp Tyr Trp Gly
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 182
<211> 112
<212> PRT
<213> Artificial Sequence

<220>
<223> VL "D7-VK3mut" of humanized "4B4" anti-CD3 antibody

<400> 182

Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly
1. 5 10 15

Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asp
20 25 30

Asn Gly Asn Thr Tyr Leu Ser Trp Ser Gln Gln Arg Pro Gly Gln Ser
35 40 45

Pro Arg Val Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80

Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gly Gln Gly
85 90 95

Thr Gln Tyr Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105 110

<210> 183

<211> 121

<212> PRT

<213> Artificial Sequence

<220>

<223> D7-VH1mut of humanized "4B4" anti-CD3 antibody

<400> 183

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1. 5 10 15

Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly Phe Thr Phe Ser Asn Ala
20 25 30

Trp Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Gly Gln Ile Lys Ala Arg Ser Asn Asn Tyr Ala Thr Tyr Tyr Ala Glu
50 55 60

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr
65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr
85 90 95

Tyr Cys Arg Gly Thr Tyr Tyr Ala Ser Lys Pro Phe Asp Tyr Trp Gly
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 184

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> CDR1-L of the VL1B, VL2B, VL1Cmofif3 and VL2F variants of the
humanized "4B4" anti-CD3 antibody

<400> 184

Gln Ser Leu Val His Asp Asn Ala Asn Thr Tyr
1. 5 10

<210> 185

<211> 182

<212> PRT

<213> Homo sapiens

<400> 185

Met Glu Gln Gly Lys Gly Leu Ala Val Leu Ile Leu Ala Ile Ile Leu
1. 5 10 15

Leu Gln Gly Thr Leu Ala Gln Ser Ile Lys Gly Asn His Leu Val Lys
20 25 30

Val Tyr Asp Tyr Gln Glu Asp Gly Ser Val Leu Leu Thr Cys Asp Ala
35 40 45

Glu Ala Lys Asn Ile Thr Trp Phe Lys Asp Gly Lys Met Ile Gly Phe
50 55 60

Leu Thr Glu Asp Lys Lys Lys Trp Asn Leu Gly Ser Asn Ala Lys Asp
65 70 75 80

Pro Arg Gly Met Tyr Gln Cys Lys Gly Ser Gln Asn Lys Ser Lys Pro
85 90 95

Leu Gln Val Tyr Tyr Arg Met Cys Gln Asn Cys Ile Glu Leu Asn Ala
100 105 110

Ala Thr Ile Ser Gly Phe Leu Phe Ala Glu Ile Val Ser Ile Phe Val
115 120 125

Leu Ala Val Gly Val Tyr Phe Ile Ala Gly Gln Asp Gly Val Arg Gln
130 135 140

Ser Arg Ala Ser Asp Lys Gln Thr Leu Leu Pro Asn Asp Gln Leu Tyr
145 150 155 160

Gln Pro Leu Lys Asp Arg Glu Asp Asp Gln Tyr Ser His Leu Gln Gly
165 170 175

Asn Gln Leu Arg Arg Asn
180

<210> 186
<211> 249
<212> PRT
<213> Artificial Sequence

<220>
<223> heavy chain sequence of "20G6-F3" Fab

<400> 186

Glu Val Gln Leu Val Glu Thr Gly Gly Ser Leu Val Gln Pro Gly Lys
1. 5 10 15

Ser Leu Lys Leu Thr Cys Ala Thr Ser Gly Phe Thr Phe Thr Lys Ala
20 25 30

Trp Met His Trp Val Arg Gln Ser Pro Glu Lys Gln Leu Glu Trp Val
35 40 45

Ala Gln Ile Lys Asp Lys Ser Asn Ser Tyr Ala Thr Tyr Tyr Ala Glu
50 55 60

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr
65 70 75 80

Ile Tyr Leu Gln Met Asn Ser Leu Lys Glu Glu Asp Thr Ala Ile Tyr
85 90 95

Tyr Cys Arg Gly Val Tyr Tyr Ala Leu Ser Pro Phe Asp Tyr Trp Gly
100 105 110

Gln Gly Val Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
115 120 125

Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
130 135 140

Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
145 150 155 160

Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
165 170 175

Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
180 185 190

Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His
195 200 205

Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys
210 215 220

Asp Lys Thr His Thr Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu Asn
225 230 235 240

Gly Ala Ala His His His His His His
245

<210> 187

<211> 219

<212> PRT
<213> Artificial Sequence

<220>
<223> light chain sequence of "20G6-F3" Fab

<400> 187

Asp Val Val Met Thr Gln Thr Pro Val Ser Leu Ser Val Ser Leu Gly
1. 5 10 15

Gly Gln Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asn
20 25 30

Asn Gly Asn Thr Tyr Leu Ser Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45

Pro Gln Ser Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Phe Ser
50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80

Ser Arg Val Asp Pro Asp Asp Leu Gly Val Tyr Tyr Cys Gly Gln Gly
85 90 95

Thr Gln Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
100 105 110

Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu
115 120 125

Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe
130 135 140

Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln
145 150 155 160

Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser
165 170 175

Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu
180 185 190

Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser
195 200 205

Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
210 215

<210> 188

<211> 250

<212> PRT

<213> Artificial Sequence

<220>

<223> heavy chain sequence of "4E7-C9" Fab

<400> 188

Glu Val Gln Val Val Glu Thr Gly Gly Ser Leu Val Gln Pro Gly Lys
1. 5 10 15

Ser Leu Lys Leu Thr Cys Ala Thr Ser Gly Phe Thr Phe Ser Asn Ala
20 25 30

Trp Met His Trp Val Arg Gln Ser Pro Glu Lys Gln Leu Glu Trp Val
35 40 45

Ala Gln Ile Lys Asp Lys Ser Asn Asn Tyr Ala Thr Tyr Tyr Ala Glu
50 55 60

Ser Leu Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Pro Lys Arg Ser
65 70 75 80

Ile Tyr Leu Gln Met Asn Ser Leu Arg Glu Glu Asp Thr Ala Ile Tyr
85 90 95

Tyr Cys Arg Tyr Val His Tyr Gly Ile Gly Tyr Ala Met Asp Ala Trp
100 105 110

Gly Gln Gly Thr Ser Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro
115 120 125

Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr
130 135 140

Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr
145 150 155 160

Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro
165 170 175

Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr
180 185 190

Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn
195 200 205

His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser
210 215 220

Cys Asp Lys Thr His Thr Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu
225 230 235 240

Asn Gly Ala Ala His His His His His
245 250

<210> 189

<211> 219

<212> PRT

<213> Artificial Sequence

<220>

<223> light chain sequence of "4E7-C9" Fab

<400> 189

Asp Val Val Met Thr Gln Thr Pro Val Ser Leu Ser Val Ser Leu Gly
1. 5 10 15

Gly Gln Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Glu His Asn
20 25 30

Asn Gly Asn Thr Tyr Leu Ser Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45

Pro Gln Pro Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Ile Ser
50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80

Ser Arg Val Glu Pro Asp Asp Leu Gly Val Tyr Tyr Cys Gly Gln Gly
85 90 95

Thr Gln Tyr Pro Phe Thr Phe Gly Pro Gly Thr Lys Leu Glu Leu Lys
100 105 110

Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu
115 120 125

Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe
130 135 140

Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln
145 150 155 160

Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser
165 170 175

Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu
180 185 190

Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser
195 200 205

Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
210 215

<210> 190

<211> 249

<212> PRT

<213> Artificial Sequence

<220>

<223> heavy chain sequence of "4B4-D7" Fab

<400> 190

Glu Val Gln Leu Val Glu Thr Gly Gly Arg Leu Val Gln Pro Gly Arg
1. 5 10 15

Ser	Leu	Lys	Leu	Thr	Cys	Ala	Thr	Ser	Gly	Phe	Thr	Phe	Ser	Asn	Ala		
			20					25					30				
Trp	Met	His	Trp	Val	Arg	Gln	Ser	Pro	Glu	Lys	Gln	Leu	Glu	Trp	Val		
		35					40					45					
Ala	Gln	Ile	Lys	Ala	Arg	Ser	Asn	Asn	Tyr	Ala	Thr	Tyr	Tyr	Ala	Glu		
	50					55					60						
Ser	Val	Lys	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asp	Ser	Lys	Ser	Thr		
65					70					75					80		
Ile	Tyr	Leu	Gln	Met	Asn	Ser	Leu	Lys	Glu	Glu	Asp	Thr	Ala	Ile	Tyr		
				85					90					95			
Tyr	Cys	Arg	Gly	Thr	Tyr	Tyr	Ala	Ser	Lys	Pro	Phe	Asp	Tyr	Trp	Gly		
			100					105					110				
Gln	Gly	Val	Met	Val	Thr	Val	Ser	Ser	Ala	Ser	Thr	Lys	Gly	Pro	Ser		
		115					120					125					
Val	Phe	Pro	Leu	Ala	Pro	Ser	Ser	Lys	Ser	Thr	Ser	Gly	Gly	Thr	Ala		
	130					135					140						
Ala	Leu	Gly	Cys	Leu	Val	Lys	Asp	Tyr	Phe	Pro	Glu	Pro	Val	Thr	Val		
145					150					155					160		
Ser	Trp	Asn	Ser	Gly	Ala	Leu	Thr	Ser	Gly	Val	His	Thr	Phe	Pro	Ala		
				165					170					175			
Val	Leu	Gln	Ser	Ser	Gly	Leu	Tyr	Ser	Leu	Ser	Ser	Val	Val	Thr	Val		
			180					185					190				
Pro	Ser	Ser	Ser	Leu	Gly	Thr	Gln	Thr	Tyr	Ile	Cys	Asn	Val	Asn	His		
		195					200					205					
Lys	Pro	Ser	Asn	Thr	Lys	Val	Asp	Lys	Lys	Val	Glu	Pro	Lys	Ser	Cys		
	210					215					220						

Asp Lys Thr His Thr Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu Asn
225 230 235 240

Gly Ala Ala His His His His His His
245

<210> 191

<211> 218

<212> PRT

<213> Artificial Sequence

<220>

<223> light chain sequence of "4B4-D7 " Fab

<400> 191

Asp Val Val Met Thr Gln Thr Pro Val Ser Leu Ser Val Ser Leu Gly
1. 5 10 15

Gly Gln Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asp
20 25 30

Asn Gly Asn Thr Tyr Leu Ser Trp Ser Leu Gln Arg Pro Gly Gln Ser
35 40 45

Pro Gln Val Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Thr Ser
50 55 60

Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80

Ser Arg Val Glu Pro Asp Asp Leu Gly Val Tyr Tyr Cys Gly Gln Gly
85 90 95

Thr Gln Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
100 105 110

Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu
115 120 125

Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe
130 135 140

Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln
145 150 155 160

Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser
165 170 175

Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu
180 185 190

Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser
195 200 205

Pro Val Thr Lys Ser Phe Asn Arg Gly Glu
210 215

<210> 192

<211> 250

<212> PRT

<213> Artificial Sequence

<220>

<223> heavy chain sequence of "18F5-H10" Fab

<400> 192

Glu Val Gln Val Val Glu Thr Gly Gly Ser Leu Val Gln Pro Gly Lys
1. 5 10 15

Ser Leu Lys Leu Thr Cys Ala Thr Ser Gly Phe Thr Phe Thr Asn Ala
20 25 30

Trp Met His Trp Val Arg Arg Ser Pro Glu Lys Gln Leu Glu Trp Val
35 40 45

Ala Gln Ile Lys Asp Lys Ser Asn Asn Tyr Ala Thr Tyr Tyr Ala Glu
50 55 60

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser
65 70 75 80

Ile Tyr Leu Gln Met Asn Ser Leu Lys Glu Glu Asp Thr Ala Ile Tyr
85 90 95

Tyr Cys Arg Tyr Val His Tyr Arg Phe Ala Tyr Ala Leu Asp Ala Trp
100 105 110

Gly Arg Gly Thr Ser Val Ser Val Ser Ser Ala Ser Thr Lys Gly Pro
115 120 125

Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr
130 135 140

Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr
145 150 155 160

Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro
165 170 175

Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr
180 185 190

Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn
195 200 205

His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser
210 215 220

Cys Asp Lys Thr His Thr Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu
225 230 235 240

Asn Gly Ala Ala His His His His His
245 250

<210> 193

<211> 219

<212> PRT

<213> Artificial Sequence

<220>

<223> light chain sequence of "18F5-H10" Fab

<400> 193

Asp Val Leu Met Thr Gln Thr Pro Val Ser Leu Ser Val Ser Leu Gly
1. 5 10 15

Gly Gln Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Thr
20 25 30

Asn Gly Asn Thr Tyr Leu Ser Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45

Pro Gln Leu Leu Ile Tyr Lys Val Ser Asn Arg Leu Ser Gly Ile Ser
50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80

Ser Arg Val Glu Pro Asp Asp Leu Gly Val Tyr Tyr Cys Gly Gln Gly
85 90 95

Thr His Tyr Pro Phe Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys
100 105 110

Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu
115 120 125

Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe
130 135 140

Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln
145 150 155 160

Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser
165 170 175

Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu
180 185 190

Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser
195 200 205

Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
210 215

<210> 194

<211> 378

<212> PRT
<213> Homo sapiens

<400> 194

Met Val Leu Leu Trp Leu Thr Leu Leu Leu Ile Ala Leu Pro Cys Leu
1. 5 10 15

Leu Gln Thr Lys Glu Asp Pro Asn Pro Pro Ile Thr Asn Leu Arg Met
20 25 30

Lys Ala Lys Ala Gln Gln Leu Thr Trp Asp Leu Asn Arg Asn Val Thr
35 40 45

Asp Ile Glu Cys Val Lys Asp Ala Asp Tyr Ser Met Pro Ala Val Asn
50 55 60

Asn Ser Tyr Cys Gln Phe Gly Ala Ile Ser Leu Cys Glu Val Thr Asn
65 70 75 80

Tyr Thr Val Arg Val Ala Asn Pro Pro Phe Ser Thr Trp Ile Leu Phe
85 90 95

Pro Glu Asn Ser Gly Lys Pro Trp Ala Gly Ala Glu Asn Leu Thr Cys
100 105 110

Trp Ile His Asp Val Asp Phe Leu Ser Cys Ser Trp Ala Val Gly Pro
115 120 125

Gly Ala Pro Ala Asp Val Gln Tyr Asp Leu Tyr Leu Asn Val Ala Asn
130 135 140

Arg Arg Gln Gln Tyr Glu Cys Leu His Tyr Lys Thr Asp Ala Gln Gly
145 150 155 160

Thr Arg Ile Gly Cys Arg Phe Asp Asp Ile Ser Arg Leu Ser Ser Gly
165 170 175

Ser Gln Ser Ser His Ile Leu Val Arg Gly Arg Ser Ala Ala Phe Gly
180 185 190

Ile Pro Cys Thr Asp Lys Phe Val Val Phe Ser Gln Ile Glu Ile Leu

195	200	205
Thr Pro Pro Asn Met Thr Ala Lys Cys Asn Lys Thr His Ser Phe Met		
210	215	220
His Trp Lys Met Arg Ser His Phe Asn Arg Lys Phe Arg Tyr Glu Leu		
225	230	235
Gln Ile Gln Lys Arg Met Gln Pro Val Ile Thr Glu Gln Val Arg Asp		
	245	250
Arg Thr Ser Phe Gln Leu Leu Asn Pro Gly Thr Tyr Thr Val Gln Ile		
	260	265
Arg Ala Arg Glu Arg Val Tyr Glu Phe Leu Ser Ala Trp Ser Thr Pro		
	275	280
Gln Arg Phe Glu Cys Asp Gln Glu Glu Gly Ala Asn Thr Arg Ala Trp		
290	295	300
Arg Thr Ser Leu Leu Ile Ala Leu Gly Thr Leu Leu Ala Leu Val Cys		
305	310	315
Val Phe Val Ile Cys Arg Arg Tyr Leu Val Met Gln Arg Leu Phe Pro		
	325	330
Arg Ile Pro His Met Lys Asp Pro Ile Gly Asp Ser Phe Gln Asn Asp		
	340	345
Lys Leu Val Val Trp Glu Ala Gly Lys Ala Gly Leu Glu Glu Cys Leu		
	355	360
Val Thr Glu Val Gln Val Val Gln Lys Thr		
370	375	

<210> 195
 <211> 378
 <212> PRT
 <213> Macaca fascicularis

 <400> 195

Met Thr Leu Leu Trp Leu Thr Leu Leu Leu Val Ala Thr Pro Cys Leu
1. 5 10 15

Leu Arg Thr Lys Glu Asp Pro Asn Ala Pro Ile Arg Asn Leu Arg Met
20 25 30

Lys Glu Lys Ala Gln Gln Leu Met Trp Asp Leu Asn Arg Asn Val Thr
35 40 45

Asp Val Glu Cys Ile Lys Gly Thr Asp Tyr Ser Met Pro Ala Met Asn
50 55 60

Asn Ser Tyr Cys Gln Phe Gly Ala Ile Ser Leu Cys Glu Val Thr Asn
65 70 75 80

Tyr Thr Val Arg Val Ala Ser Pro Pro Phe Ser Thr Trp Ile Leu Phe
85 90 95

Pro Glu Asn Ser Gly Thr Pro Arg Ala Gly Ala Glu Asn Leu Thr Cys
100 105 110

Trp Val His Asp Val Asp Phe Leu Ser Cys Ser Trp Val Val Gly Pro
115 120 125

Ala Ala Pro Ala Asp Val Gln Tyr Asp Leu Tyr Leu Asn Asn Pro Asn
130 135 140

Ser His Glu Gln Tyr Arg Cys Leu His Tyr Lys Thr Asp Ala Arg Gly
145 150 155 160

Thr Gln Ile Gly Cys Arg Phe Asp Asp Ile Ala Pro Leu Ser Arg Gly
165 170 175

Ser Gln Ser Ser His Ile Leu Val Arg Gly Arg Ser Ala Ala Val Ser
180 185 190

Ile Pro Cys Thr Asp Lys Phe Val Phe Phe Ser Gln Ile Glu Arg Leu
195 200 205

Thr Pro Pro Asn Met Thr Gly Glu Cys Asn Glu Thr His Ser Phe Met
210 215 220

His Trp Lys Met Lys Ser His Phe Asn Arg Lys Phe Arg Tyr Glu Leu
225 230 235 240

Arg Ile Gln Lys Arg Met Gln Pro Val Arg Thr Glu Gln Val Arg Asp
245 250 255

Thr Thr Ser Phe Gln Leu Pro Asn Pro Gly Thr Tyr Thr Val Gln Ile
260 265 270

Arg Ala Arg Glu Thr Val Tyr Glu Phe Leu Ser Ala Trp Ser Thr Pro
275 280 285

Gln Arg Phe Glu Cys Asp Gln Glu Glu Gly Ala Ser Ser Arg Ala Trp
290 295 300

Arg Thr Ser Leu Leu Ile Ala Leu Gly Thr Leu Leu Ala Leu Leu Cys
305 310 315 320

Val Phe Leu Ile Cys Arg Arg Tyr Leu Val Met Gln Arg Leu Phe Pro
325 330 335

Arg Ile Pro His Met Lys Asp Pro Ile Gly Asp Thr Phe Gln Gln Asp
340 345 350

Lys Leu Val Val Trp Glu Ala Gly Lys Ala Gly Leu Glu Glu Cys Leu
355 360 365

Val Ser Glu Val Gln Val Val Glu Lys Thr
370 375

<210> 196
<211> 523
<212> PRT
<213> Homo sapiens

<220>
<221> DOMAIN
<222> (1)..(284)
<223> extracellular domain of human CD123

<220>

<221> MISC_FEATURE
<222> (285)..(519)
<223> Strep-II tagged Fc-Fusion

<400> 196

Thr Lys Glu Asp Pro Asn Pro Pro Ile Thr Asn Leu Arg Met Lys Ala
1. 5 10 15

Lys Ala Gln Gln Leu Thr Trp Asp Leu Asn Arg Asn Val Thr Asp Ile
20 25 30

Glu Cys Val Lys Asp Ala Asp Tyr Ser Met Pro Ala Val Asn Asn Ser
35 40 45

Tyr Cys Gln Phe Gly Ala Ile Ser Leu Cys Glu Val Thr Asn Tyr Thr
50 55 60

Val Arg Val Ala Asn Pro Pro Phe Ser Thr Trp Ile Leu Phe Pro Glu
65 70 75 80

Asn Ser Gly Lys Pro Trp Ala Gly Ala Glu Asn Leu Thr Cys Trp Ile
85 90 95

His Asp Val Asp Phe Leu Ser Cys Ser Trp Ala Val Gly Pro Gly Ala
100 105 110

Pro Ala Asp Val Gln Tyr Asp Leu Tyr Leu Asn Val Ala Asn Arg Arg
115 120 125

Gln Gln Tyr Glu Cys Leu His Tyr Lys Thr Asp Ala Gln Gly Thr Arg
130 135 140

Ile Gly Cys Arg Phe Asp Asp Ile Ser Arg Leu Ser Ser Gly Ser Gln
145 150 155 160

Ser Ser His Ile Leu Val Arg Gly Arg Ser Ala Ala Phe Gly Ile Pro
165 170 175

Cys Thr Asp Lys Phe Val Val Phe Ser Gln Ile Glu Ile Leu Thr Pro
180 185 190

Pro Asn Met Thr Ala Lys Cys Asn Lys Thr His Ser Phe Met His Trp
195 200 205

Lys Met Arg Ser His Phe Asn Arg Lys Phe Arg Tyr Glu Leu Gln Ile
210 215 220

Gln Lys Arg Met Gln Pro Val Ile Thr Glu Gln Val Arg Asp Arg Thr
225 230 235 240

Ser Phe Gln Leu Leu Asn Pro Gly Thr Tyr Thr Val Gln Ile Arg Ala
245 250 255

Arg Glu Arg Val Tyr Glu Phe Leu Ser Ala Trp Ser Thr Pro Gln Arg
260 265 270

Phe Glu Cys Asp Gln Glu Glu Gly Ala Asn Thr Arg Ala Trp Arg Asp
275 280 285

Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly
290 295 300

Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
305 310 315 320

Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu
325 330 335

Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
340 345 350

Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg
355 360 365

Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
370 375 380

Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu
385 390 395 400

Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
405 410 415

Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu
420 425 430

Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
435 440 445

Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
450 455 460

Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp
465 470 475 480

Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His
485 490 495

Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro
500 505 510

Gly Ser Ala Trp Ser His Pro Gln Phe Glu Lys
515 520

<210> 197
<211> 519
<212> PRT
<213> Macaca fascicularis

<220>
<221> DOMAIN
<222> (1)..(284)
<223> extracellular domain of Macaca fascicularis CD123

<220>
<221> MISC_FEATURE
<222> (285)..(516)
<223> Strep-II tagged Fc-fusion

<400> 197

Thr Lys Glu Asp Pro Asn Ala Pro Ile Arg Asn Leu Arg Met Lys Glu
1. 5 10 15

Lys Ala Gln Gln Leu Met Trp Asp Leu Asn Arg Asn Val Thr Asp Val
20 25 30

Glu Cys Ile Lys Gly Thr Asp Tyr Ser Met Pro Ala Met Asn Asn Ser
35 40 45

Tyr Cys Gln Phe Gly Ala Ile Ser Leu Cys Glu Val Thr Asn Tyr Thr
50 55 60

Val Arg Val Ala Ser Pro Pro Phe Ser Thr Trp Ile Leu Phe Pro Glu
65 70 75 80

Asn Thr Gly Thr Pro Arg Ala Gly Ala Glu Asn Leu Thr Cys Trp Val
85 90 95

His Asp Val Asp Phe Leu Ser Cys Ser Trp Val Val Gly Pro Ala Ala
100 105 110

Pro Ala Asp Val Gln Tyr Asp Leu Tyr Leu Asn Asn Pro Asn Ser His
115 120 125

Glu Gln Tyr Arg Cys Leu His Tyr Lys Thr Asp Ala Arg Gly Thr Gln
130 135 140

Ile Gly Cys Arg Phe Asp Asp Ile Ala Arg Leu Ser Arg Gly Ser Gln
145 150 155 160

Ser Ser His Ile Leu Val Arg Gly Arg Ser Ala Ala Val Ser Ile Pro
165 170 175

Cys Thr Asp Lys Phe Val Phe Phe Ser Gln Ile Glu Arg Leu Thr Pro
180 185 190

Pro Asn Met Thr Gly Glu Cys Asn Glu Thr His Ser Phe Met His Trp
195 200 205

Lys Met Lys Ser His Phe Asn Arg Lys Phe Arg Tyr Glu Leu Arg Ile
210 215 220

Gln Lys Arg Met Gln Pro Val Arg Thr Glu Gln Val Arg Asp Thr Thr
225 230 235 240

Ser Phe Gln Leu Pro Asn Pro Gly Thr Tyr Thr Val Gln Ile Arg Ala
245 250 255

Arg Glu Thr Val Tyr Glu Phe Leu Ser Ala Trp Ser Thr Pro Gln Arg
260 265 270

Phe Glu Cys Asp Gln Glu Glu Gly Ala Ser Ser Arg Ala Trp Arg Gly
275 280 285

Ser Gly Gly Ser Gly Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala
290 295 300

Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro
305 310 315 320

Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val
325 330 335

Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val
340 345 350

Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln
355 360 365

Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln
370 375 380

Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala
385 390 395 400

Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro
405 410 415

Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr
420 425 430

Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser
435 440 445

Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr
450 455 460

Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr
465 470 475 480

Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe
485 490 495

Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys
500 505 510

Ser Leu Ser Leu Ser Pro Gly
515

<210> 198
<211> 119
<212> PRT
<213> Artificial Sequence

<220>
<223> VH of the so-called "1E1-G5" anti-CD123 antibody

<400> 198

Gln Val Gln Leu Gln Glu Ser Gly Pro Thr Leu Val Lys Pro Gly Asp
1. 5 10 15

Ser Val Lys Met Ser Cys Lys Ala Phe Gly Tyr Thr Phe Thr Asp His
20 25 30

Ile Ile His Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile
35 40 45

Gly Tyr Ile Asn Pro Tyr Ser Gly Gly Thr Asn Tyr Asn Glu Lys Phe
50 55 60

Lys Ser Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
65 70 75 80

Met Glu Phe Ser Arg Leu Thr Ser Glu Asp Ser Ala Ile Cys Tyr Cys
85 90 95

Ala Leu Asn Tyr Gly Ser Tyr Tyr Ala Met Asp Ala Trp Gly Gln Gly
100 105 110

Thr Ser Val Thr Val Ser Ser
115

<210> 199

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> CDR1-H of the so-called "1E1-G5" and "8B11-B7" anti-CD123
antibodies

<400> 199

Gly Tyr Thr Phe Thr Asp His Ile
1. 5

<210> 200

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> CDR2-H of the so-called "1E1-G5" and "6D6-B8" anti-CD123
antibodies

<400> 200

Ile Asn Pro Tyr Ser Gly Gly Thr
1. 5

<210> 201

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> CDR3-H of the so-called "1E1-G5", "6D6-B8", "8B11-B7" and
"9F6-G3" anti-CD123 antibodies

<400> 201

Ala Leu Asn Tyr Gly Ser Tyr Tyr Ala Met Asp Ala
1. 5 10

<210> 202

<211> 107

<212> PRT

<213> Artificial Sequence

<220>

<223> VL of the so-called "1E1-G5" anti-CD123 antibody

<400> 202

Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Leu Gly
1. 5 10 15

Gln Thr Val Thr Ile Glu Cys Arg Pro Ser Glu Asp Ile Tyr Ser Asn
20 25 30

Leu Ala Trp Phe Gln Gln Lys Pro Gly Ser Ser Pro Gln Leu Leu Ile
35 40 45

Tyr Asp Ala Asn Asn Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Gln Tyr Ser Leu Lys Ile Asn Ser Leu Gln Ser
65 70 75 80

Glu Asp Val Ala Ser Tyr Phe Cys Gln Gln Tyr Asn Lys Tyr Pro Tyr
85 90 95

Thr Phe Gly Thr Gly Thr Lys Leu Glu Leu Lys
100 105

<210> 203

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> CDR1-L of the so-called "1E1-G5" anti-CD123 antibody

<400> 203

Glu Asp Ile Tyr Ser Asn
1. 5

<210> 204

<211> 9

<212> PRT

<213> Artificial Sequence

<220>
<223> CDR1-L of the so-called "1E1-G5" anti-CD123 antibody

<400> 204

Gln Gln Tyr Asn Lys Tyr Pro Tyr Thr
1. 5

<210> 205
<211> 119
<212> PRT
<213> Artificial Sequence

<220>
<223> VH of the so-called "2B8-F3" anti-CD123 antibody

<400> 205

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg
1. 5 10 15

Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr
20 25 30

Asn Met Ala Trp Val Arg Gln Ala Pro Lys Lys Gly Leu Glu Trp Val
35 40 45

Ala Thr Ile Leu Tyr Asp Gly Gly Arg Thr Tyr Tyr Arg Gly Ser Val
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Ser Thr Leu Tyr
65 70 75 80

Leu Arg Met Asp Ser Leu Arg Ser Glu Asp Thr Ala Thr Tyr Tyr Cys
85 90 95

Ala Thr His Ser Arg Gly Thr Asp Tyr Phe Asp Tyr Trp Gly Gln Gly
100 105 110

Val Met Val Thr Val Ser Ser
115

<210> 206
<211> 8
<212> PRT

<213> Artificial Sequence

<220>

<223> CDR1-H of the so-called "2B8-F3" anti-CD123 antibody

<400> 206

Gly Phe Thr Phe Ser Asp Tyr Asn

1. 5

<210> 207

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> CDR2-H of the so-called "2B8-F3" anti-CD123 antibody

<400> 207

Ile Leu Tyr Asp Gly Gly Arg Thr

1. 5

<210> 208

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> CDR3-H of the so-called "2B8-F3" anti-CD123 antibody

<400> 208

Ala Thr His Ser Arg Gly Thr Asp Tyr Phe Asp Tyr

1. 5

10

<210> 209

<211> 106

<212> PRT

<213> Artificial Sequence

<220>

<223> VL of the so-called "2B8-F3" anti-CD123 antibody

<400> 209

Glu Ile Val Leu Thr Gln Ser Pro Thr Ser Met Thr Ala Ser Pro Gly

1. 5

10

15

Glu Gln Val Thr Ile Thr Cys Arg Ala Ser Ser Ser Ile Asn Tyr Met

20

25

30

His Trp Tyr Gln Gln Lys Pro Gly Ala Ser Pro Arg Pro Trp Ile Tyr
 35 40 45

Glu Thr Ser Lys Leu Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser
 50 55 60

Ala Ser Gly Thr Ser Tyr Ser Leu Thr Ile Asn Asn Met Glu Ala Glu
 65 70 75 80

Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Asn Tyr Pro Ser Trp Thr
 85 90 95

Phe Gly Gly Gly Thr Lys Leu Glu Leu Lys
 100 105

<210> 210
 <211> 5
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CDR1-L of the so-called "2B8-F3" anti-CD123 antibody

<400> 210

Ser Ser Ile Asn Tyr
 1. 5

<210> 211
 <211> 9
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CDR3-L of the so-called "2B8-F3" anti-CD123 antibody

<400> 211

Gln Gln Trp Asn Tyr Pro Ser Trp Thr
 1. 5

<210> 212
 <211> 123
 <212> PRT

<213> Artificial Sequence

<220>

<223> VH of the so-called "2F8-D6" anti-CD123 antibody

<400> 212

Gln Val Gln Leu Lys Glu Ser Gly Pro Gly Leu Val Gln Pro Ser Gln
1. 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser Tyr
20 25 30

Gly Val Ser Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45

Ala Thr Ile Ser Ser Ala Gly Ser Thr Tyr Tyr Asp Leu Val Leu Lys
50 55 60

Ser Arg Leu Ser Ile Thr Arg Asp Thr Ser Lys Ser Gln Val Phe Leu
65 70 75 80

Lys Val His Ser Leu Gln Thr Glu Asp Thr Ala Ile Tyr Leu Cys Ala
85 90 95

Arg Asp Ala Pro Val Phe Asn Tyr Gly Ser Tyr Asn Ala Met Asp Ser
100 105 110

Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser
115 120

<210> 213

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> CDR1-H of the so-called "2F8-D6" anti-CD123 antibody

<400> 213

Gly Phe Ser Leu Thr Ser Tyr Gly
1. 5

<210> 214

<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR2-H of the so-called "2F8-D6" anti-CD123 antibody

<400> 214

Ile Ser Ser Ala Gly Ser Thr
1. 5

<210> 215
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR3-H of the so-called "2F8-D6" anti-CD123 antibody

<400> 215

Ala Arg Asp Ala Pro Val Phe Asn Tyr Gly Ser Tyr Asn Ala Met Asp
1. 5 10 15

Ser

<210> 216
<211> 106
<212> PRT
<213> Artificial Sequence

<220>
<223> VL of the so-called "2F8-D6" anti-CD123 antibody

<400> 216

Asp Ile Gln Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Thr Val Gly
1. 5 10 15

Asp Arg Val Thr Ile Asn Cys Lys Ala Ser Gln Asn Ile Asn Lys Tyr
20 25 30

Leu Asn Trp Tyr Gln Gln Lys Leu Gly Glu Ala Pro Lys Arg Leu Ile
35 40 45

Tyr Asn Thr Asn Ser Leu Gln Thr Gly Ile Pro Ser Arg Phe Ser Gly

50

55

60

Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80

Glu Asp Val Ala Thr Tyr Phe Cys Leu Gln His Lys Ser Gly Leu Thr
 85 90 95

Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
 100 105

<210> 217

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> CDR1-L of the so-called "2F8-D6" anti-CD123 antibody

<400> 217

Gln Asn Ile Asn Lys Tyr

1. 5

<210> 218

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> CDR3-L of the so-called "2F8-D6" anti-CD123 antibody

<400> 218

Leu Gln His Lys Ser Gly Leu Thr

1. 5

<210> 219

<211> 125

<212> PRT

<213> Artificial Sequence

<220>

<223> VH of the so-called "3B10-E6" anti-CD123 antibody

<400> 219

Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Arg Arg Pro Gly Ser

15

30

45

60

80

95

110

125

<213> Artificial Sequence

<223> CDR1-H of the so-called "3B10-E6" anti-CD123 antibody

$\langle 400 \rangle$ 220

1.5

<213> Artificial Sequence

<223> CDR2-H of the so-called "3B10-E6" anti-CD123 antibody

$\langle 400 \rangle$ 221

Ile Asp Pro Glu Asp Gly Glu Thr
1. 5

<210> 222
<211> 18
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR3-H of the so-called "3B10-E6" anti-CD123 antibody

<400> 222

Ala Arg Trp Gly Asp Val Tyr Tyr Gly Leu Met Arg Gly His Val Met
1. 5 10 15

Asp Ala

<210> 223
<211> 113
<212> PRT
<213> Artificial Sequence

<220>
<223> VL of the so-called "3B10-E6" anti-CD123 antibody

<400> 223

Asp Val Leu Met Thr Gln Thr Pro Val Ser Leu Pro Val Ser Leu Gly
1. 5 10 15

Gly Gln Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser
20 25 30

Asp Gly Asp Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45

Pro Gln Leu Leu Ile Tyr Arg Val Ser Asn Arg Phe Ser Gly Val Pro
50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80

Ser Arg Val Glu Pro Glu Asp Leu Gly Leu Tyr Tyr Cys Leu Gln Thr

85

90

95

Thr His Phe Pro Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Met
 100 105 110

Lys

<210> 224
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CDR1-L of the so-called "3B10-E6" anti-CD123 antibody

<400> 224

Gln Ser Leu Val His Ser Asp Gly Asp Thr Tyr
 1. 5 10

<210> 225
 <211> 10
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CDR3-L of the so-called "3B10-E6" anti-CD123 antibody

<400> 225

Leu Gln Thr Thr His Phe Pro Pro Trp Thr
 1. 5 10

<210> 226
 <211> 118
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> VH of the so-called "3E3-D3" anti-CD123 antibody

<400> 226

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Gln Pro Ser Gln
 1. 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Thr Tyr

	20		25		30										
Asp	Val	His	Trp	Val	Arg	Gln	Pro	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Met
	35						40					45			
Gly	Arg	Ile	Gln	Asn	Gly	Gly	Ile	Thr	Asp	Tyr	Asn	Ser	Ala	Leu	Lys
	50					55					60				
Ser	Arg	Leu	Ile	Ile	Ser	Arg	Asp	Thr	Ser	Lys	Ser	Gln	Val	Phe	Leu
65					70					75					80
Lys	Met	Asn	Ser	Val	Gln	Thr	Glu	Asp	Thr	Ala	Met	Tyr	Phe	Cys	Ala
				85					90					95	
Lys	Thr	Gly	Ser	Tyr	Phe	Tyr	Ala	Phe	Asp	His	Trp	Gly	Gln	Gly	Thr
			100					105					110		
Leu	Val	Thr	Val	Ser	Ser										
			115												

<210> 227
 <211> 8
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CDR1-H of the so-called "3E3-D3" anti-CD123 antibody
 <400> 227

Gly Phe Ser Leu Thr Thr Tyr Asp
 1. 5

<210> 228
 <211> 7
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CDR2-H of the so-called "3E3-D3" anti-CD123 antibody
 <400> 228

Ile Gln Asn Gly Gly Ile Thr
 1. 5

<210> 229
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR3-H of the so-called "3E3-D3" anti-CD123 antibody

<400> 229

Ala Lys Thr Gly Ser Tyr Phe Tyr Ala Phe Asp His
1. 5 10

<210> 230
<211> 111
<212> PRT
<213> Artificial Sequence

<220>
<223> VL of the so-called "3E3-D3" anti-CD123 antibody

<400> 230

Gln Phe Val Leu Thr Gln Pro Asn Ser Val Ser Thr Asn Leu Gly Ser
1. 5 10 15

Thr Val Lys Leu Ser Cys Lys Arg Asn Thr Gly Asn Ile Gly Ser Asn
20 25 30

Tyr Val Asn Trp Tyr Gln Gln His Glu Gly Arg Ser Pro Thr Thr Met
35 40 45

Ile Tyr Arg Asp Asp Lys Arg Pro Asp Gly Val Pro Asp Arg Phe Ser
50 55 60

Gly Ser Ile Asp Arg Ser Ser Asn Ser Ala Leu Leu Thr Ile Asn Asn
65 70 75 80

Val Gln Thr Glu Asp Glu Ala Asp Tyr Phe Cys Gln Ser Tyr Ser Ser
85 90 95

Gly Ile Asn Ile Ile Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110

<210> 231

<211> 8
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> CDR1-L of the so-called "3E3-D3" anti-CD123 antibody

 <400> 231

Thr Gly Asn Ile Gly Ser Asn Tyr
 1. 5

<210> 232
 <211> 10
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> CDR3-L of the so-called "3E3-D3" anti-CD123 antibody

 <400> 232

Gln Ser Tyr Ser Ser Gly Ile Asn Ile Ile
 1. 5 10

<210> 233
 <211> 120
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> VH of the so-called "5A5-B4" anti-CD123 antibody

 <400> 233

Gln Ile Gln Ile Val Gln Ser Gly Ser Asp Val Thr Ser Thr Cys Asn
 1. 5 10 15

Gly Cys Gly Thr Cys Tyr Phe Ser Gly Phe Ser Leu Ser Thr Thr Gly
 20 25 30

Ile Cys Val Ser Trp Ile Arg Gln Pro Ser Gly Lys Gly Gln Glu Trp
 35 40 45

Leu Ala Asp Phe Cys Trp Asp Asp Gly Lys Gly Tyr Asn Pro Ser Leu
 50 55 60

Lys Asn Arg Leu Ser Ile Ser Lys Asp Thr Ser Asn Asn Gln Val Phe

65		70		75		80									
Leu	Lys	Ile	Thr	Ser	Val	Asp	Thr	Ala	Asp	Thr	Ala	Thr	Tyr	Tyr	Cys
				85					90					95	

Ala	Arg	Arg	Arg	Val	Tyr	Tyr	Gly	Ile	Tyr	Phe	Asp	Tyr	Trp	Gly	Gln
				100				105						110	

Gly	Val	Met	Val	Thr	Val	Ser	Ser
		115					120

<210> 234
 <211> 10
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CDR1-H of the so-called "5A5-B4" anti-CD123 antibody

<400> 234

Gly	Phe	Ser	Leu	Ser	Thr	Thr	Gly	Ile	Cys
1.	5							10	

<210> 235
 <211> 7
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CDR2-H of the so-called "5A5-B4" anti-CD123 antibody

<400> 235

Phe	Cys	Trp	Asp	Asp	Gly	Lys
1.	5					

<210> 236
 <211> 13
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CDR3-H of the so-called "5A5-B4" anti-CD123 antibody

<400> 236

Ala	Arg	Arg	Arg	Val	Tyr	Tyr	Gly	Ile	Tyr	Phe	Asp	Tyr
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

1. 5 10

<210> 237
<211> 106
<212> PRT
<213> Artificial Sequence

<220>
<223> VL of the so-called "5A5-B4" anti-CD123 antibody

<400> 237

Asp Ile Val Met Thr Gln Ser Pro Ala Leu Ala Val Ser Pro Gly Glu
1. 5 10 15

Arg Val Ser Ile Ser Cys Arg Ala Ser Asn Ser Val Ser Thr Arg Met
20 25 30

His Trp Tyr Gln Gln Lys Pro Gly Gln Gln Pro Lys Leu Leu Ile Tyr
35 40 45

Gly Ala Ser Asn Leu Glu Ser Gly Val Pro Ala Arg Phe Ser Gly Ser
50 55 60

Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Asp Pro Val Glu Ala Asp
65 70 75 80

Asp Ile Ala Thr Tyr Phe Cys Gln Gln Ser Trp Asn Asp Pro Leu Thr
85 90 95

Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
100 105

<210> 238
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR1-L of the so-called "5A5-B4" anti-CD123 antibody

<400> 238

Asn Ser Val Ser Thr Arg
1. 5

<210> 239
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR3-L of the so-called "5A5-B4" anti-CD123 antibody

<400> 239

Gln Gln Ser Trp Asn Asp Pro Leu Thr
1. 5

<210> 240
<211> 117
<212> PRT
<213> Artificial Sequence

<220>
<223> VH of the so-called "6B10-E4" anti-CD123 antibody

<400> 240

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg
1. 5 10 15

Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser His Tyr
20 25 30

Asn Met Ala Trp Val Arg Gln Ala Pro Lys Lys Gly Leu Glu Trp Val
35 40 45

Ala Thr Ile Thr Tyr Asp Asp His Ser Thr Tyr Tyr Arg Asp Ser Val
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Thr Ala Lys Ser Thr Leu Tyr
65 70 75 80

Leu Gln Met Asp Ser Leu Arg Ser Glu Asp Thr Ala Thr Tyr Tyr Cys
85 90 95

Ala Arg Leu Val Asn Tyr Ala Phe Ala Tyr Trp Gly Gln Gly Thr Leu
100 105 110

Val Thr Val Ser Ser

<210> 241
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR1-H of the so-called "6B10-E4" anti-CD123 antibody

<400> 241

Gly Phe Thr Phe Ser His Tyr Asn
1. 5

<210> 242
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR2-H of the so-called "6B10-E4" anti-CD123 antibody

<400> 242

Ile Thr Tyr Asp Asp His Ser Thr
1. 5

<210> 243
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR3-H of the so-called "6B10-E4" anti-CD123 antibody

<400> 243

Ala Arg Leu Val Asn Tyr Ala Phe Ala Tyr
1. 5 10

<210> 244
<211> 106
<212> PRT
<213> Artificial Sequence

<220>
<223> VL of the so-called "6B10-E4" anti-CD123 antibody

<400> 244

Asn Ile Val Met Thr Gln Ser Pro Lys Ser Met Ser Ile Ser Val Gly
1. 5 10 15

Asp Arg Val Thr Met Asn Cys Lys Ala Ser Gln Thr Val Gly Asn Asn
20 25 30

Ile Ala Trp Tyr Gln Gln Lys Pro Gly Leu Ser Pro Gln Leu Leu Ile
35 40 45

Asp Tyr Ala Ser Asn Arg Tyr Thr Gly Val Pro Asn Arg Phe Thr Gly
50 55 60

Gly Gly Tyr Gly Thr Asp Phe Ile Leu Thr Ile Asn Ser Val Gln Ala
65 70 75 80

Glu Asp Ala Ala Phe Tyr Tyr Cys Gln Arg Met Tyr Asn Ser Pro Thr
85 90 95

Phe Gly Gly Gly Thr Lys Leu Glu Leu Lys
100 105

<210> 245
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR1-L of the so-called "6B10-E4" anti-CD123 antibody

<400> 245

Gln Thr Val Gly Asn Asn
1. 5

<210> 246
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR3-L of the so-called "6B10-E4" anti-CD123 antibody

<400> 246

Gln Arg Met Tyr Asn Ser Pro Thr

1. 5

<210> 247

<211> 116

<212> PRT

<213> Artificial Sequence

<220>

<223> VH of the so-called "6C10-C4" anti-CD123 antibody

<400> 247

Glu Val Lys Leu Gln Glu Ser Gly Pro Ser Leu Val Gln Pro Ser Glu
1. 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser Tyr
20 25 30

Ser Val His Trp Val Arg Gln His Ser Gly Lys Ser Leu Glu Trp Met
35 40 45

Gly Arg Met Trp Asn Asp Gly Asp Thr Ser Tyr Asn Ser Ala Phe Thr
50 55 60

Ser Arg Leu Ser Ile Ser Arg Asp Thr Ser Lys Gly Gln Val Phe Leu
65 70 75 80

Lys Met Asn Ser Leu Gln Thr Glu Asp Thr Gly Thr Tyr Tyr Cys Ala
85 90 95

Arg Gly His Arg Thr Pro Phe Asp Tyr Trp Gly Gln Gly Val Met Val
100 105 110

Thr Val Ser Ser
115

<210> 248

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> CDR1-H of the so-called "6C10-C4" anti-CD123 antibody

<400> 248

Gly Phe Ser Leu Thr Ser Tyr Ser
1. 5

<210> 249
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR2-H of the so-called "6C10-C4" anti-CD123 antibody

<400> 249

Met Trp Asn Asp Gly Asp Thr
1. 5

<210> 250
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR3-H of the so-called "6C10-C4" anti-CD123 antibody

<400> 250

Ala Arg Gly His Arg Thr Pro Phe Asp Tyr
1. 5 10

<210> 251
<211> 113
<212> PRT
<213> Artificial Sequence

<220>
<223> VL of the so-called "6C10-C4" and "9B8-G6" anti-CD123
antibodies

<400> 251

Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ala Val Ser Ala Gly
1. 5 10 15

Glu Thr Val Thr Ile Asn Cys Lys Ser Ser Gln Ser Phe Leu Ser Ser
20 25 30

Gly Asp Glu Arg Asn Tyr Val Ala Trp Tyr Gln His Lys Pro Gly Gln
35 40 45

Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg His Ser Gly Val
50 55 60

Pro Asp Arg Phe Ile Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
65 70 75 80

Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Ile Tyr Tyr Cys Gln Gln
85 90 95

Tyr Tyr Asp Thr Pro Leu Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile
100 105 110

Lys

<210> 252

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> CDR1-L of the so-called "6C10-C4" and "9B8-G6" anti-CD123
antibodies

<400> 252

Gln Ser Phe Leu Ser Ser Gly Asp Glu Arg Asn Tyr
1. 5 10

<210> 253

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> CDR3-L of the so-called "6C10-C4", "9B8-G6" and "9D7-G3"
anti-CD123 antibodies

<400> 253

Gln Gln Tyr Tyr Asp Thr Pro Leu Thr
1. 5

<210> 254

<211> 119

<212> PRT
<213> Artificial Sequence

<220>
<223> VH of the so-called "6D6-B8" anti-CD123 antibody

<400> 254

Gln Val Gln Leu Gln Glu Ser Gly Pro Thr Leu Val Lys Pro Gly Asp
1. 5 10 15

Ser Val Lys Met Ser Cys Lys Ala Ser Ala Tyr Thr Phe Thr Asp Asn
20 25 30

Ile Ile His Trp Val Lys Gln Ser His Gly Lys Ser Leu Asp Trp Ile
35 40 45

Gly Tyr Ile Asn Pro Tyr Ser Gly Gly Thr Asn Tyr Asn Gly Trp Phe
50 55 60

Arg Ser Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
65 70 75 80

Met Glu Phe Ser Arg Leu Thr Ser Asp Asp Ser Ala Ile Tyr Tyr Cys
85 90 95

Ala Leu Asn Tyr Gly Ser Tyr Tyr Ala Met Asp Ala Trp Gly Gln Gly
100 105 110

Thr Ser Val Thr Val Ser Ser
115

<210> 255
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR1-H of the so-called "6D6-B8" anti-CD123 antibody

<400> 255

Ala Tyr Thr Phe Thr Asp Asn Ile
1. 5

<210> 256
<211> 107
<212> PRT
<213> Artificial Sequence

<220>
<223> VL of the so-called "6D6-B8" anti-CD123 antibody

<400> 256

Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Leu Gly
1. 5 10 15

Glu Thr Val Thr Ile Asp Cys Arg Pro Ser Glu Asp Ile Phe Asn Asn
20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Asn Ser Pro Gln Leu Leu Ile
35 40 45

Tyr Asp Ala Asn Ser Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Gln Tyr Ser Leu Met Ile Ile Arg Leu Gln Ser
65 70 75 80

Glu Asp Val Ala Ser Tyr Phe Cys His Gln Tyr Asn Ile Tyr Pro Tyr
85 90 95

Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys
100 105

<210> 257
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR1-L of the so-called "6D6-B8" anti-CD123 antibody

<400> 257

Glu Asp Ile Phe Asn Asn
1. 5

<210> 258
<211> 9

<212> PRT
<213> Artificial Sequence

<220>
<223> CDR3-L of the so-called "6D6-B8" anti-CD123 antibody

<400> 258

His Gln Tyr Asn Ile Tyr Pro Tyr Thr
1. 5

<210> 259
<211> 119
<212> PRT
<213> Artificial Sequence

<220>
<223> VH of the so-called "8B11-B7" anti-CD123 antibody.

<400> 259

Gln Val Gln Leu Gln Glu Ser Gly Pro Thr Leu Val Asn Pro Gly Asp
1. 5 10 15

Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp His
20 25 30

Ile Ile His Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile
35 40 45

Gly Tyr Ile Asn Pro Tyr Ser Gly Gly Ala Asn Tyr Asn Gly Lys Phe
50 55 60

Lys Ser Lys Ala Thr Leu Thr Ile Asp Lys Ser Ser Ser Thr Ala Tyr
65 70 75 80

Met Glu Phe Ser Arg Leu Thr Ser Gly Asp Ser Ala Ile Tyr Tyr Cys
85 90 95

Ala Leu Asn Tyr Gly Ser Tyr Tyr Ala Met Asp Ala Trp Gly Gln Gly
100 105 110

Thr Ser Val Thr Val Ser Ser
115

<210> 260
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR2-H of the so-called "8B11-B7" anti-CD123 antibody

<400> 260

Ile Asn Pro Tyr Ser Gly Gly Ala
1. 5

<210> 261
<211> 107
<212> PRT
<213> Artificial Sequence

<220>
<223> VL of the so-called "8B11-B7" anti-CD123 antibody

<400> 261

Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Leu Gly
1. 5 10 15

Glu Thr Val Thr Ile Glu Cys Arg Thr Ser Lys Asp Ile Tyr Ser Asn
20 25 30

Leu Ala Trp Phe Gln Gln Glu Pro Gly Asn Ser Pro Gln Leu Leu Ile
35 40 45

Tyr Asp Ala Ser Asn Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Gln Tyr Ser Leu Gln Ile Asn Asn Leu Gln Ser
65 70 75 80

Glu Asp Val Ala Ser Tyr Phe Cys His Gln Tyr Asn Asn Tyr Pro Tyr
85 90 95

Thr Phe Gly Thr Gly Thr Lys Leu Glu Leu Lys
100 105

<210> 262
<211> 6

<212> PRT
<213> Artificial Sequence

<220>
<223> CDR1-L of the so-called "8B11-B7" anti-CD123 antibody

<400> 262

Lys Asp Ile Tyr Ser Asn
1. 5

<210> 263
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR3-L of the so-called "8B11-B7" anti-CD123 antibody

<400> 263

His Gln Tyr Asn Asn Tyr Pro Tyr Thr
1. 5

<210> 264
<211> 121
<212> PRT
<213> Artificial Sequence

<220>
<223> VH of the so-called "9B8-G6" anti-CD123 antibody

<400> 264

Glu Val Lys Leu Gln Glu Ser Gly Pro Ser Leu Val Gln Ser Ser Gln
1. 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser Tyr
20 25 30

His Ile His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Met
35 40 45

Gly Val Met Trp Ser Asp Gly Asp Thr Ser Tyr Ser Ser Ala Leu Lys
50 55 60

Ser Arg Leu Ser Ile Ser Arg Asp Thr Ser Gln Ser Gln Val Phe Leu
65 70 75 80

Lys Met Asn Ser Leu Gln Thr Glu Asp Thr Ala Thr Tyr Tyr Cys Ala
85 90 95

Arg Gly Asp Tyr Ser Ser Tyr Ile Tyr Leu Trp Phe Ala Tyr Trp Gly
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 265
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR1-H of the so-called "9B8-G6" and "9D7-C8" anti-CD123
antibodies

<400> 265

Gly Phe Ser Leu Thr Ser Tyr His
1. 5

<210> 266
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR2-H of the so-called "9B8-G6" and "9D7-C8" anti-CD123
antibodies

<400> 266

Met Trp Ser Asp Gly Asp Thr
1. 5

<210> 267
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR3-H of the so-called "9B8-G6" anti-CD123 antibody

<400> 267

Ala Arg Gly Asp Tyr Ser Ser Tyr Ile Tyr Leu Trp Phe Ala Tyr
1. 5 10 15

<210> 268
<211> 121
<212> PRT
<213> Artificial Sequence

<220>
<223> VH of the so-called "9D7-C8" anti-CD123 antibody

<400> 268

Glu Val Lys Leu Gln Glu Ser Gly Pro Ser Leu Val Gln Ser Ser Gln
1. 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser Tyr
20 25 30

His Ile His Trp Val Arg Gln Thr Pro Gly Lys Gly Leu Glu Trp Met
35 40 45

Gly Val Met Trp Ser Asp Gly Asp Thr Ser Tyr Asn Ser Ala Leu Lys
50 55 60

Ser Arg Leu Ser Ile Ser Arg Asp Thr Ser Gln Ser Gln Val Phe Leu
65 70 75 80

Lys Met Asn Ser Leu Gln Thr Glu Asp Thr Ala Thr Tyr Tyr Cys Ala
85 90 95

Arg Gly Tyr Tyr Ser Ser Tyr Leu Tyr Leu Trp Phe Ala Tyr Trp Gly
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 269
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR3-H of the so-called "9D7-C8" anti-CD123 antibody

<400> 269

Ala Arg Gly Tyr Tyr Ser Ser Tyr Leu Tyr Leu Trp Phe Ala Tyr
1. 5 10 15

<210> 270

<211> 113

<212> PRT

<213> Artificial Sequence

<220>

<223> VL of the so-called "9D7-C8" anti-CD123 antibody

<400> 270

Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ala Val Ser Glu Gly
1. 5 10 15

Glu Thr Val Thr Ile Asn Cys Lys Ser Ser Gln Ser Phe Leu Ser Ser
20 25 30

Gly Asp Gly Lys Asn Tyr Val Ala Trp Tyr Gln Tyr Lys Pro Gly Gln
35 40 45

Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Gln Ser Gly Val
50 55 60

Pro Asp Arg Phe Ile Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
65 70 75 80

Ile Ser Thr Val Gln Ala Glu Asp Leu Ala Ile Tyr Tyr Cys Gln Gln
85 90 95

Tyr Tyr Asp Thr Pro Leu Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile
100 105 110

Lys

<210> 271

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> CDR1-L of the so-called "9D7-C8" anti-CD123 antibody

<400> 271

Gln Ser Phe Leu Ser Ser Gly Asp Gly Lys Asn Tyr
1. 5 10

<210> 272

<211> 119

<212> PRT

<213> Artificial Sequence

<220>

<223> VH of the so-called "9F6-G3" anti-CD123 antibody

<400> 272

Gln Val Gln Leu Gln Glu Ser Gly Pro Thr Leu Val Lys Pro Gly Asp
1. 5 10 15

Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
20 25 30

Ile Ile His Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile
35 40 45

Gly Tyr Ile Asn Pro Tyr Ser Asp Gly Thr Asn Tyr Asn Glu Lys Phe
50 55 60

Lys Ser Lys Ala Thr Leu Thr Val Asp Lys Ser Thr Ser Thr Ala Tyr
65 70 75 80

Met Glu Phe Ser Arg Leu Thr Ser Glu Asp Ser Ala Ile Tyr Phe Cys
85 90 95

Ala Leu Asn Tyr Gly Ser Tyr Tyr Ala Met Asp Ala Trp Gly Gln Gly
100 105 110

Thr Ser Val Thr Val Ser Ser
115

<210> 273

<211> 8

<212> PRT

<213> Artificial Sequence

<220>
<223> CDR1-H of the so-called "9F6-G3" anti-CD123 antibody

<400> 273

Gly Tyr Thr Phe Thr Asp Tyr Ile
1. 5

<210> 274
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR2-H of the so-called "9F6-G3" anti-CD123 antibody

<400> 274

Ile Asn Pro Tyr Ser Asp Gly Thr
1. 5

<210> 275
<211> 107
<212> PRT
<213> Artificial Sequence

<220>
<223> VL of the so-called "9F6-G3" anti-CD123 antibody

<400> 275

Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Leu Gly
1. 5 10 15

Glu Thr Val Thr Ile Glu Cys Arg Pro Ser Glu Asp Ile His Ser Asn
20 25 30

Val Ala Trp Tyr Gln Gln Lys Pro Gly Asn Ser Pro Gln Leu Leu Ile
35 40 45

Tyr Asp Ala Ser Asn Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Gln Tyr Ser Leu Lys Ile Asn Ser Leu Gln Ser
65 70 75 80

Glu Asp Val Ala Ser Tyr Phe Cys His Gln Tyr Asn Ile Tyr Pro Tyr
85 90 95

Thr Phe Gly Ser Gly Thr Lys Leu Glu Leu Lys
100 105

<210> 276
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR1-L of the so-called "9F6-G3" anti-CD123 antibody

<400> 276

Glu Asp Ile His Ser Asn
1. 5

<210> 277
<211> 118
<212> PRT
<213> Artificial Sequence

<220>
<223> VH_G45A of humanized "3E3" anti-CD123 antibody

<400> 277

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Gln Pro Ser Gln
1. 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Thr Tyr
20 25 30

Asp Val His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Met
35 40 45

Gly Arg Ile Gln Asn Ala Gly Ile Thr Asp Tyr Asn Ser Ala Leu Lys
50 55 60

Ser Arg Leu Ile Ile Ser Arg Asp Thr Ser Lys Ser Gln Val Phe Leu
65 70 75 80

Lys Met Asn Ser Val Gln Thr Glu Asp Thr Ala Met Tyr Phe Cys Ala
85 90 95

Lys Thr Gly Ser Tyr Phe Tyr Ala Phe Asp His Trp Gly Gln Gly Thr
100 105 110

Leu Val Thr Val Ser Ser
115

<210> 278

<211> 118

<212> PRT

<213> Artificial Sequence

<220>

<223> VHMDG variant of "3E3" anti-CD123 antibody

<400> 278

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Gln Pro Ser Gln
1. 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Thr Tyr
20 25 30

Asp Val His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Met
35 40 45

Gly Arg Ile Gln Asp Gly Gly Ile Thr Asp Tyr Asn Ser Ala Leu Lys
50 55 60

Ser Arg Leu Ile Ile Ser Arg Asp Thr Ser Lys Ser Gln Val Phe Leu
65 70 75 80

Lys Met Asn Ser Val Gln Thr Glu Asp Thr Ala Met Tyr Phe Cys Ala
85 90 95

Lys Thr Gly Ser Tyr Phe Tyr Ala Phe Asp His Trp Gly Gln Gly Thr
100 105 110

Leu Val Thr Val Ser Ser
115

<210> 279

<211> 6

<212> PRT
<213> Artificial Sequence

<220>
<223> CDR2-H of VHmDG variant of "3E3" and CDR2H of humanized "3E3"
anti-CD123 antibody

<400> 279

Gln Asp Gly Gly Ile Thr
1. 5

<210> 280
<211> 118
<212> PRT
<213> Artificial Sequence

<220>
<223> VH1A of humanized "3E3" anti-CD123 antibody

<400> 280

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1. 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Thr Tyr
20 25 30

Asp Val His Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45

Gly Arg Ile Gln Asn Ala Gly Ile Thr Asp Tyr Asn Pro Ser Leu Lys
50 55 60

Ser Arg Val Thr Ile Ser Arg Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80

Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95

Lys Thr Gly Ser Tyr Phe Tyr Ala Phe Asp His Trp Gly Gln Gly Thr
100 105 110

Leu Val Thr Val Ser Ser
115

<210> 281
<211> 118
<212> PRT
<213> Artificial Sequence

<220>
<223> VH1B of humanized "3E3" anti-CD123 antibody

<400> 281

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1. 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Thr Tyr
20 25 30

Asp Val His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45

Gly Arg Ile Gln Asn Ala Gly Ile Thr Asp Tyr Asn Pro Ser Leu Lys
50 55 60

Ser Arg Val Thr Ile Ser Arg Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80

Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Phe Cys Ala
85 90 95

Lys Thr Gly Ser Tyr Phe Tyr Ala Phe Asp His Trp Gly Gln Gly Thr
100 105 110

Leu Val Thr Val Ser Ser
115

<210> 282
<211> 118
<212> PRT
<213> Artificial Sequence

<220>
<223> VH1C of humanized "3E3" anti-CD123 antibody

<400> 282

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1. 5

10

15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Thr Tyr
20 25 30

Asp Val His Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Met
35 40 45

Gly Arg Ile Gln Asn Ala Gly Ile Thr Asp Tyr Asn Pro Ser Leu Lys
50 55 60

Ser Arg Leu Thr Ile Ser Arg Asp Thr Ser Lys Asn Gln Val Ser Leu
65 70 75 80

Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95

Lys Thr Gly Ser Tyr Phe Tyr Ala Phe Asp His Trp Gly Gln Gly Thr
100 105 110

Leu Val Thr Val Ser Ser
115

<210> 283

<211> 118

<212> PRT

<213> Artificial Sequence

<220>

<223> VH1D of humanized "3E3" anti-CD123 antibody

<400> 283

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1. 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Thr Tyr
20 25 30

Asp Val His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Met
35 40 45

Gly Arg Ile Gln Asn Ala Gly Ile Thr Asp Tyr Asn Pro Ser Leu Lys

50		55		60
Ser Arg Leu Thr Ile	Ser Arg Asp Thr Ser	Lys Asn Gln Val Ser	Leu	
65	70	75	80	
Lys Leu Ser Ser Val	Thr Ala Ala Asp Thr	Ala Val Tyr Phe	Cys Ala	
	85	90	95	
Lys Thr Gly Ser Tyr	Phe Tyr Ala Phe	Asp His Trp Gly	Gln Gly Thr	
	100	105	110	
Leu Val Thr Val Ser	Ser			
	115			
<210>	284			
<211>	118			
<212>	PRT			
<213>	Artificial Sequence			
<220>				
<223>	VH1E of humanized "3E3" anti-CD123 antibody			
<400>	284			
Gln Val Gln Leu Gln	Glu Ser Gly Pro Gly	Leu Val Lys Pro	Ser Glu	
1. 5	10	15		
Thr Leu Ser Leu Thr	Cys Thr Val Ser	Gly Phe Ser Leu	Thr Thr Tyr	
	20	25	30	
Asp Val His Trp Val	Arg Gln Pro Pro	Gly Lys Gly Leu	Glu Trp Met	
	35	40	45	
Gly Arg Ile Gln Asn	Ala Gly Ile Thr	Asp Tyr Asn Pro	Ser Leu Lys	
	50	55	60	
Ser Arg Leu Thr Ile	Ser Arg Asp Thr Ser	Lys Ser Gln Val	Ser Leu	
65	70	75	80	
Lys Leu Ser Ser Val	Thr Ala Ala Asp Thr	Ala Val Tyr Phe	Cys Ala	
	85	90	95	
Lys Thr Gly Ser Tyr	Phe Tyr Ala Phe	Asp His Trp Gly	Gln Gly Thr	

100

105

110

Leu Val Thr Val Ser Ser
115

<210> 285

<211> 118

<212> PRT

<213> Artificial Sequence

<220>

<223> VH1F of humanized "3E3" anti-CD123 antibody

<400> 285

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1. 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Thr Tyr
20 25 30

Asp Val His Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Met
35 40 45

Gly Arg Ile Gln Asn Ala Gly Ile Thr Asp Tyr Asn Pro Ala Leu Lys
50 55 60

Ser Arg Leu Thr Ile Ser Arg Asp Thr Ser Lys Ser Gln Val Phe Leu
65 70 75 80

Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95

Lys Thr Gly Ser Tyr Phe Tyr Ala Phe Asp His Trp Gly Gln Gly Thr
100 105 110

Leu Val Thr Val Ser Ser
115

<210> 286

<211> 118

<212> PRT

<213> Artificial Sequence

<220>

<223> VH1G of humanized "3E3" anti-CD123 antibody

<400> 286

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1. 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Thr Tyr
20 25 30

Asp Val His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Met
35 40 45

Gly Arg Ile Gln Asn Ala Gly Ile Thr Asp Tyr Asn Pro Ala Leu Lys
50 55 60

Ser Arg Leu Thr Ile Ser Arg Asp Thr Ser Lys Ser Gln Val Phe Leu
65 70 75 80

Lys Leu Ser Ser Val Gln Ala Ala Asp Thr Ala Val Tyr Phe Cys Ala
85 90 95

Lys Thr Gly Ser Tyr Phe Tyr Ala Phe Asp His Trp Gly Gln Gly Thr
100 105 110

Leu Val Thr Val Ser Ser
115

<210> 287

<211> 118

<212> PRT

<213> Artificial Sequence

<220>

<223> VH1Fm1 of humanized "3E3" anti-CD123 antibody

<400> 287

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1. 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Thr Tyr
20 25 30

Asp Val His Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Met
35 40 45

Gly Arg Ile Gln Asn Ala Gly Ile Thr Asp Tyr Asn Pro Ala Leu Lys
50 55 60

Ser Arg Leu Thr Ile Ser Arg Asp Thr Ser Lys Ser Gln Val Phe Leu
65 70 75 80

Lys Met Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95

Lys Thr Gly Ser Tyr Phe Tyr Ala Phe Asp His Trp Gly Gln Gly Thr
100 105 110

Leu Val Thr Val Ser Ser
115

<210> 288

<211> 118

<212> PRT

<213> Artificial Sequence

<220>

<223> VH1Fm2 of humanized "3E3" anti-CD123 antibody

<400> 288

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1. 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Thr Tyr
20 25 30

Asp Val His Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Met
35 40 45

Gly Arg Ile Gln Asn Ala Gly Ile Thr Asp Tyr Asn Pro Ser Leu Lys
50 55 60

Ser Arg Leu Thr Ile Ser Arg Asp Thr Ser Lys Ser Gln Val Ser Leu
65 70 75 80

Lys Met Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95

Lys Thr Gly Ser Tyr Phe Tyr Ala Phe Asp His Trp Gly Gln Gly Thr
100 105 110

Leu Val Thr Val Ser Ser
115

<210> 289
<211> 118
<212> PRT
<213> Artificial Sequence

<220>
<223> VH1Fm2DG of humanized "3E3" anti-CD123 antibody

<400> 289

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1. 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Thr Tyr
20 25 30

Asp Val His Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Met
35 40 45

Gly Arg Ile Gln Asp Gly Gly Ile Thr Asp Tyr Asn Pro Ser Leu Lys
50 55 60

Ser Arg Leu Thr Ile Ser Arg Asp Thr Ser Lys Ser Gln Val Ser Leu
65 70 75 80

Lys Met Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95

Lys Thr Gly Ser Tyr Phe Tyr Ala Phe Asp His Trp Gly Gln Gly Thr
100 105 110

Leu Val Thr Val Ser Ser
115

<210> 290
<211> 118
<212> PRT
<213> Artificial Sequence

<220>
<223> VH1Dm1 of humanized "3E3" anti-CD123 antibody

<400> 290

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1. 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Thr Tyr
20 25 30

Asp Val His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Met
35 40 45

Gly Arg Ile Gln Asn Ala Gly Ile Thr Asp Tyr Asn Pro Ser Leu Lys
50 55 60

Ser Arg Leu Thr Ile Ser Arg Asp Thr Ser Lys Asn Gln Val Ser Leu
65 70 75 80

Lys Met Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Phe Cys Ala
85 90 95

Lys Thr Gly Ser Tyr Phe Tyr Ala Phe Asp His Trp Gly Gln Gly Thr
100 105 110

Leu Val Thr Val Ser Ser
115

<210> 291
<211> 118
<212> PRT
<213> Artificial Sequence

<220>
<223> VH1Em1 of humanized "3E3" anti-CD123 antibody

<400> 291

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

1. 5

10

15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Thr Tyr
20 25 30

Asp Val His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Met
35 40 45

Gly Arg Ile Gln Asn Ala Gly Ile Thr Asp Tyr Asn Pro Ala Leu Lys
50 55 60

Ser Arg Leu Thr Ile Ser Arg Asp Thr Ser Lys Ser Gln Val Ser Leu
65 70 75 80

Lys Met Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Phe Cys Ala
85 90 95

Lys Thr Gly Ser Tyr Phe Tyr Ala Phe Asp His Trp Gly Gln Gly Thr
100 105 110

Leu Val Thr Val Ser Ser
115

<210> 292

 $\langle 211 \rangle$ 111

<212> PRT

<213> Artificial Sequence

 $\langle 220 \rangle$

<223> VL1A of humanized "3E3" anti-CD123 antibody

<400> 292

Asn Phe Val Leu Thr Gln Pro His Ser Val Ser Glu Ser Pro Gly Lys
1. 5 10 15

Thr Val Thr Ile Ser Cys Thr Arg Asn Thr Gly Asn Ile Gly Ser Asn
20 25 30

Tyr Val Gln Trp Tyr Gln Gln Arg Pro Gly Ser Ser Pro Thr Thr Val
35 40 45

Ile Tyr Arg Asp Asp Lys Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50		55		60											
Gly	Ser	Ile	Asp	Ser	Ser	Ser	Asn	Ser	Ala	Ser	Leu	Thr	Ile	Ser	Gly
65					70					75					80
Leu	Lys	Thr	Glu	Asp	Glu	Ala	Asp	Tyr	Tyr	Cys	Gln	Ser	Tyr	Ser	Ser
				85					90					95	
Gly	Ile	Asn	Ile	Ile	Phe	Gly	Gly	Gly	Thr	Lys	Leu	Thr	Val	Leu	
			100					105						110	

<210> 293
 <211> 111
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> VL1B of humanized "3E3" anti-CD123 antibody

<400> 293

Asn	Phe	Val	Leu	Thr	Gln	Pro	His	Ser	Val	Ser	Glu	Ser	Pro	Gly	Lys
1.	5					10					15				
Thr	Val	Thr	Ile	Ser	Cys	Thr	Arg	Asn	Thr	Gly	Asn	Ile	Gly	Ser	Asn
			20					25					30		
Tyr	Val	Asn	Trp	Tyr	Gln	Gln	Arg	Pro	Gly	Ser	Ser	Pro	Thr	Thr	Val
		35					40					45			
Ile	Tyr	Arg	Asp	Asp	Lys	Arg	Pro	Ser	Gly	Val	Pro	Asp	Arg	Phe	Ser
	50					55					60				
Gly	Ser	Ile	Asp	Ser	Ser	Ser	Asn	Ser	Ala	Ser	Leu	Thr	Ile	Ser	Gly
65					70					75					80
Leu	Lys	Thr	Glu	Asp	Glu	Ala	Asp	Tyr	Phe	Cys	Gln	Ser	Tyr	Ser	Ser
				85					90					95	
Gly	Ile	Asn	Ile	Ile	Phe	Gly	Gly	Gly	Thr	Lys	Leu	Thr	Val	Leu	
			100					105						110	

<210> 294

<211> 111
<212> PRT
<213> Artificial Sequence

<220>
<223> VL1C of humanized "3E3" anti-CD123 antibody

<400> 294

Asn Phe Val Leu Thr Gln Pro His Ser Val Ser Glu Ser Pro Gly Lys
1. 5 10 15

Thr Val Thr Ile Ser Cys Thr Arg Asn Thr Gly Asn Ile Gly Ser Asn
20 25 30

Tyr Val Asn Trp Tyr Gln Gln Arg Pro Gly Ser Ser Pro Thr Thr Met
35 40 45

Ile Tyr Arg Asp Asp Lys Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60

Gly Ser Ile Asp Ser Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly
65 70 75 80

Leu Lys Thr Glu Asp Glu Ala Asp Tyr Phe Cys Gln Ser Tyr Ser Ser
85 90 95

Gly Ile Asn Ile Ile Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110

<210> 295
<211> 111
<212> PRT
<213> Artificial Sequence

<220>
<223> VL1D of humanized "3E3" anti-CD123 antibody

<400> 295

Asn Phe Val Leu Thr Gln Pro His Ser Val Ser Glu Ser Pro Gly Lys
1. 5 10 15

Thr Val Thr Ile Ser Cys Thr Arg Asn Thr Gly Asn Ile Gly Ser Asn
20 25 30

Tyr Val Asn Trp Tyr Gln Gln His Pro Gly Ser Ser Pro Thr Thr Met
35 40 45

Ile Tyr Arg Asp Asp Lys Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60

Gly Ser Ile Asp Ser Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly
65 70 75 80

Leu Lys Thr Glu Asp Glu Ala Asp Tyr Phe Cys Gln Ser Tyr Ser Ser
85 90 95

Gly Ile Asn Ile Ile Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110

<210> 296

<211> 111

<212> PRT

<213> Artificial Sequence

<220>

<223> VL1E of humanized "3E3" anti-CD123 antibody

<400> 296

Asn Phe Val Leu Thr Gln Pro His Ser Val Ser Thr Ser Pro Gly Ser
1. 5 10 15

Thr Val Thr Ile Ser Cys Thr Arg Asn Thr Gly Asn Ile Gly Ser Asn
20 25 30

Tyr Val Asn Trp Tyr Gln Gln Arg Pro Gly Ser Ser Pro Thr Thr Met
35 40 45

Ile Tyr Arg Asp Asp Lys Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60

Gly Ser Ile Asp Ser Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly
65 70 75 80

Leu Lys Thr Glu Asp Glu Ala Asp Tyr Phe Cys Gln Ser Tyr Ser Ser
85 90 95

Gly Ile Asn Ile Ile Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110

<210> 297

<211> 111

<212> PRT

<213> Artificial Sequence

<220>

<223> VL1F of humanized "3E3" anti-CD123 antibody

<400> 297

Asn Phe Val Leu Thr Gln Pro His Ser Val Ser Thr Ser Pro Gly Ser
1. 5 10 15

Thr Val Thr Ile Ser Cys Thr Arg Asn Thr Gly Asn Ile Gly Ser Asn
20 25 30

Tyr Val Asn Trp Tyr Gln Gln Arg Pro Gly Ser Ser Pro Thr Thr Met
35 40 45

Ile Tyr Arg Asp Asp Lys Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60

Gly Ser Ile Asp Ser Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly
65 70 75 80

Val Lys Thr Glu Asp Glu Ala Asp Tyr Phe Cys Gln Ser Tyr Ser Ser
85 90 95

Gly Ile Asn Ile Ile Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110

<210> 298

<211> 111

<212> PRT

<213> Artificial Sequence

<220>

<223> VL1G of humanized "3E3" anti-CD123 antibody

<400> 298

Asn Phe Val Leu Thr Gln Pro His Ser Val Ser Thr Ser Pro Gly Ser

1. 5

10

15

Thr Val Thr Ile Ser Cys Thr Arg Asn Thr Gly Asn Ile Gly Ser Asn
20 25 30

Tyr Val Asn Trp Tyr Gln Gln His Pro Gly Ser Ser Pro Thr Thr Met
35 40 45

Ile Tyr Arg Asp Asp Lys Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60

Gly Ser Ile Asp Ser Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly
65 70 75 80

Val Lys Thr Glu Asp Glu Ala Asp Tyr Phe Cys Gln Ser Tyr Ser Ser
85 90 95

Gly Ile Asn Ile Ile Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110

<210> 299

<211> 111

<212> PRT

<213> Artificial Sequence

<220>

<223> VL1Fm1 of humanized "3E3" anti-CD123 antibody

<400> 299

Asn Phe Val Leu Thr Gln Pro His Ser Val Ser Thr Ser Pro Gly Ser
1. 5 10 15

Thr Val Thr Ile Ser Cys Thr Arg Asn Thr Gly Asn Ile Gly Ser Asn
20 25 30

Tyr Val Asn Trp Tyr Gln Gln Arg Pro Gly Ser Ser Pro Thr Thr Met
35 40 45

Ile Tyr Arg Asp Asp Lys Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60

Gly Ser Ile Asp Arg Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly

65		70		75		80									
Val	Lys	Thr	Glu	Asp	Glu	Ala	Asp	Tyr	Phe	Cys	Gln	Ser	Tyr	Ser	Ser
				85					90					95	

Gly	Ile	Asn	Ile	Ile	Phe	Gly	Gly	Gly	Thr	Lys	Leu	Thr	Val	Leu
			100					105						110

<210> 300
 <211> 111
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> VL1Fm2 of humanized "3E3" anti-CD123 antibody

<400> 300

Asn	Phe	Val	Leu	Thr	Gln	Pro	His	Ser	Val	Ser	Thr	Ser	Pro	Gly	Ser
1.	5					10				15					

Thr	Val	Thr	Leu	Ser	Cys	Thr	Arg	Asn	Thr	Gly	Asn	Ile	Gly	Ser	Asn
			20					25					30		

Tyr	Val	Asn	Trp	Tyr	Gln	Gln	Arg	Pro	Gly	Ser	Ser	Pro	Thr	Thr	Met
		35					40					45			

Ile	Tyr	Arg	Asp	Asp	Lys	Arg	Pro	Asp	Gly	Val	Pro	Asp	Arg	Phe	Ser
	50					55					60				

Gly	Ser	Ile	Asp	Arg	Ser	Ser	Asn	Ser	Ala	Ser	Leu	Thr	Ile	Ser	Gly
65					70					75					80

Val	Lys	Thr	Glu	Asp	Glu	Ala	Asp	Tyr	Phe	Cys	Gln	Ser	Tyr	Ser	Ser
				85					90					95	

Gly	Ile	Asn	Ile	Ile	Phe	Gly	Gly	Gly	Thr	Lys	Leu	Thr	Val	Leu
			100					105						110

<210> 301
 <211> 118
 <212> PRT
 <213> Artificial Sequence

<220>

<223> VH2A of humanized "3E3" anti-CD123 antibody

<400> 301

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1. 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Thr Tyr
20 25 30

Asp Val His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Met
35 40 45

Gly Arg Ile Gln Asn Ala Gly Ile Thr Asp Tyr Asn Ser Ala Leu Lys
50 55 60

Ser Arg Leu Ile Ile Ser Arg Asp Thr Ser Lys Ser Gln Val Phe Leu
65 70 75 80

Lys Met Asn Ser Val Thr Thr Ala Asp Thr Ala Met Tyr Phe Cys Ala
85 90 95

Lys Thr Gly Ser Tyr Phe Tyr Ala Phe Asp His Trp Gly Gln Gly Thr
100 105 110

Leu Val Thr Val Ser Ser
115

<210> 302

<211> 118

<212> PRT

<213> Artificial Sequence

<220>

<223> VH3A of humanized "3E3" anti-CD123 antibody

<400> 302

Gln Val Thr Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln
1. 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Thr Tyr
20 25 30

Asp Val His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Met
35 40 45

Gly Arg Ile Gln Asn Ala Gly Ile Thr Asp Tyr Asn Ser Ala Leu Lys
50 55 60

Ser Arg Leu Ile Ile Ser Arg Asp Thr Ser Lys Ser Gln Val Phe Leu
65 70 75 80

Lys Met Asn Ser Val Asp Thr Val Asp Thr Ala Met Tyr Phe Cys Ala
85 90 95

Lys Thr Gly Ser Tyr Phe Tyr Ala Phe Asp His Trp Gly Gln Gly Thr
100 105 110

Leu Val Thr Val Ser Ser
115

<210> 303
<211> 111
<212> PRT
<213> Artificial Sequence

<220>
<223> VL2A of humanized "3E3" anti-CD123 antibody.

<400> 303

Gln Phe Val Leu Thr Gln Pro Pro Ser Val Ser Thr Asn Pro Gly Ser
1. 5 10 15

Thr Val Lys Leu Ser Cys Lys Arg Asn Thr Gly Asn Ile Gly Ser Asn
20 25 30

Tyr Val Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Thr Thr Met
35 40 45

Ile Tyr Arg Asp Asp Lys Arg Pro Asp Gly Val Pro Asp Arg Phe Ser
50 55 60

Gly Ser Ile Asp Arg Ser Ser Asn Ser Ala Leu Leu Thr Ile Asn Asn
65 70 75 80

Val Gln Thr Glu Asp Glu Ala Asp Tyr Phe Cys Gln Ser Tyr Ser Ser
85 90 95

Gly Ile Asn Ile Ile Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110

<210> 304

<211> 111

<212> PRT

<213> Artificial Sequence

<220>

<223> VL2Am1 of humanized "3E3" anti-CD123 antibody

<400> 304

Gln Phe Val Leu Thr Gln Pro His Ser Val Ser Thr Asn Pro Gly Ser
1. 5 10 15

Thr Val Lys Leu Ser Cys Lys Arg Asn Thr Gly Asn Ile Gly Ser Asn
20 25 30

Tyr Val Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Thr Thr Met
35 40 45

Ile Tyr Arg Asp Asp Lys Arg Pro Asp Gly Val Pro Asp Arg Phe Ser
50 55 60

Gly Ser Ile Asp Arg Ser Ser Asn Ser Ala Leu Leu Thr Ile Asn Asn
65 70 75 80

Val Gln Thr Glu Asp Glu Ala Asp Tyr Phe Cys Gln Ser Tyr Ser Ser
85 90 95

Gly Ile Asn Ile Ile Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110

<210> 305

<211> 111

<212> PRT

<213> Artificial Sequence

<220>

<223> VL2Am2 of humanized "3E3" anti-CD123 antibody.

<400> 305

Gln Phe Val Leu Thr Gln Pro His Ser Val Ser Thr Asn Pro Gly Ser
1. 5 10 15

Thr Val Lys Leu Ser Cys Lys Arg Asn Thr Gly Asn Ile Gly Ser Asn
20 25 30

Tyr Val Asn Trp Tyr Gln Gln Arg Pro Gly Ser Ser Pro Thr Thr Met
35 40 45

Ile Tyr Arg Asp Asp Lys Arg Pro Asp Gly Val Pro Asp Arg Phe Ser
50 55 60

Gly Ser Ile Asp Arg Ser Ser Asn Ser Ala Leu Leu Thr Ile Asn Asn
65 70 75 80

Val Gln Thr Glu Asp Glu Ala Asp Tyr Phe Cys Gln Ser Tyr Ser Ser
85 90 95

Gly Ile Asn Ile Ile Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110

<210> 306

<211> 344

<212> PRT

<213> Artificial Sequence

<220>

<223> polypeptide I of the so-called CODV-Fab "7G3 x 20G6"
antibody-like binding protein

<400> 306

Asp Val Val Met Thr Gln Thr Pro Val Ser Leu Ser Val Ser Leu Gly
1. 5 10 15

Gly Gln Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asn
20 25 30

Asn Gly Asn Thr Tyr Leu Ser Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45

Pro Gln Ser Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Phe Ser
50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80

Ser Arg Val Asp Pro Asp Asp Leu Gly Val Tyr Tyr Cys Gly Gln Gly
85 90 95

Thr Gln Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
100 105 110

Gly Gln Pro Lys Ala Ala Pro Asp Phe Val Met Thr Gln Ser Pro Ser
115 120 125

Ser Leu Thr Val Thr Ala Gly Glu Lys Val Thr Met Ser Cys Lys Ser
130 135 140

Ser Gln Ser Leu Leu Asn Ser Gly Asn Gln Lys Asn Tyr Leu Thr Trp
145 150 155 160

Tyr Leu Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala
165 170 175

Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser
180 185 190

Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Ala Glu Asp Leu
195 200 205

Ala Val Tyr Tyr Cys Gln Asn Asp Tyr Ser Tyr Pro Tyr Thr Phe Gly
210 215 220

Gly Gly Thr Lys Leu Glu Ile Lys Thr Lys Gly Pro Ser Arg Thr Val
225 230 235 240

Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys
245 250 255

Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg
260 265 270

Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn
275 280 285

Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser
290 295 300

Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys
305 310 315 320

Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr
325 330 335

Lys Ser Phe Asn Arg Gly Glu Cys
340

<210> 307

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> L1 of the so-called CODV-Fab "7G3x20G6", "7G3x4E7", "7G3x4B4",
"7G3x18F5", "hz20G6x7G3", "7G3xhz4B4", "hz4B4x3E3" and CODV-Fab
"hz20G6x7G3-TL4" antibody-like binding proteins

<400> 307

Gly Gln Pro Lys Ala Ala Pro
1. 5

<210> 308

<211> 113

<212> PRT

<213> Artificial Sequence

<220>

<223> VL1 or VL2 domain of the so-called CODV-Fab "7G3x20G6",
"7G3x4E7", "7G3x4B4", "7G3x18F5", "hz20G6x7G3", "7G3xhz4B4" and
CODV-Fab "hz20G6x7G3-TL4" antibody-like binding proteins

<400> 308

Asp Phe Val Met Thr Gln Ser Pro Ser Ser Leu Thr Val Thr Ala Gly
1. 5 10 15

Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser
20 25 30

Gly Asn Gln Lys Asn Tyr Leu Thr Trp Tyr Leu Gln Lys Pro Gly Gln
35 40 45

Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
50 55 60

Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
65 70 75 80

Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Asn
85 90 95

Asp Tyr Ser Tyr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile
100 105 110

Lys

<210> 309

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> L2 of the so-called CODV-Fab "7G3x20G6", "7G3x4E7", "7G3x4B4",
"7G3x18F5", "hz20G6x7G3", "7G3xhz4B4", "hz4B4x3E3" and CODV-Fab
"hz20G6x7G3-TL4" antibody-like binding proteins

<400> 309

Thr Lys Gly Pro Ser

1. 5

<210> 310

<211> 107

<212> PRT

<213> Artificial Sequence

<220>

<223> CL of the so-called CODV-Fab "7G3x20G6", "7G3x4E7", "7G3x4B4",
"7G3x18F5", "hz20G6x7G3", "7G3xhz4B4" and "hz4B4x3E3"
antibody-like binding proteins

<400> 310

Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu
1. 5 10 15

Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe
20 25 30

Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln
35 40 45

Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser
50 55 60

Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu
65 70 75 80

Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser
85 90 95

Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
100 105

<210> 311

<211> 342

<212> PRT

<213> Artificial Sequence

<220>

<223> polypeptide II of the so-called CODV-Fab "7G3 x 20G6"
antibody-like binding protein

<400> 311

Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
1. 5 10 15

Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
20 25 30

Tyr Met Lys Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile
35 40 45

Gly Asp Ile Ile Pro Ser Asn Gly Ala Thr Phe Tyr Asn Gln Lys Phe

50		55		60													
Lys	Gly	Lys	Ala	Thr	Leu	Thr	Val	Asp	Arg	Ser	Ser	Ser	Thr	Ala	Tyr		
65					70					75					80		
Met	His	Leu	Asn	Ser	Leu	Thr	Ser	Glu	Asp	Ser	Ala	Val	Tyr	Tyr	Cys		
			85						90					95			
Thr	Arg	Ser	His	Leu	Leu	Arg	Ala	Ser	Trp	Phe	Ala	Tyr	Trp	Gly	Gln		
			100					105					110				
Gly	Thr	Leu	Val	Thr	Val	Ser	Ala	Ser	Glu	Val	Gln	Leu	Val	Glu	Thr		
		115					120					125					
Gly	Gly	Ser	Leu	Val	Gln	Pro	Gly	Lys	Ser	Leu	Lys	Leu	Thr	Cys	Ala		
	130					135					140						
Thr	Ser	Gly	Phe	Thr	Phe	Thr	Lys	Ala	Trp	Met	His	Trp	Val	Arg	Gln		
145					150					155					160		
Ser	Pro	Glu	Lys	Gln	Leu	Glu	Trp	Val	Ala	Gln	Ile	Lys	Asp	Lys	Ser		
				165					170					175			
Asn	Ser	Tyr	Ala	Thr	Tyr	Tyr	Ala	Glu	Ser	Val	Lys	Gly	Arg	Phe	Thr		
			180					185					190				
Ile	Ser	Arg	Asp	Asp	Ser	Lys	Ser	Thr	Ile	Tyr	Leu	Gln	Met	Asn	Ser		
		195					200					205					
Leu	Lys	Glu	Glu	Asp	Thr	Ala	Ile	Tyr	Tyr	Cys	Arg	Gly	Val	Tyr	Tyr		
	210					215					220						
Ala	Leu	Ser	Pro	Phe	Asp	Tyr	Trp	Gly	Gln	Gly	Val	Met	Val	Thr	Val		
225					230					235					240		
Ser	Ser	Arg	Thr	Ala	Ser	Thr	Lys	Gly	Pro	Ser	Val	Phe	Pro	Leu	Ala		
				245					250					255			
Pro	Ser	Ser	Lys	Ser	Thr	Ser	Gly	Gly	Thr	Ala	Ala	Leu	Gly	Cys	Leu		
			260				265						270				

Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly
275 280 285

Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser
290 295 300

Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu
305 310 315 320

Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr
325 330 335

Lys Val Asp Lys Lys Val
340

<210> 312

<211> 120

<212> PRT

<213> Artificial Sequence

<220>

<223> VH1 or VH2 domain of the so-called CODV-Fab "7G3x20G6",
"7G3x4E7", "7G3x4B4", "7G3x18F5", "hz20G6x7G3", "7G3xhz4B4" and
CODV-Fab "hz20G6x7G3-TL4" antibody-like binding proteins

<400> 312

Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
1. 5 10 15

Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
20 25 30

Tyr Met Lys Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile
35 40 45

Gly Asp Ile Ile Pro Ser Asn Gly Ala Thr Phe Tyr Asn Gln Lys Phe
50 55 60

Lys Gly Lys Ala Thr Leu Thr Val Asp Arg Ser Ser Ser Thr Ala Tyr
65 70 75 80

Met His Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys

85

90

95

Thr Arg Ser His Leu Leu Arg Ala Ser Trp Phe Ala Tyr Trp Gly Gln
 100 105 110

Gly Thr Leu Val Thr Val Ser Ala
 115 120

<210> 313

<211> 98

<212> PRT

<213> Artificial Sequence

<220>

<223> CH1 of the so-called CODV-Fab "7G3x20G6", "7G3x4E7", "7G3x4B4",
 "7G3x18F5", "hz20G6x7G3", "7G3xhz4B4", "hz4B4x3E3" antibody-

like

binding proteins

<400> 313

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
 1. 5 10 15

Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
 20 25 30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
 35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
 50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
 65 70 75 80

Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
 85 90 95

Lys Val

<210> 314

<211> 344

<212> PRT

<213> Artificial Sequence

<220>

<223> polypeptide I of the so-called CODV-Fab "7G3 x 4E7" antibody-like
binding protein

<400> 314

Asp Val Val Met Thr Gln Thr Pro Val Ser Leu Ser Val Ser Leu Gly
1. 5 10 15

Gly Gln Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Glu His Asn
20 25 30

Asn Gly Asn Thr Tyr Leu Ser Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45

Pro Gln Pro Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Ile Ser
50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80

Ser Arg Val Glu Pro Asp Asp Leu Gly Val Tyr Tyr Cys Gly Gln Gly
85 90 95

Thr Gln Tyr Pro Phe Thr Phe Gly Pro Gly Thr Lys Leu Glu Leu Lys
100 105 110

Gly Gln Pro Lys Ala Ala Pro Asp Phe Val Met Thr Gln Ser Pro Ser
115 120 125

Ser Leu Thr Val Thr Ala Gly Glu Lys Val Thr Met Ser Cys Lys Ser
130 135 140

Ser Gln Ser Leu Leu Asn Ser Gly Asn Gln Lys Asn Tyr Leu Thr Trp
145 150 155 160

Tyr Leu Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala
165 170 175

Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser
180 185 190

Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Ala Glu Asp Leu
195 200 205

Ala Val Tyr Tyr Cys Gln Asn Asp Tyr Ser Tyr Pro Tyr Thr Phe Gly
210 215 220

Gly Gly Thr Lys Leu Glu Ile Lys Thr Lys Gly Pro Ser Arg Thr Val
225 230 235 240

Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys
245 250 255

Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg
260 265 270

Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn
275 280 285

Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser
290 295 300

Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys
305 310 315 320

Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr
325 330 335

Lys Ser Phe Asn Arg Gly Glu Cys
340

<210> 315

<211> 343

<212> PRT

<213> Artificial Sequence

<220>

<223> polypeptide II of the so-called CODV-Fab "7G3 x 4E7"
antibody-like binding protein

<400> 315

Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
1. 5 10 15

Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
20 25 30

Tyr Met Lys Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile
35 40 45

Gly Asp Ile Ile Pro Ser Asn Gly Ala Thr Phe Tyr Asn Gln Lys Phe
50 55 60

Lys Gly Lys Ala Thr Leu Thr Val Asp Arg Ser Ser Ser Thr Ala Tyr
65 70 75 80

Met His Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
85 90 95

Thr Arg Ser His Leu Leu Arg Ala Ser Trp Phe Ala Tyr Trp Gly Gln
100 105 110

Gly Thr Leu Val Thr Val Ser Ala Ser Glu Val Gln Val Val Glu Thr
115 120 125

Gly Gly Ser Leu Val Gln Pro Gly Lys Ser Leu Lys Leu Thr Cys Ala
130 135 140

Thr Ser Gly Phe Thr Phe Ser Asn Ala Trp Met His Trp Val Arg Gln
145 150 155 160

Ser Pro Glu Lys Gln Leu Glu Trp Val Ala Gln Ile Lys Asp Lys Ser
165 170 175

Asn Asn Tyr Ala Thr Tyr Tyr Ala Glu Ser Leu Lys Gly Arg Phe Thr
180 185 190

Ile Ser Arg Asp Asp Pro Lys Arg Ser Ile Tyr Leu Gln Met Asn Ser
195 200 205

Leu Arg Glu Glu Asp Thr Ala Ile Tyr Tyr Cys Arg Tyr Val His Tyr

210		215		220
Gly Ile Gly Tyr Ala Met Asp Ala Trp Gly Gln Gly Thr Ser Val Thr				
225		230		235
Val Ser Ser Arg Thr Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu				
	245		250	255
Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys				
	260		265	270
Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser				
	275		280	285
Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser				
	290		295	300
Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser				
305		310		315
Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn				
	325		330	335
Thr Lys Val Asp Lys Lys Val				
	340			
<210> 316				
<211> 344				
<212> PRT				
<213> Artificial Sequence				
<220>				
<223> polypeptide I of the so-called CODV-Fab "7G3 x 4B4" antibody-				
like				
binding protein				
<400> 316				
Asp Val Val Met Thr Gln Thr Pro Val Ser Leu Ser Val Ser Leu Gly				
1. 5		10		15
Gly Gln Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asp				
	20		25	30

Asn Gly Asn Thr Tyr Leu Ser Trp Ser Leu Gln Arg Pro Gly Gln Ser
35 40 45

Pro Gln Val Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Thr Ser
50 55 60

Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80

Ser Arg Val Glu Pro Asp Asp Leu Gly Val Tyr Tyr Cys Gly Gln Gly
85 90 95

Thr Gln Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
100 105 110

Gly Gln Pro Lys Ala Ala Pro Asp Phe Val Met Thr Gln Ser Pro Ser
115 120 125

Ser Leu Thr Val Thr Ala Gly Glu Lys Val Thr Met Ser Cys Lys Ser
130 135 140

Ser Gln Ser Leu Leu Asn Ser Gly Asn Gln Lys Asn Tyr Leu Thr Trp
145 150 155 160

Tyr Leu Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala
165 170 175

Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser
180 185 190

Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Ala Glu Asp Leu
195 200 205

Ala Val Tyr Tyr Cys Gln Asn Asp Tyr Ser Tyr Pro Tyr Thr Phe Gly
210 215 220

Gly Gly Thr Lys Leu Glu Ile Lys Thr Lys Gly Pro Ser Arg Thr Val
225 230 235 240

Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys

Lys Gly Lys Ala Thr Leu Thr Val Asp Arg Ser Ser Ser Thr Ala Tyr
65 70 75 80

Met His Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
85 90 95

Thr Arg Ser His Leu Leu Arg Ala Ser Trp Phe Ala Tyr Trp Gly Gln
100 105 110

Gly Thr Leu Val Thr Val Ser Ala Ser Glu Val Gln Leu Val Glu Thr
115 120 125

Gly Gly Arg Leu Val Gln Pro Gly Arg Ser Leu Lys Leu Thr Cys Ala
130 135 140

Thr Ser Gly Phe Thr Phe Ser Asn Ala Trp Met His Trp Val Arg Gln
145 150 155 160

Ser Pro Glu Lys Gln Leu Glu Trp Val Ala Gln Ile Lys Ala Arg Ser
165 170 175

Asn Asn Tyr Ala Thr Tyr Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr
180 185 190

Ile Ser Arg Asp Asp Ser Lys Ser Thr Ile Tyr Leu Gln Met Asn Ser
195 200 205

Leu Lys Glu Glu Asp Thr Ala Ile Tyr Tyr Cys Arg Gly Thr Tyr Tyr
210 215 220

Ala Ser Lys Pro Phe Asp Tyr Trp Gly Gln Gly Val Met Val Thr Val
225 230 235 240

Ser Ser Arg Thr Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala
245 250 255

Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu
260 265 270

Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly
275 280 285

Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser
290 295 300

Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu
305 310 315 320

Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr
325 330 335

Lys Val Asp Lys Lys Val
340

<210> 318

<211> 344

<212> PRT

<213> Artificial Sequence

<220>

<223> polypeptide I of the so-called CODV-Fab "7G3x18F5" antibody-
like
binding protein.

<400> 318

Asp Val Leu Met Thr Gln Thr Pro Val Ser Leu Ser Val Ser Leu Gly
1. 5 10 15

Gly Gln Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Thr
20 25 30

Asn Gly Asn Thr Tyr Leu Ser Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45

Pro Gln Leu Leu Ile Tyr Lys Val Ser Asn Arg Leu Ser Gly Ile Ser
50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80

Ser Arg Val Glu Pro Asp Asp Leu Gly Val Tyr Tyr Cys Gly Gln Gly
85 90 95

Thr	His	Tyr	Pro	Phe	Thr	Phe	Gly	Ala	Gly	Thr	Lys	Leu	Glu	Leu	Lys	100	105	110
Gly	Gln	Pro	Lys	Ala	Ala	Pro	Asp	Phe	Val	Met	Thr	Gln	Ser	Pro	Ser	115	120	125
Ser	Leu	Thr	Val	Thr	Ala	Gly	Glu	Lys	Val	Thr	Met	Ser	Cys	Lys	Ser	130	135	140
Ser	Gln	Ser	Leu	Leu	Asn	Ser	Gly	Asn	Gln	Lys	Asn	Tyr	Leu	Thr	Trp	145	150	155
Tyr	Leu	Gln	Lys	Pro	Gly	Gln	Pro	Pro	Lys	Leu	Leu	Ile	Tyr	Trp	Ala	165	170	175
Ser	Thr	Arg	Glu	Ser	Gly	Val	Pro	Asp	Arg	Phe	Thr	Gly	Ser	Gly	Ser	180	185	190
Gly	Thr	Asp	Phe	Thr	Leu	Thr	Ile	Ser	Ser	Val	Gln	Ala	Glu	Asp	Leu	195	200	205
Ala	Val	Tyr	Tyr	Cys	Gln	Asn	Asp	Tyr	Ser	Tyr	Pro	Tyr	Thr	Phe	Gly	210	215	220
Gly	Gly	Thr	Lys	Leu	Glu	Ile	Lys	Thr	Lys	Gly	Pro	Ser	Arg	Thr	Val	225	230	235
Ala	Ala	Pro	Ser	Val	Phe	Ile	Phe	Pro	Pro	Ser	Asp	Glu	Gln	Leu	Lys	245	250	255
Ser	Gly	Thr	Ala	Ser	Val	Val	Cys	Leu	Leu	Asn	Asn	Phe	Tyr	Pro	Arg	260	265	270
Glu	Ala	Lys	Val	Gln	Trp	Lys	Val	Asp	Asn	Ala	Leu	Gln	Ser	Gly	Asn	275	280	285
Ser	Gln	Glu	Ser	Val	Thr	Glu	Gln	Asp	Ser	Lys	Asp	Ser	Thr	Tyr	Ser	290	295	300
Leu	Ser	Ser	Thr	Leu	Thr	Leu	Ser	Lys	Ala	Asp	Tyr	Glu	Lys	His	Lys	305	310	315

Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr
325 330 335

Lys Ser Phe Asn Arg Gly Glu Cys
340

<210> 319

<211> 343

<212> PRT

<213> Artificial Sequence

<220>

<223> polypeptide II of the so-called CODV-Fab "7G3x18F5" antibody-
like
binding protein.

<400> 319

Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
1. 5 10 15

Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
20 25 30

Tyr Met Lys Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile
35 40 45

Gly Asp Ile Ile Pro Ser Asn Gly Ala Thr Phe Tyr Asn Gln Lys Phe
50 55 60

Lys Gly Lys Ala Thr Leu Thr Val Asp Arg Ser Ser Ser Thr Ala Tyr
65 70 75 80

Met His Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
85 90 95

Thr Arg Ser His Leu Leu Arg Ala Ser Trp Phe Ala Tyr Trp Gly Gln
100 105 110

Gly Thr Leu Val Thr Val Ser Ala Ser Glu Val Gln Val Val Glu Thr
115 120 125

Gly Gly Ser Leu Val Gln Pro Gly Lys Ser Leu Lys Leu Thr Cys Ala
130 135 140

Thr Ser Gly Phe Thr Phe Thr Asn Ala Trp Met His Trp Val Arg Arg
145 150 155 160

Ser Pro Glu Lys Gln Leu Glu Trp Val Ala Gln Ile Lys Asp Lys Ser
165 170 175

Asn Asn Tyr Ala Thr Tyr Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr
180 185 190

Ile Ser Arg Asp Asp Ser Lys Ser Ser Ile Tyr Leu Gln Met Asn Ser
195 200 205

Leu Lys Glu Glu Asp Thr Ala Ile Tyr Tyr Cys Arg Tyr Val His Tyr
210 215 220

Arg Phe Ala Tyr Ala Leu Asp Ala Trp Gly Arg Gly Thr Ser Val Ser
225 230 235 240

Val Ser Ser Arg Thr Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu
245 250 255

Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys
260 265 270

Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser
275 280 285

Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser
290 295 300

Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser
305 310 315 320

Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn
325 330 335

Thr Lys Val Asp Lys Lys Val
340

<210> 320
<211> 344
<212> PRT
<213> Artificial Sequence

<220>
<223> polypeptide I of the so-called CODV-Fab "hz20G6 x 7G3"
antibody-like binding protein

<400> 320

Asp Phe Val Met Thr Gln Ser Pro Ser Ser Leu Thr Val Thr Ala Gly
1. 5 10 15

Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser
20 25 30

Gly Asn Gln Lys Asn Tyr Leu Thr Trp Tyr Leu Gln Lys Pro Gly Gln
35 40 45

Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
50 55 60

Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
65 70 75 80

Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Asn
85 90 95

Asp Tyr Ser Tyr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile
100 105 110

Lys Gly Gln Pro Lys Ala Ala Pro Asp Ile Val Met Thr Gln Thr Pro
115 120 125

Leu Ser Leu Ser Val Thr Pro Gly Gln Pro Ala Ser Ile Ser Cys Lys
130 135 140

Ser Ser Gln Ser Leu Val His Asn Asn Gly Asn Thr Tyr Leu Ser Trp
145 150 155 160

Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Ser Leu Ile Tyr Lys Val

antibody-like binding protein

<400> 321

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1. 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Thr Lys Ala
20 25 30

Trp Met His Trp Val Arg Gln Ala Pro Gly Lys Gln Leu Glu Trp Val
35 40 45

Ala Gln Ile Lys Asp Lys Ser Asn Ser Tyr Ala Thr Tyr Tyr Ala Asp
50 55 60

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr
65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr
85 90 95

Tyr Cys Arg Gly Val Tyr Tyr Ala Leu Ser Pro Phe Asp Tyr Trp Gly
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser Ser Glu Val Gln Leu Gln Gln
115 120 125

Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Met Ser Cys
130 135 140

Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Tyr Met Lys Trp Val Lys
145 150 155 160

Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Asp Ile Ile Pro Ser
165 170 175

Asn Gly Ala Thr Phe Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu
180 185 190

Thr Val Asp Arg Ser Ser Ser Thr Ala Tyr Met His Leu Asn Ser Leu
195 200 205

Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Thr Arg Ser His Leu Leu
210 215 220

Arg Ala Ser Trp Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val
225 230 235 240

Ser Ala Arg Thr Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala
245 250 255

Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu
260 265 270

Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly
275 280 285

Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser
290 295 300

Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu
305 310 315 320

Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr
325 330 335

Lys Val Asp Lys Lys Val
340

<210> 322

<211> 344

<212> PRT

<213> Artificial Sequence

<220>

<223> polypeptide I of the so-called CODV-Fab 7G3 x hz4B4"
antibody-like binding protein

<400> 322

Asp Val Val Met Thr Gln Thr Pro Val Ser Leu Ser Val Ser Val Gly
1. 5 10 15

Gly Arg Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asp

20					25					30					
Asn	Gly	Asn	Thr	Tyr	Leu	Ser	Trp	Ser	Leu	Gln	Lys	Pro	Gly	Lys	Ser
		35					40					45			
Pro	Lys	Val	Leu	Ile	Tyr	Lys	Val	Ser	Asn	Arg	Phe	Ser	Gly	Val	Ser
	50					55					60				
Ser	Arg	Phe	Thr	Gly	Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Lys	Ile
65					70					75					80
Ser	Ser	Val	Gln	Pro	Asp	Asp	Leu	Gly	Val	Tyr	Tyr	Cys	Gly	Gln	Gly
				85					90					95	
Thr	Gln	Tyr	Pro	Phe	Thr	Phe	Gly	Ser	Gly	Thr	Lys	Leu	Glu	Ile	Lys
			100					105					110		
Gly	Gln	Pro	Lys	Ala	Ala	Pro	Asp	Phe	Val	Met	Thr	Gln	Ser	Pro	Ser
		115					120					125			
Ser	Leu	Thr	Val	Thr	Ala	Gly	Glu	Lys	Val	Thr	Met	Ser	Cys	Lys	Ser
	130					135					140				
Ser	Gln	Ser	Leu	Leu	Asn	Ser	Gly	Asn	Gln	Lys	Asn	Tyr	Leu	Thr	Trp
145					150					155					160
Tyr	Leu	Gln	Lys	Pro	Gly	Gln	Pro	Pro	Lys	Leu	Leu	Ile	Tyr	Trp	Ala
				165					170					175	
Ser	Thr	Arg	Glu	Ser	Gly	Val	Pro	Asp	Arg	Phe	Thr	Gly	Ser	Gly	Ser
			180					185					190		
Gly	Thr	Asp	Phe	Thr	Leu	Thr	Ile	Ser	Ser	Val	Gln	Ala	Glu	Asp	Leu
		195					200					205			
Ala	Val	Tyr	Tyr	Cys	Gln	Asn	Asp	Tyr	Ser	Tyr	Pro	Tyr	Thr	Phe	Gly
	210					215					220				
Gly	Gly	Thr	Lys	Leu	Glu	Ile	Lys	Thr	Lys	Gly	Pro	Ser	Arg	Thr	Val
225					230					235					240

Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys
245 250 255

Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg
260 265 270

Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn
275 280 285

Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser
290 295 300

Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys
305 310 315 320

Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr
325 330 335

Lys Ser Phe Asn Arg Gly Glu Cys
340

<210> 323
<211> 342
<212> PRT
<213> Artificial Sequence

<220>
<223> polypeptide II of the so-called CODV-Fab "7G3 x hz4B4"
antibody-like binding protein

<400> 323

Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
1. 5 10 15

Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
20 25 30

Tyr Met Lys Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile
35 40 45

Gly Asp Ile Ile Pro Ser Asn Gly Ala Thr Phe Tyr Asn Gln Lys Phe
50 55 60

Lys Gly Lys Ala Thr Leu Thr Val Asp Arg Ser Ser Ser Thr Ala Tyr
65 70 75 80

Met His Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
85 90 95

Thr Arg Ser His Leu Leu Arg Ala Ser Trp Phe Ala Tyr Trp Gly Gln
100 105 110

Gly Thr Leu Val Thr Val Ser Ala Ser Gln Val Gln Leu Val Glu Thr
115 120 125

Gly Gly Gly Leu Val Lys Pro Gly Gln Ser Leu Lys Leu Thr Cys Ala
130 135 140

Thr Ser Gly Phe Thr Phe Ser Asn Ala Trp Met His Trp Val Arg Gln
145 150 155 160

Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Gln Ile Lys Ala Arg Ser
165 170 175

Asn Asn Tyr Ala Thr Tyr Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr
180 185 190

Ile Ser Arg Asp Asp Ser Lys Ser Thr Ile Tyr Leu Gln Met Asn Ser
195 200 205

Leu Thr Pro Glu Asp Thr Ala Ile Tyr Tyr Cys Arg Gly Thr Tyr Tyr
210 215 220

Ala Ser Lys Pro Phe Asp Tyr Trp Gly Gln Gly Val Met Val Thr Val
225 230 235 240

Ser Ser Arg Thr Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala
245 250 255

Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu
260 265 270

Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly
275 280 285

Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser
290 295 300

Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu
305 310 315 320

Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr
325 330 335

Lys Val Asp Lys Lys Val
340

<210> 324
<211> 342
<212> PRT
<213> Artificial Sequence

<220>
<223> polypeptide I of the so-called CODV-Fab "hz4B4 x 3E3"
antibody-like binding protein

<400> 324

Gln Phe Val Leu Thr Gln Pro Asn Ser Val Ser Thr Asn Leu Gly Ser
1. 5 10 15

Thr Val Lys Leu Ser Cys Lys Arg Asn Thr Gly Asn Ile Gly Ser Asn
20 25 30

Tyr Val Asn Trp Tyr Gln Gln His Glu Gly Arg Ser Pro Thr Thr Met
35 40 45

Ile Tyr Arg Asp Asp Lys Arg Pro Asp Gly Val Pro Asp Arg Phe Ser
50 55 60

Gly Ser Ile Asp Arg Ser Ser Asn Ser Ala Leu Leu Thr Ile Asn Asn
65 70 75 80

Val Gln Thr Glu Asp Glu Ala Asp Tyr Phe Cys Gln Ser Tyr Ser Ser
85 90 95

Gly Ile Asn Ile Ile Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly
100 105 110

Gln Pro Lys Ala Ala Pro Asp Val Val Met Thr Gln Thr Pro Val Ser
115 120 125

Leu Ser Val Ser Val Gly Gly Arg Val Ser Ile Ser Cys Arg Ser Ser
130 135 140

Gln Ser Leu Val His Asp Asn Gly Asn Thr Tyr Leu Ser Trp Ser Leu
145 150 155 160

Gln Lys Pro Gly Lys Ser Pro Lys Val Leu Ile Tyr Lys Val Ser Asn
165 170 175

Arg Phe Ser Gly Val Ser Ser Arg Phe Thr Gly Ser Gly Ser Gly Thr
180 185 190

Asp Phe Thr Leu Lys Ile Ser Ser Val Gln Pro Asp Asp Leu Gly Val
195 200 205

Tyr Tyr Cys Gly Gln Gly Thr Gln Tyr Pro Phe Thr Phe Gly Ser Gly
210 215 220

Thr Lys Leu Glu Ile Lys Thr Lys Gly Pro Ser Arg Thr Val Ala Ala
225 230 235 240

Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
245 250 255

Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
260 265 270

Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
275 280 285

Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
290 295 300

Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr

305 310 315 320

Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
325 330 335

Phe Asn Arg Gly Glu Cys
340

<210> 325
<211> 340
<212> PRT
<213> Artificial Sequence

<220>
<223> polypeptide II of the so-called CODV-Fab "hz4B4 x 3E3"
antibody-like binding protein

<400> 325

Gln Val Gln Leu Val Glu Thr Gly Gly Gly Leu Val Lys Pro Gly Gln
1. 5 10 15

Ser Leu Lys Leu Thr Cys Ala Thr Ser Gly Phe Thr Phe Ser Asn Ala
20 25 30

Trp Met His Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val
35 40 45

Ala Gln Ile Lys Ala Arg Ser Asn Asn Tyr Ala Thr Tyr Tyr Ala Glu
50 55 60

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr
65 70 75 80

Ile Tyr Leu Gln Met Asn Ser Leu Thr Pro Glu Asp Thr Ala Ile Tyr
85 90 95

Tyr Cys Arg Gly Thr Tyr Tyr Ala Ser Lys Pro Phe Asp Tyr Trp Gly
100 105 110

Gln Gly Val Met Val Thr Val Ser Ser Ser Gln Val Gln Leu Gln Glu
115 120 125

Ser Gly Pro Gly Leu Val Gln Pro Ser Gln Thr Leu Ser Leu Thr Cys
130 135 140

Thr Val Ser Gly Phe Ser Leu Thr Thr Tyr Asp Val His Trp Val Arg
145 150 155 160

Gln Pro Pro Gly Lys Gly Leu Glu Trp Met Gly Arg Ile Gln Asn Gly
165 170 175

Gly Ile Thr Asp Tyr Asn Ser Ala Leu Lys Ser Arg Leu Ile Ile Ser
180 185 190

Arg Asp Thr Ser Lys Ser Gln Val Phe Leu Lys Met Asn Ser Val Gln
195 200 205

Thr Glu Asp Thr Ala Met Tyr Phe Cys Ala Lys Thr Gly Ser Tyr Phe
210 215 220

Tyr Ala Phe Asp His Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
225 230 235 240

Arg Thr Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser
245 250 255

Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys
260 265 270

Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu
275 280 285

Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu
290 295 300

Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr
305 310 315 320

Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val
325 330 335

Asp Lys Lys Val
340

<210> 326
 <211> 572
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> polypeptide I of the so-called CODV-Fab "hz20G6 x 7G3 TL4"
 antibody-like binding protein

 <400> 326

 Asp Phe Val Met Thr Gln Ser Pro Ser Ser Leu Thr Val Thr Ala Gly
 1. 5 10 15

 Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser
 20 25 30

 Gly Asn Gln Lys Asn Tyr Leu Thr Trp Tyr Leu Gln Lys Pro Gly Gln
 35 40 45

 Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
 50 55 60

 Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
 65 70 75 80

 Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Asn
 85 90 95

 Asp Tyr Ser Tyr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile
 100 105 110

 Lys Gly Gln Pro Lys Ala Ala Pro Asp Ile Val Met Thr Gln Thr Pro
 115 120 125

 Leu Ser Leu Ser Val Thr Pro Gly Gln Pro Ala Ser Ile Ser Cys Lys
 130 135 140

 Ser Ser Gln Ser Leu Val His Asn Asn Gly Asn Thr Tyr Leu Ser Trp
 145 150 155 160

 Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Ser Leu Ile Tyr Lys Val

				165						170						175
Ser	Asn	Arg	Phe	Ser	Gly	Val	Pro	Asp	Arg	Phe	Ser	Gly	Ser	Gly	Ser	
			180					185					190			
Gly	Thr	Asp	Phe	Thr	Leu	Lys	Ile	Ser	Arg	Val	Glu	Ala	Glu	Asp	Val	
		195					200					205				
Gly	Val	Tyr	Tyr	Cys	Gly	Gln	Gly	Thr	Gln	Tyr	Pro	Phe	Thr	Phe	Gly	
	210					215					220					
Ser	Gly	Thr	Lys	Val	Glu	Ile	Lys	Thr	Lys	Gly	Pro	Ser	Arg	Thr	Val	
225					230					235					240	
Ala	Ala	Pro	Ser	Val	Phe	Ile	Phe	Pro	Pro	Ser	Asp	Glu	Gln	Leu	Lys	
				245					250					255		
Ser	Gly	Thr	Ala	Ser	Val	Val	Cys	Leu	Leu	Asn	Asn	Phe	Tyr	Pro	Arg	
			260					265					270			
Glu	Ala	Lys	Val	Gln	Trp	Lys	Val	Asp	Asn	Ala	Leu	Gln	Ser	Gly	Asn	
		275					280					285				
Ser	Gln	Glu	Ser	Val	Thr	Glu	Gln	Asp	Ser	Lys	Asp	Ser	Thr	Tyr	Ser	
	290					295					300					
Leu	Ser	Ser	Thr	Leu	Thr	Leu	Ser	Lys	Ala	Asp	Tyr	Glu	Lys	His	Lys	
305					310					315					320	
Val	Tyr	Ala	Cys	Glu	Val	Thr	His	Gln	Gly	Leu	Ser	Ser	Pro	Val	Thr	
				325					330					335		
Lys	Ser	Phe	Asn	Arg	Gly	Glu	Cys	Glu	Ser	Lys	Tyr	Gly	Pro	Pro	Cys	
			340					345					350			
Pro	Pro	Cys	Pro	Ala	Pro	Glu	Phe	Glu	Gly	Gly	Pro	Ser	Val	Phe	Leu	
		355					360					365				
Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	Arg	Thr	Pro	Glu	
	370					375					380					

Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln
385 390 395 400

Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys
405 410 415

Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu
420 425 430

Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys
435 440 445

Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys
450 455 460

Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser
465 470 475 480

Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys
485 490 495

Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln
500 505 510

Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly
515 520 525

Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln
530 535 540

Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn
545 550 555 560

Arg Phe Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly
565 570

<210> 327

<211> 228

<212> PRT

<213> Artificial Sequence

<220>

<223> amino acid sequence Fc2 of the so-called CODV-Fab
"hz20G6x7G3-TL4" antibody-like binding protein

<400> 327

Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe
1. 5 10 15

Glu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
20 25 30

Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
35 40 45

Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val
50 55 60

Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser
65 70 75 80

Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
85 90 95

Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser
100 105 110

Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
115 120 125

Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln
130 135 140

Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
145 150 155 160

Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
165 170 175

Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu
180 185 190

Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser
195 200 205

Val Met His Glu Ala Leu His Asn Arg Phe Thr Gln Lys Ser Leu Ser
210 215 220

Leu Ser Leu Gly
225

<210> 328

<211> 570

<212> PRT

<213> Artificial Sequence

<220>

<223> polypeptide III of the so-called CODV-Fab "hz20G6 x 7G3 TL4"
antibody-like binding protein

<400> 328

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1. 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Thr Lys Ala
20 25 30

Trp Met His Trp Val Arg Gln Ala Pro Gly Lys Gln Leu Glu Trp Val
35 40 45

Ala Gln Ile Lys Asp Lys Ser Asn Ser Tyr Ala Thr Tyr Tyr Ala Asp
50 55 60

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr
65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr
85 90 95

Tyr Cys Arg Gly Val Tyr Tyr Ala Leu Ser Pro Phe Asp Tyr Trp Gly
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser Ser Glu Val Gln Leu Gln Gln
115 120 125

Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Met Ser Cys
130 135 140

Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Tyr Met Lys Trp Val Lys
145 150 155 160

Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Asp Ile Ile Pro Ser
165 170 175

Asn Gly Ala Thr Phe Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu
180 185 190

Thr Val Asp Arg Ser Ser Ser Thr Ala Tyr Met His Leu Asn Ser Leu
195 200 205

Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Thr Arg Ser His Leu Leu
210 215 220

Arg Ala Ser Trp Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val
225 230 235 240

Ser Ala Arg Thr Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala
245 250 255

Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu
260 265 270

Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly
275 280 285

Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser
290 295 300

Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu
305 310 315 320

Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr
325 330 335

Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro

				340					345					350			
Cys	Pro	Ala	Pro	Glu	Phe	Glu	Gly	Gly	Pro	Ser	Val	Phe	Leu	Phe	Pro		
		355					360					365					
Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	Arg	Thr	Pro	Glu	Val	Thr		
	370					375					380						
Cys	Val	Val	Val	Asp	Val	Ser	Gln	Glu	Asp	Pro	Glu	Val	Gln	Phe	Asn		
385					390					395					400		
Trp	Tyr	Val	Asp	Gly	Val	Glu	Val	His	Asn	Ala	Lys	Thr	Lys	Pro	Arg		
				405					410					415			
Glu	Glu	Gln	Phe	Asn	Ser	Thr	Tyr	Arg	Val	Val	Ser	Val	Leu	Thr	Val		
			420					425					430				
Leu	His	Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys	Cys	Lys	Val	Ser		
		435					440					445					
Asn	Lys	Gly	Leu	Pro	Ser	Ser	Ile	Glu	Lys	Thr	Ile	Ser	Lys	Ala	Lys		
	450					455					460						
Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro	Ser	Gln	Glu		
465					470					475					480		
Glu	Met	Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu	Val	Lys	Gly	Phe		
				485					490					495			
Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn	Gly	Gln	Pro	Glu		
			500					505					510				
Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser	Asp	Gly	Ser	Phe		
		515					520					525					
Phe	Leu	Tyr	Ser	Arg	Leu	Thr	Val	Asp	Lys	Ser	Arg	Trp	Gln	Glu	Gly		
	530					535					540						
Asn	Val	Phe	Ser	Cys	Ser	Val	Met	His	Glu	Ala	Leu	His	Asn	His	Tyr		
545					550					555					560		

Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly
565 570

<210> 329

<211> 97

<212> PRT

<213> Artificial Sequence

<220>

<223> CH1 of the so-called CODV-Fab "hz20G6x7G3-TL4"antibody-like
binding protein

<400> 329

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg
1. 5 10 15

Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
20 25 30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr
65 70 75 80

Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys
85 90 95

Arg

<210> 330

<211> 229

<212> PRT

<213> Artificial Sequence

<220>

<223> Fc of the so-called CODV-Fab "hz20G6x7G3-TL4"antibody-like
binding protein

<400> 330

Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu
1. 5 10 15

Phe Glu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp
20 25 30

Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
35 40 45

Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly
50 55 60

Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn
65 70 75 80

Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp
85 90 95

Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro
100 105 110

Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu
115 120 125

Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn
130 135 140

Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
145 150 155 160

Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
165 170 175

Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg
180 185 190

Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys
195 200 205

Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu

210

215

220

Ser Leu Ser Leu Gly
225

<210> 331

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Consensus sequence CDR1-H of anti-CD3 antibodies

<220>

<221> MISC_FEATURE

<222> (3)..(3)

<223> Xaa is T or S

<220>

<221> MISC_FEATURE

<222> (4)..(4)

<223> Xaa is F or V

<220>

<221> MISC_FEATURE

<222> (5)..(5)

<223> Xaa is S or T

<220>

<221> MISC_FEATURE

<222> (6)..(6)

<223> Xaa is N, K, L or Y

<400> 331

Gly Phe Xaa Xaa Xaa Xaa Ala Trp
1. 5

<210> 332

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Consensus sequence for CDR2-H of anti-CD3 antibodies

<220>

<221> MISC_FEATURE

<222> (3)..(3)

<223> Xaa is A or D

<220>

<221> MISC_FEATURE

<222> (4)..(4)

<223> Xaa is K or R

<220>

<221> MISC_FEATURE

<222> (5)..(5)

<223> Xaa is S or A

<220>

<221> MISC_FEATURE

<222> (7)..(7)

<223> Xaa is N or S

<220>

<221> MISC_FEATURE

<222> (9)..(9)

<223> Xaa is A or E

<400> 332

Ile Lys Xaa Xaa Xaa Asn Xaa Tyr Xaa Thr

1. 5 10

<210> 333

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Consensus sequence for CDRF-H of anti-CD3 antibodies

<220>

<221> MISC_FEATURE

<222> (2)..(2)

<223> Xaa is Y or G

<220>

<221> MISC_FEATURE

<222> (2)..(2)

<223> Xaa is Y, G or A

<220>

<221> MISC_FEATURE

<222> (3)..(3)

<223> Xaa is V, T or L

<220>

<221> MISC_FEATURE

```

<222> (4)..(4)
<223> Xaa is H, N, Y or Q

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> Xaa is G, R or A

<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> Xaa is F or V or no amino acid

<220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> Xaa is R or no amino acid

<220>
<221> MISC_FEATURE
<222> (9)..(9)
<223> Xaa is F, S or I or no amino acid

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> Xaa is F, L, N, M, Y, S, A or G

<220>
<221> MISC_FEATURE
<222> (11)..(11)
<223> Xaa is Y, A, K, S, N, T, F or L

<220>
<221> MISC_FEATURE
<222> (12)..(12)
<223> Xaa is A, P, G or T

<220>
<221> MISC_FEATURE
<222> (13)..(13)
<223> Xaa is M, L, F or S

<220>
<221> MISC_FEATURE
<222> (15)..(15)
<223> Xaa is A, V, Y or G

<220>
<221> MISC_FEATURE
<222> (15)..(15)
<223> Xaa is A, V or Y

<400> 333

```

Arg Xaa Xaa Xaa Tyr Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asp Xaa
1. 5 10 15

<210> 334
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Consensus sequence for CDR1-L of anti-CD3 antibodies

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa is R or S

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Xaa is V or E

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> Xaa is N, D or T

<220>
<221> MISC_FEATURE
<222> (9)..(9)
<223> Xaa is N or Y

<400> 334

Gln Xaa Leu Xaa His Xaa Asn Gly Xaa Thr Tyr
1. 5 10

<210> 335
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> consensus sequence for CDR3-L of anti-CD3 antibodies

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Xaa is T, A or S

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> Xaa is H, E or Q

<400> 335

Gly Gln Gly Xaa Xaa Tyr Pro Phe Thr
1. 5

<210> 336
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Consensus sequence for CDR1-H of the so-called "1E1-G5",
"6D6-B8", "8B11-B7", "9F6-G3" anti-CD123 antibodies

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa is G or A

<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> Xaa is H, Y or N

<400> 336

Xaa Tyr Thr Phe Thr Asp Xaa Ile
1. 5

<210> 337
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> consensus sequence for CDR2-H of the so-called "1E1-G5",
"6D6-B8", "8B11-B7", "9F6-G3" anti-CD123 antibodies

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> Xaa is G or D

<220>
<221> MISC_FEATURE

<222> (8)..(8)
<223> Xaa is T or A

<400> 337

Ile Asn Pro Tyr Ser Xaa Gly Xaa
1. 5

<210> 338
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> consensus sequence for CDR1-L of the so-called "1E1-G5",
"6D6-B8", "8B11-B7", "9F6-G3" anti-CD123 antibodies

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa is E or K

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Xaa is F, H or Y

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> Xaa is N or S

<400> 338

Xaa Asp Ile Xaa Xaa Asn
1. 5

<210> 339
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> consensus sequence for CDR3-L of the so-called "1E1-G5",
"6D6-B8", "8B11-B7", "9F6-G3" anti-CD123 antibodies

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa is H or Q

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> Xaa is I, K or N

<400> 339

Xaa Gln Tyr Asn Xaa Tyr Pro Tyr Thr
1. 5

<210> 340
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> consensus sequence for CDR1-H of the so-called "6C10-C4",
9B8-G6", "9D7-C8" anti-CD123 antibodies

<220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> Xaa is H or S

<400> 340

Gly Phe Ser Leu Thr Ser Tyr Xaa
1. 5

<210> 341
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Consensus sequence for CDR2-H of the so-called "1E1-G5",
"6D6-B8", "8B11-B7", "9F6-G3" anti-CD123 antibodies

<220>
<221> misc_feature
<222> (3)..(3)
<223> Xaa can be any naturally occurring amino acid

<400> 341

Met Trp Xaa Asp Gly Asp Thr
1. 5

<210> 342
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> consensus sequence for CDR3-H of the so-called "1E1-G5",
"6D6-B8", "8B11-B7", "9F6-G3" anti-CD123 antibodies

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Xaa is D, Y or H

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> Xaa is Y or R

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> Xaa is S or T

<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> Xaa is S or P

<220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> Xaa is Y or no amino acid

<220>
<221> MISC_FEATURE
<222> (9)..(9)
<223> Xaa is L, I or no amino acid

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> Xaa is Y or no amino acid

<220>
<221> MISC_FEATURE
<222> (11)..(11)
<223> Xaa is L or no amino acid

<220>
<221> MISC_FEATURE
<222> (12)..(12)
<223> Xaa s W or no amino acid

<220>
<221> MISC_FEATURE
<222> (14)..(14)
<223> Xaa is A or D

<400> 342

Ala Arg Gly Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Phe Xaa Tyr
1. 5 10 15

<210> 343
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Consensus sequence for CDR1-L of "1E1-G5", "6D6-B8",
"8B11-B7", "9F6-G3" anti-CD123 antibodies

<220>
<221> MISC_FEATURE
<222> (9)..(9)
<223> Xaa is E or G

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> Xaa is R or K

<400> 343

Gln Ser Phe Leu Ser Ser Gly Asp Xaa Xaa Asn Tyr
1. 5 10

<210> 344
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> amino acid sequence of a linker sequence

<400> 344

Gly Gly Gly Gly Ser
1. 5

<210> 345
<211> 10

<212> PRT
<213> Artificial Sequence

<220>
<223> amino acid sequence of a linker sequence

<400> 345

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
1. 5 10

<210> 346
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> amino acid sequence of a linker sequence

<400> 346

Thr Val Ala Ala Pro
1. 5

<210> 347
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> amino acid sequence of a linker sequence

<400> 347

Gln Pro Lys Ala Ala
1. 5

<210> 348
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> amino acid sequence of a linker sequence

<400> 348

Gln Arg Ile Glu Gly
1. 5

<210> 349
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> amino acid sequence of a linker sequence

<400> 349

Ala Ser Thr Lys Gly Pro Ser
1. 5

<210> 350
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> amino acid sequence of a linker sequence

<400> 350

Ala Ser Thr Lys Gly Pro Ser
1. 5

<210> 351
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> amino acid sequence of a linker sequence

<400> 351

His Ile Asp Ser Pro Asn Lys
1. 5

<210> 352
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> linker and Histag sequence

<400> 352

Glu Pro Lys Ser Cys Asp Lys Thr His Thr His His His His His His
1. 5 10 15

<210> 353
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR2-H variant of the so-called "3E3" anti-CD123 antibody.

<400> 353

Ile Gln Asn Ala Gly Ile Thr
1. 5

<210> 354
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> amino acid sequence of a linker sequence

<400> 354

Gly Gly Gly Ser
1

<210> 355
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> shows the amino acid sequence of a linker sequence

<400> 355

Ser Gly Gly Gly Ser
1. 5

<210> 356
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> amino acid sequence of a linker sequence

<400> 356

Gly Ser Gly Gly Gly Gly Ser
1. 5

<210> 357
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> amino acid sequence of a linker sequence

<400> 357

Gly Gly Ser Gly Gly Gly Gly Ser
1. 5

<210> 358
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> amino acid sequence of a linker sequence

<400> 358

Gly Gly Gly Ser Gly Gly Gly Gly Ser
1. 5

<210> 359
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> amino acid sequence of a linker sequence

<400> 359

Lys Thr His Thr
1

<210> 360
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> amino acid sequence of a linker sequence

<400> 360

Lys Thr His Thr Ser
1. 5

<210> 361

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> amino acid sequence of a linker sequence

<400> 361

Asp Lys Thr His Thr Ser
1. 5

<210> 362

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> amino acid sequence of a linker sequence

<400> 362

Asp Lys Thr His Thr Ser Pro
1. 5

<210> 363

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> amino acid sequence of a linker sequence

<400> 363

Ser Asp Lys Thr His Thr Ser Pro
1. 5

<210> 364

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> amino acid sequence of a linker sequence

<400> 364

Ser Asp Lys Thr His Thr Ser Pro Pro
1. 5

<210> 365

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> amino acid sequence of a linker sequence

<400> 365

Lys Ser Asp Lys Thr His Thr Ser Pro Pro Ser
1. 5 10

<210> 366

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> amino acid sequence of a linker sequence

<400> 366

Pro Lys Ser Asp Lys Thr His Thr Ser Pro Pro Ser
1. 5 10

<210> 367

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> amino acid sequence of a linker sequence

<400> 367

Pro Lys Ser Asp Lys Thr His Thr Ser Pro Pro Ser Pro
1. 5 10

<210> 368

<211> 14

<212> PRT

<213> Artificial Sequence

<220>
<223> amino acid sequence of a linker sequence

<400> 368

Glu Pro Lys Ser Asp Lys Thr His Thr Ser Pro Pro Ser Pro
1. 5 10

<210> 369
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> the amino acid sequence of a linker sequence

<400> 369

Glu Pro Lys Ser Asp Lys Thr His Thr Ser Pro Pro Ser Pro Gly
1. 5 10 15

<210> 370
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> amino acid sequence of a linker sequence

<400> 370

Gly Glu Pro Lys Ser Asp Lys Thr His Thr Ser Pro Pro Ser Pro Gly
1. 5 10 15

<210> 371
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> amino acid sequence of a linker sequence

<400> 371

Gly Glu Pro Lys Ser Asp Lys Thr His Thr Ser Pro Pro Ser Pro Gly
1. 5 10 15

Gly

<210> 372
<211> 18
<212> PRT
<213> Artificial Sequence

<220>
<223> amino acid sequence of a linker sequence

<400> 372

Gly Gly Glu Pro Lys Ser Asp Lys Thr His Thr Ser Pro Pro Ser Pro
1. 5 10 15

Gly Gly

<210> 373
<211> 19
<212> PRT
<213> Artificial Sequence

<220>
<223> amino acid sequence of a linker sequence

<400> 373

Gly Gly Glu Pro Lys Ser Asp Lys Thr His Thr Ser Pro Pro Ser Pro
1. 5 10 15

Gly Gly Gly

<210> 374
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> amino acid sequence of a linker sequence

<400> 374

Gly Gly Gly Glu Pro Lys Ser Asp Lys Thr His Thr Ser Pro Pro Ser
1. 5 10 15

Pro Gly Gly Gly
20

<210> 375
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR1-H of the so-called "7G3" antibody.

<400> 375

Gly Tyr Thr Phe Thr Asp Tyr Tyr
1. 5

<210> 376
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR2-H of the so-called "7G3" antibody.

<400> 376

Ile Ile Pro Ser Asn Gly Ala Thr
1. 5

<210> 377
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR3-H of the so-called "7G3" antibody.

<400> 377

Thr Arg Ser His Leu Leu Arg Ala Ser Trp Phe Ala Tyr
1. 5 10

<210> 378
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR1-L of the so-called "7G3" antibody.

<400> 378

Gln Ser Leu Leu Asn Ser Gly Asn Gln Lys Asn Tyr
1. 5 10

<210> 379
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR3-L of the so-called "7G3" antibody.

<400> 379

Gln Asn Asp Tyr Ser Tyr Pro Tyr Thr
1. 5

<210> 380
<211> 120
<212> PRT
<213> Artificial Sequence

<220>
<223> VH variant amino acid sequence of the so-called humanized "7G3"
antibody.

<400> 380

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
1. 5 10 15

Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Asp Tyr
20 25 30

Tyr Met Lys Trp Ala Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met
35 40 45

Gly Asp Ile Ile Pro Ser Asn Gly Ala Thr Phe Tyr Asn Gln Lys Phe
50 55 60

Lys Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Thr Tyr
65 70 75 80

Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys
85 90 95

Ala Arg Ser His Leu Leu Arg Ala Ser Trp Phe Ala Tyr Trp Gly Gln

100

105

110

Gly Thr Met Val Thr Val Ser Ser
 115 120

<210> 381

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> CDR1-H of the so-called humanized "7G3" antibody

<400> 381

Gly Tyr Ser Phe Thr Asp Tyr Tyr
 1. 5

<210> 382

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> CDR3-H of the so-called humanized "7G3" antibody.

<400> 382

Ala Arg Ser His Leu Leu Arg Ala Ser Trp Phe Ala Tyr
 1. 5 10

<210> 383

<211> 120

<212> PRT

<213> Artificial Sequence

<220>

<223> VH varaint of the so-called humanized "7G3" antibody.

<400> 383

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
 1. 5 10 15

Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Asp Tyr
 20 25 30

Tyr Met Lys Trp Ala Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met

35

40

45

Gly Asp Ile Ile Pro Ser Ser Gly Ala Thr Phe Tyr Asn Gln Lys Phe
 50 55 60

Lys Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Thr Tyr
 65 70 75 80

Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys
 85 90 95

Ala Arg Ser His Leu Leu Arg Ala Ser Trp Phe Ala Tyr Trp Gly Gln
 100 105 110

Gly Thr Met Val Thr Val Ser Ser
 115 120

<210> 384

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> CDR2-H of one of the so-called humanized "7G3" antibody.

<400> 384

Ile Ile Pro Ser Ser Gly Ala Thr
 1. 5

<210> 385

<211> 113

<212> PRT

<213> Artificial Sequence

<220>

<223> VL varaint of the so-called humanized "7G3" antibody.

<400> 385

Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
 1. 5 10 15

Glu Arg Ala Thr Ile Asn Cys Glu Ser Ser Gln Ser Leu Leu Asn Ser
 20 25 30

Gly Asn Gln Lys Asn Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Gln
35 40 45

Pro Pro Lys Pro Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
50 55 60

Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
65 70 75 80

Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Asn
85 90 95

Asp Tyr Ser Tyr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile
100 105 110

Lys

<210> 386

<211> 272

<212> PRT

<213> Artificial Sequence

<220>

<223> SEQ ID NO:1 of WO2015/026892

<400> 386

Gln Ala Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly
1. 5 10 15

Thr Val Thr Leu Thr Cys Arg Ser Ser Thr Gly Ala Val Thr Thr Ser
20 25 30

Asn Tyr Ala Asn Trp Val Gln Gln Lys Pro Gly Gln Ala Pro Arg Gly
35 40 45

Leu Ile Gly Gly Thr Asn Lys Arg Ala Pro Trp Thr Pro Ala Arg Phe
50 55 60

Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Ile Thr Gly Ala
65 70 75 80

Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Leu Trp Tyr Ser Asn
85 90 95

Leu Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gly Gly
100 105 110

Gly Ser Gly Gly Gly Gly Glu Val Gln Leu Val Gln Ser Gly Ala Glu
115 120 125

Leu Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly
130 135 140

Tyr Thr Phe Thr Asp Tyr Tyr Met Lys Trp Val Arg Gln Ala Pro Gly
145 150 155 160

Gln Gly Leu Glu Trp Ile Gly Asp Ile Ile Pro Ser Asn Gly Ala Thr
165 170 175

Phe Tyr Asn Gln Lys Phe Lys Gly Arg Val Thr Ile Thr Val Asp Lys
180 185 190

Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp
195 200 205

Thr Ala Val Tyr Tyr Cys Ala Arg Ser His Leu Leu Arg Ala Ser Trp
210 215 220

Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly
225 230 235 240

Cys Gly Gly Gly Glu Val Ala Ala Leu Glu Lys Glu Val Ala Ala Leu
245 250 255

Glu Lys Glu Val Ala Ala Leu Glu Lys Glu Val Ala Ala Leu Glu Lys
260 265 270

<210> 387
<211> 280
<212> PRT
<213> Artificial Sequence

<220>

<223> SEQ ID NO:3 of WO2015/026892

<400> 387

Asp Phe Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
1. 5 10 15

Glu Arg Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser
20 25 30

Gly Asn Gln Lys Asn Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Gln
35 40 45

Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
50 55 60

Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
65 70 75 80

Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Asn
85 90 95

Asp Tyr Ser Tyr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile
100 105 110

Lys Gly Gly Gly Ser Gly Gly Gly Gly Glu Val Gln Leu Val Glu Ser
115 120 125

Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala
130 135 140

Ala Ser Gly Phe Thr Phe Ser Thr Tyr Ala Met Asn Trp Val Arg Gln
145 150 155 160

Ala Pro Gly Lys Gly Leu Glu Trp Val Gly Arg Ile Arg Ser Lys Tyr
165 170 175

Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr
180 185 190

Ile Ser Arg Asp Asp Ser Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser

195 200 205
 Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg His Gly Asn
 210 215 220

 Phe Gly Asn Ser Tyr Val Ser Trp Phe Ala Tyr Trp Gly Gln Gly Thr
 225 230 235 240

 Leu Val Thr Val Ser Ser Gly Gly Cys Gly Gly Gly Lys Val Ala Ala
 245 250 255

 Leu Lys Glu Lys Val Ala Ala Leu Lys Glu Lys Val Ala Ala Leu Lys
 260 265 270

 Glu Lys Val Ala Ala Leu Lys Glu
 275 280

 <210> 388
 <211> 352
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> polypeptide I of the so-called CODV-Fab "hz20G6xhz7G3",
 CODV-Fab-OL1 "hz20G6xhz7G3" and CODV-Fab-OL1a "hz20G6xhz7G3"
 antibody-like binding proteins

 <400> 388

 Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
 1. 5 10 15

 Glu Arg Ala Thr Ile Asn Cys Glu Ser Ser Gln Ser Leu Leu Asn Ser
 20 25 30

 Gly Asn Gln Lys Asn Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Gln
 35 40 45

 Pro Pro Lys Pro Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
 50 55 60

 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
 65 70 75 80

Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Asn
85 90 95

Asp Tyr Ser Tyr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile
100 105 110

Lys Gly Gly Ser Gly Ser Ser Gly Ser Gly Gly Asp Ile Val Met Thr
115 120 125

Gln Thr Pro Leu Ser Leu Ser Val Thr Pro Gly Gln Pro Ala Ser Ile
130 135 140

Ser Cys Lys Ser Ser Gln Ser Leu Val His Asn Asn Ala Asn Thr Tyr
145 150 155 160

Leu Ser Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Ser Leu Ile
165 170 175

Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly
180 185 190

Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala
195 200 205

Glu Asp Val Gly Val Tyr Tyr Cys Gly Gln Gly Thr Gln Tyr Pro Phe
210 215 220

Thr Phe Gly Ser Gly Thr Lys Val Glu Ile Lys Gly Gly Ser Gly Ser
225 230 235 240

Ser Gly Ser Gly Gly Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe
245 250 255

Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys
260 265 270

Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val
275 280 285

Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln

290		295		300
Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser				
305		310		315 320
Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His				
	325		330	335
Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys				
	340		345	350
<210> 389				
<211> 10				
<212> PRT				
<213> Artificial Sequence				
<220>				
<223> Linker				
<400> 389				
Gly Gly Ser Gly Ser Ser Gly Ser Gly Gly				
1. 5		10		
<210> 390				
<211> 339				
<212> PRT				
<213> Artificial Sequence				
<220>				
<223> polypeptide II of the so-called CODV-Fab "hz20G6xhz7G3"				
antibody-like binding protein				
<400> 390				
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg				
1. 5		10		15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Thr Lys Ala				
	20		25	30
Trp Met His Trp Val Arg Gln Ala Pro Gly Lys Gln Leu Glu Trp Val				
	35		40	45
Ala Gln Ile Lys Asp Lys Ser Asn Ser Tyr Ala Thr Tyr Tyr Ala Asp				
50		55		60

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr
65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr
85 90 95

Tyr Cys Arg Gly Val Tyr Tyr Ala Leu Ser Pro Phe Asp Tyr Trp Gly
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser Glu Val Gln Leu Val Gln Ser
115 120 125

Gly Ala Glu Val Lys Lys Pro Gly Glu Ser Leu Lys Ile Ser Cys Lys
130 135 140

Gly Ser Gly Tyr Ser Phe Thr Asp Tyr Tyr Met Lys Trp Ala Arg Gln
145 150 155 160

Met Pro Gly Lys Gly Leu Glu Trp Met Gly Asp Ile Ile Pro Ser Ser
165 170 175

Gly Ala Thr Phe Tyr Asn Gln Lys Phe Lys Gly Gln Val Thr Ile Ser
180 185 190

Ala Asp Lys Ser Ile Ser Thr Thr Tyr Leu Gln Trp Ser Ser Leu Lys
195 200 205

Ala Ser Asp Thr Ala Met Tyr Tyr Cys Ala Arg Ser His Leu Leu Arg
210 215 220

Ala Ser Trp Phe Ala Tyr Trp Gly Gln Gly Thr Met Val Thr Val Ser
225 230 235 240

Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser
245 250 255

Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp
260 265 270

Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr
275 280 285

Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr
290 295 300

Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln
305 310 315 320

Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp
325 330 335

Lys Lys Val

<210> 391

<211> 578

<212> PRT

<213> Artificial Sequence

<220>

<223> polypeptide IV of the so-called CODV-Fab-TL1 "hz20G6xhz7G3"
antibody-like binding protein

<400> 391

Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
1. 5 10 15

Glu Arg Ala Thr Ile Asn Cys Glu Ser Ser Gln Ser Leu Leu Asn Ser
20 25 30

Gly Asn Gln Lys Asn Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Gln
35 40 45

Pro Pro Lys Pro Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
50 55 60

Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
65 70 75 80

Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Asn
85 90 95

Asp Tyr Ser Tyr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile
100 105 110

Lys Gly Gly Ser Gly Ser Ser Gly Ser Gly Gly Asp Ile Val Met Thr
115 120 125

Gln Thr Pro Leu Ser Leu Ser Val Thr Pro Gly Gln Pro Ala Ser Ile
130 135 140

Ser Cys Lys Ser Ser Gln Ser Leu Val His Asn Asn Ala Asn Thr Tyr
145 150 155 160

Leu Ser Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Ser Leu Ile
165 170 175

Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly
180 185 190

Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala
195 200 205

Glu Asp Val Gly Val Tyr Tyr Cys Gly Gln Gly Thr Gln Tyr Pro Phe
210 215 220

Thr Phe Gly Ser Gly Thr Lys Val Glu Ile Lys Gly Gly Ser Gly Ser
225 230 235 240

Ser Gly Ser Gly Gly Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe
245 250 255

Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys
260 265 270

Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val
275 280 285

Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln
290 295 300

Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser

305					310					315				320	
Lys	Ala	Asp	Tyr	Glu	Lys	His	Lys	Val	Tyr	Ala	Cys	Glu	Val	Thr	His
				325					330					335	
Gln	Gly	Leu	Ser	Ser	Pro	Val	Thr	Lys	Ser	Phe	Asn	Arg	Gly	Glu	Cys
			340					345					350		
Asp	Lys	Thr	His	Thr	Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu	Ala	Ala	Gly
		355						360				365			
Gly	Pro	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met
	370					375					380				
Ile	Ser	Arg	Thr	Pro	Glu	Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser	His
385					390					395					400
Glu	Asp	Pro	Glu	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu	Val
				405					410					415	
His	Asn	Ala	Lys	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Asn	Ser	Thr	Tyr
			420					425					430		
Arg	Val	Val	Ser	Val	Leu	Thr	Val	Leu	His	Gln	Asp	Trp	Leu	Asn	Gly
		435					440					445			
Lys	Glu	Tyr	Lys	Cys	Lys	Val	Ser	Asn	Lys	Ala	Leu	Pro	Ala	Pro	Ile
	450					455					460				
Glu	Lys	Thr	Ile	Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val
465					470					475					480
Tyr	Thr	Leu	Pro	Pro	Ser	Arg	Asp	Glu	Leu	Thr	Lys	Asn	Gln	Val	Ser
				485					490					495	
Leu	Thr	Cys	Leu	Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu
			500					505					510		
Trp	Glu	Ser	Asn	Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro
		515					520					525			

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
530 535 540

Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
545 550 555 560

His Glu Ala Leu His Asn Arg Phe Thr Gln Lys Ser Leu Ser Leu Ser
565 570 575

Pro Gly

<210> 392

<211> 226

<212> PRT

<213> Artificial Sequence

<220>

<223> Fc2 of the so-called CODV-Fab-TL1 "hz20G6xhz7G3" antibody-like
binding protein

<400> 392

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly
1. 5 10 15

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
20 25 30

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
35 40 45

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
50 55 60

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
65 70 75 80

Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
85 90 95

Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
100 105 110

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
115 120 125

Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
130 135 140

Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
145 150 155 160

Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
165 170 175

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
180 185 190

Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
195 200 205

His Glu Ala Leu His Asn Arg Phe Thr Gln Lys Ser Leu Ser Leu Ser
210 215 220

Pro Gly
225

<210> 393

<211> 570

<212> PRT

<213> Artificial Sequence

<220>

<223> polypeptide III of the so-called CODV-Fab-TL1 "hz20G6xhz7G3"
antibody-like binding protein

<400> 393

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1. 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Thr Lys Ala
20 25 30

Trp Met His Trp Val Arg Gln Ala Pro Gly Lys Gln Leu Glu Trp Val

35

40

45

Ala Gln Ile Lys Asp Lys Ser Asn Ser Tyr Ala Thr Tyr Tyr Ala Asp
50 55 60

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr
65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr
85 90 95

Tyr Cys Arg Gly Val Tyr Tyr Ala Leu Ser Pro Phe Asp Tyr Trp Gly
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser Glu Val Gln Leu Val Gln Ser
115 120 125

Gly Ala Glu Val Lys Lys Pro Gly Glu Ser Leu Lys Ile Ser Cys Lys
130 135 140

Gly Ser Gly Tyr Ser Phe Thr Asp Tyr Tyr Met Lys Trp Ala Arg Gln
145 150 155 160

Met Pro Gly Lys Gly Leu Glu Trp Met Gly Asp Ile Ile Pro Ser Ser
165 170 175

Gly Ala Thr Phe Tyr Asn Gln Lys Phe Lys Gly Gln Val Thr Ile Ser
180 185 190

Ala Asp Lys Ser Ile Ser Thr Thr Tyr Leu Gln Trp Ser Ser Leu Lys
195 200 205

Ala Ser Asp Thr Ala Met Tyr Tyr Cys Ala Arg Ser His Leu Leu Arg
210 215 220

Ala Ser Trp Phe Ala Tyr Trp Gly Gln Gly Thr Met Val Thr Val Ser
225 230 235 240

Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser
245 250 255

Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp
260 265 270

Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr
275 280 285

Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr
290 295 300

Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln
305 310 315 320

Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp
325 330 335

Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro
340 345 350

Cys Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro
355 360 365

Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr
370 375 380

Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn
385 390 395 400

Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg
405 410 415

Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val
420 425 430

Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser
435 440 445

Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys
450 455 460

Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp

465 470 475 480

Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe
485 490 495

Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu
500 505 510

Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe
515 520 525

Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly
530 535 540

Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr
545 550 555 560

Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
565 570

<210> 394
<211> 231
<212> PRT
<213> Artificial Sequence

<220>
<223> Fc region of the so-called CODV-Fab-TL1 "hz20G6xhz7G3"
antibody-like binding protein

<400> 394

Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala
1. 5 10 15

Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro
20 25 30

Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val
35 40 45

Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val
50 55 60

Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln
65 70 75 80

Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln
85 90 95

Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala
100 105 110

Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro
115 120 125

Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr
130 135 140

Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser
145 150 155 160

Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr
165 170 175

Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr
180 185 190

Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe
195 200 205

Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys
210 215 220

Ser Leu Ser Leu Ser Pro Gly
225 230

<210> 395

<211> 570

<212> PRT

<213> Artificial Sequence

<220>

<223> polypeptide II of the so-called CODV-Fab-OL1 "hz20G6xhz7G3"
antibody-like binding protein

<400> 395

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1. 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Thr Lys Ala
20 25 30

Trp Met His Trp Val Arg Gln Ala Pro Gly Lys Gln Leu Glu Trp Val
35 40 45

Ala Gln Ile Lys Asp Lys Ser Asn Ser Tyr Ala Thr Tyr Tyr Ala Asp
50 55 60

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr
65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr
85 90 95

Tyr Cys Arg Gly Val Tyr Tyr Ala Leu Ser Pro Phe Asp Tyr Trp Gly
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser Glu Val Gln Leu Val Gln Ser
115 120 125

Gly Ala Glu Val Lys Lys Pro Gly Glu Ser Leu Lys Ile Ser Cys Lys
130 135 140

Gly Ser Gly Tyr Ser Phe Thr Asp Tyr Tyr Met Lys Trp Ala Arg Gln
145 150 155 160

Met Pro Gly Lys Gly Leu Glu Trp Met Gly Asp Ile Ile Pro Ser Ser
165 170 175

Gly Ala Thr Phe Tyr Asn Gln Lys Phe Lys Gly Gln Val Thr Ile Ser
180 185 190

Ala Asp Lys Ser Ile Ser Thr Thr Tyr Leu Gln Trp Ser Ser Leu Lys
195 200 205

Ala Ser Asp Thr Ala Met Tyr Tyr Cys Ala Arg Ser His Leu Leu Arg

210		215		220
Ala Ser Trp Phe Ala Tyr Trp Gly Gln Gly Thr Met Val Thr Val Ser				
225		230		235
Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser				
	245		250	255
Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp				
	260		265	270
Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr				
	275		280	285
Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr				
	290		295	300
Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln				
305		310		315
Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp				
	325		330	335
Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro				
	340		345	350
Cys Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro				
	355		360	365
Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr				
	370		375	380
Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn				
385		390		395
Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg				
	405		410	415
Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val				
	420		425	430

Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser
435 440 445

Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys
450 455 460

Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Cys Arg Asp
465 470 475 480

Glu Leu Thr Lys Asn Gln Val Ser Leu Trp Cys Leu Val Lys Gly Phe
485 490 495

Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu
500 505 510

Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe
515 520 525

Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly
530 535 540

Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn Arg Phe
545 550 555 560

Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
565 570

<210> 396

<211> 231

<212> PRT

<213> Artificial Sequence

<220>

<223> Fc region of the so-called CODV-Fab-OL1 "hz20G6xhz7G3"
antibody-like binding protein

<400> 396

Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala
1. 5 10 15

Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro
20 25 30

Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val
35 40 45

Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val
50 55 60

Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln
65 70 75 80

Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln
85 90 95

Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala
100 105 110

Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro
115 120 125

Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Cys Arg Asp Glu Leu Thr
130 135 140

Lys Asn Gln Val Ser Leu Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser
145 150 155 160

Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr
165 170 175

Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr
180 185 190

Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe
195 200 205

Ser Cys Ser Val Met His Glu Ala Leu His Asn Arg Phe Thr Gln Lys
210 215 220

Ser Leu Ser Leu Ser Pro Gly
225 230

<210> 397
 <211> 228
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Fc3 of the so-called CODV-Fab-OL1 "hz20G6xhz7G3" antibody-like binding protein

 <400> 397

Gly Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
 1. 5 10 15

Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
 20 25 30

Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
 35 40 45

Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
 50 55 60

Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
 65 70 75 80

Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
 85 90 95

Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
 100 105 110

Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
 115 120 125

Gln Val Cys Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln
 130 135 140

Val Ser Leu Ser Cys Ala Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
 145 150 155 160

Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
 165 170 175

Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Val Ser Lys Leu
180 185 190

Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
195 200 205

Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
210 215 220

Leu Ser Pro Gly
225

<210> 398
<211> 228
<212> PRT
<213> Artificial Sequence

<220>
<223> Fc3 of the so-called CODV-Fab-OL1a "hz20G6xhz7G3"

<400> 398

Gly Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
1. 5 10 15

Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
20 25 30

Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
35 40 45

Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
50 55 60

Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
65 70 75 80

Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
85 90 95

Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
100 105 110

Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
115 120 125

Gln Val Cys Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln
130 135 140

Val Ser Leu Ser Cys Ala Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
145 150 155 160

Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
165 170 175

Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Val Ser Lys Leu
180 185 190

Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
195 200 205

Val Met His Glu Ala Leu His Asn Arg Phe Thr Gln Lys Ser Leu Ser
210 215 220

Leu Ser Pro Gly
225

<210> 399
<211> 570
<212> PRT
<213> Artificial Sequence

<220>
<223> polypeptide of formula II of the so-called CODV-Fab-OL1a
"hz20G6xhz7G3"

<400> 399

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1. 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Thr Lys Ala
20 25 30

Trp Met His Trp Val Arg Gln Ala Pro Gly Lys Gln Leu Glu Trp Val
35 40 45

Ala Gln Ile Lys Asp Lys Ser Asn Ser Tyr Ala Thr Tyr Tyr Ala Asp
50 55 60

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr
65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr
85 90 95

Tyr Cys Arg Gly Val Tyr Tyr Ala Leu Ser Pro Phe Asp Tyr Trp Gly
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser Glu Val Gln Leu Val Gln Ser
115 120 125

Gly Ala Glu Val Lys Lys Pro Gly Glu Ser Leu Lys Ile Ser Cys Lys
130 135 140

Gly Ser Gly Tyr Ser Phe Thr Asp Tyr Tyr Met Lys Trp Ala Arg Gln
145 150 155 160

Met Pro Gly Lys Gly Leu Glu Trp Met Gly Asp Ile Ile Pro Ser Ser
165 170 175

Gly Ala Thr Phe Tyr Asn Gln Lys Phe Lys Gly Gln Val Thr Ile Ser
180 185 190

Ala Asp Lys Ser Ile Ser Thr Thr Tyr Leu Gln Trp Ser Ser Leu Lys
195 200 205

Ala Ser Asp Thr Ala Met Tyr Tyr Cys Ala Arg Ser His Leu Leu Arg
210 215 220

Ala Ser Trp Phe Ala Tyr Trp Gly Gln Gly Thr Met Val Thr Val Ser
225 230 235 240

Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser
245 250 255

Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp
260 265 270

Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr
275 280 285

Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr
290 295 300

Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln
305 310 315 320

Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp
325 330 335

Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro
340 345 350

Cys Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro
355 360 365

Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr
370 375 380

Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn
385 390 395 400

Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg
405 410 415

Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val
420 425 430

Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser
435 440 445

Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys
450 455 460

Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Cys Arg Asp
465 470 475 480

Glu Leu Thr Lys Asn Gln Val Ser Leu Trp Cys Leu Val Lys Gly Phe
485 490 495

Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu
500 505 510

Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe
515 520 525

Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly
530 535 540

Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr
545 550 555 560

Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
565 570

<210> 400

<211> 231

<212> PRT

<213> Artificial Sequence

<220>

<223> Fc3 of the so-called CODV-Fab-OL1a "hz20G6xhz7G3" antibody-like
binding protein

<400> 400

Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala
1. 5 10 15

Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro
20 25 30

Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val
35 40 45

Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val
50 55 60

Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln

80

95

110

125

140

160

175

190

205

220

230